TW201030055A - Liquid crystal aligning agent and liquid crystal display element using same - Google Patents

Liquid crystal aligning agent and liquid crystal display element using same Download PDF

Info

Publication number
TW201030055A
TW201030055A TW098132085A TW98132085A TW201030055A TW 201030055 A TW201030055 A TW 201030055A TW 098132085 A TW098132085 A TW 098132085A TW 98132085 A TW98132085 A TW 98132085A TW 201030055 A TW201030055 A TW 201030055A
Authority
TW
Taiwan
Prior art keywords
liquid crystal
ring
formula
crystal alignment
group
Prior art date
Application number
TW098132085A
Other languages
Chinese (zh)
Other versions
TWI457368B (en
Inventor
Kohei Goto
Noritoshi Miki
Kazuyoshi Hosaka
Koji Sonoyama
Masaaki Katayama
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of TW201030055A publication Critical patent/TW201030055A/en
Application granted granted Critical
Publication of TWI457368B publication Critical patent/TWI457368B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/1042Copolyimides derived from at least two different tetracarboxylic compounds or two different diamino compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/1075Partially aromatic polyimides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/1075Partially aromatic polyimides
    • C08G73/1078Partially aromatic polyimides wholly aromatic in the diamino moiety
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
    • C08L79/08Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Liquid Crystal (AREA)

Abstract

A liquid crystal aligning agent which is characterized by comprising a copolymer produced by reacting a diamine component with tetracarboxylic dianhydride, wherein the diamine component comprises a diamine compound (A) represented by formula [1], a diamine compound (B) represented by formula [2] and a diamine compound (C) having a carboxyl group in the molecule. [In formula [1], p represents an integer of 0 or 1; X1 represents a phenylene; X2 represents a phenylene or a cyclohexylene; X3 represents a cyclohexylene; and X4 represents an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. In formula [2], Y1 represents -O-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH2O-, -OCO-, -CON(CH3)- or -N(CH3)CO-; Y2 represents a single bond, an aliphatic hydrocarbon group having 1 to 20 carbon atoms, a non-aromatic cyclic hydrocarbon group, or an aromatic hydrocarbon group; Y3 represents a single bond, -O-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -COO-, -OCO-, -CON(CH3)-, -N(CH3)CO- or -O(CH2)m- (wherein m represents an integer of 1 to 5); Y4 represents a nitrogenated aromatic heterocyclic ring; and n represents an integer of 1 to 4.]

Description

201030055 六、發明說明: 【發明所屬之技術領域】 本發明係關於製作液晶配向膜時所使用的液晶配向處 理劑及使用其之液晶顯示元件。 【先前技術】 現今作爲液晶顯示元件之液晶配向膜,使用將塗佈將[Technical Field] The present invention relates to a liquid crystal alignment agent used in the production of a liquid crystal alignment film and a liquid crystal display element using the same. [Prior Art] Nowadays, as a liquid crystal alignment film of a liquid crystal display element, the coating will be used

_ 聚醯胺酸等聚醯亞胺前驅體或可溶性聚醯亞胺之溶液作爲 P 主成分的液晶配向處理劑後並燒成之所謂的聚醯亞胺系的 液晶配向膜爲主。 _ 作爲液晶配向膜所求特性之一,可將對於基板面之液 . 晶分子的配向傾斜角保持於任意値,有著所謂液晶之預傾 角控制。已知該預傾角之尺寸,可由選擇構成液晶配向膜 之聚醯亞胺的結構而變更。 藉由聚醯亞胺之結構控制預傾角的技術中,亦以將具 Φ 有側鏈之二胺作爲聚醯亞胺原料一部份使用的方法,因配 合該二胺之使用比率,預傾角會變大,故較容易控制目的 預傾角,作爲變大預傾角之手段爲有用。作爲使液晶之預 傾角變大之二胺的側鏈結構,已被提出含有類固醇骨架( 例如,參照專利文獻1 )、苯基或環己基等環結構(例如 ,參照專利文獻2 )者。且,將彼等環結構於側鏈上具有3 個至4個之二胺亦被提案出(例如,參照專利文獻3 )。 另一方面,液晶配向膜製作之步驟中,將聚醯胺酸的 溶液或溶劑可溶性聚醯亞胺之溶液塗佈於基板時,於工業 -5- 201030055 上一般可進行彈性印刷等,塗佈液之溶劑,除聚合物之溶 解性優良的N-甲基-2-吡咯烷酮或丁內酯等以外,亦以 形成均勻且無缺陷之薄膜爲目的下可混合丁基賽路蘇等。 然而,丁基賽路蘇等的溶劑因使聚醯胺酸或聚醯亞胺溶解 的能力差,故若多量混合時會有產生析出的問題(例如, 參照專利文獻4 )。特別爲溶劑可溶性聚醯亞胺之溶液中 ,該問題更爲顯著呈現。 又,如前述使用具有側鏈之二胺所得之聚醯亞胺,因 有著降低溶液之塗佈均勻性的傾向,故必須使丁基賽路蘇 等塗佈性改善溶劑之混合量增多,如此溶劑之混合可接受 量亦成爲聚醯亞胺之重要特性。 又,隨著液晶顯TfC元件之高精細化,由液晶顯示元件 之對比降低的抑制或殘像顯像之減低的觀點來看,於此所 使用之液晶配向膜中,電壓保持率亦高、或外加直流電壓 時的累積電荷較少,又藉由直流電壓所累積之殘留電荷的 緩和較快的特性逐漸重要。 聚醯亞胺系的液晶配向膜中,作爲經直流電壓所產生 的殘像至消失的時間較短者,除聚醯胺酸或含有亞胺基之 聚醯胺酸以外’已知使用含有特定結構之3級胺的液晶配 向處理劑(例如’參照專利文獻5 )、或使用將具有吡啶 骨架等之特定二胺使用於原料上之含有可溶性聚醯亞胺的 液晶配向處理劑者(例如’參照專利文獻6 )等爲已知。 又’作爲電壓保持率高,且經直流電壓所產生的殘像至消 失的時間較短者,除聚醯胺酸或其亞胺化聚合物等,已知 • 6 - 201030055 含有極少量的選自分子内含有1個羧酸基之化合物、分子 内含有1個羧酸酐基之化合物及分子内含有1個3級胺基之 化合物的液晶配向處理劑(例如’參照專利文獻7) ° 然而,近年來,大畫面且高精細之液晶電視已廣泛地 實用化,如此用途中之液晶顯示元件中,與以文字或靜止 畫爲主顯示之顯示器用途相比較,對殘像之要求更爲嚴格 ,且要求具有可耐住於過度嚴酷使用環境下的長期使用之 _ 特性。因此,所使用之液晶配向膜與過去相比,信賴性高 者更爲必要,要求有關液晶配向膜之電氣特性,不僅於初 期特性良好,例如高溫下經長時間曝光後,亦可維持良好 _ 特性者。 [先行技術文獻] [專利文獻] [專利文獻1]特開平4-281427號公報 φ [專利文獻2]特開平9-278724號公報 [專利文獻3]特開2004-67589號公報 [專利文獻4]特開平2_3 7324號公報 [專利文獻5 ]特開平9 _ 3丨6 2 〇 〇號公報 [專利文獻6]特開平i〇_1〇4633號公報 [專利文獻7]特開平8_76 1 28號公報 【發明內容】 [解決發明之課題] 201030055 本發明的目的爲提供一種液晶配向處理劑,其爲於液 晶配向處理劑之塗佈液中混合弱溶劑時不容易產生析出, 且具有使液晶之預傾角變大之特性,即使爲較少使用比率 下亦可使液晶於垂直方向進行配向,亦可得到電壓保持率 高,且即使於高溫下經長時間曝光後,經直流電壓所累積 之殘留電荷的緩和快速的液晶配向膜。且,本發明的目的 爲藉由使用該液晶配向處理劑,提供一種耐住過度嚴酷使 用環境下的長期使用之信賴性高的液晶顯示元件。_ A polyimine-based liquid crystal alignment film in which a solution of a polyimine precursor such as polyacrylamide or a solution of a soluble polyimine is used as a liquid crystal alignment agent of P as a main component and is fired. _ As one of the characteristics of the liquid crystal alignment film, the alignment tilt angle of the liquid crystal molecules on the substrate surface can be kept at any 値, and there is a so-called liquid crystal pretilt angle control. It is known that the size of the pretilt angle can be changed by selecting the structure of the polyimine which constitutes the liquid crystal alignment film. In the technique of controlling the pretilt angle by the structure of polyimine, a method in which a diamine having a side chain of Φ is used as a part of a polyimine raw material, a pretilt angle due to the use ratio of the diamine It will become larger, so it is easier to control the pretilt angle of the purpose, which is useful as a means to increase the pretilt angle. As a side chain structure of a diamine which increases the pretilt angle of the liquid crystal, a steroid skeleton (for example, see Patent Document 1), a ring structure such as a phenyl group or a cyclohexyl group (for example, see Patent Document 2) has been proposed. Further, it has also been proposed to have three to four diamines in the side chain of the ring structure (for example, refer to Patent Document 3). On the other hand, in the step of producing a liquid crystal alignment film, when a solution of a polyamic acid solution or a solvent-soluble polyimine solution is applied to a substrate, elastic printing or the like can be generally performed on Industrial-5-201030055, and coating is performed. The solvent of the liquid, in addition to N-methyl-2-pyrrolidone or butyrolactone having excellent solubility of the polymer, can also be mixed with butyl sarbuta for the purpose of forming a uniform and defect-free film. However, since the solvent such as butyl sulphate is inferior in the ability to dissolve polyglycine or polyimine, precipitation occurs when a large amount of the mixture is mixed (for example, refer to Patent Document 4). This problem is more pronounced especially in solutions of solvent soluble polyimine. Further, since the polyimine obtained by using the diamine having a side chain as described above tends to lower the uniformity of coating of the solution, it is necessary to increase the amount of the coating improving solvent such as butyl sarbuta. The acceptable amount of solvent mixture also becomes an important property of polyimine. Further, with the high definition of the liquid crystal display TfC element, the liquid crystal alignment film has a high voltage holding ratio from the viewpoint of suppression of reduction in contrast of the liquid crystal display element or reduction of afterimage development. It is more important that the accumulated charge is less when the DC voltage is applied, and the relaxation of the residual charge accumulated by the DC voltage is faster. In the polyimine-based liquid crystal alignment film, the shorter the time from the afterimage of the DC voltage to the disappearance, except for the poly-proline or the polyamine containing the imine group, the known use contains a specific A liquid crystal alignment treatment agent of a tertiary amine having a structure (for example, 'refer to Patent Document 5), or a liquid crystal alignment treatment agent containing a soluble polyimine using a specific diamine having a pyridine skeleton or the like (for example, ' Reference is made to Patent Document 6) and the like. In addition, as a high voltage holding ratio and a short time from the residual voltage to the disappearance of the DC voltage, in addition to poly-proline or its imidized polymer, it is known that • 6 - 201030055 contains a very small amount of selection. A liquid crystal alignment treatment agent containing a compound having one carboxylic acid group in the molecule, a compound containing one carboxylic acid anhydride group in the molecule, and a compound containing one tertiary amino group in the molecule (for example, 'see Patent Document 7). In recent years, large-screen and high-definition liquid crystal televisions have been widely put into practical use. In the liquid crystal display elements of such applications, the requirements for afterimages are more stringent than those of displays using text or still pictures as main displays. It is also required to have the characteristics of long-term use that can withstand harsh and harsh environments. Therefore, the liquid crystal alignment film used is more necessary than the past, and the electrical characteristics of the liquid crystal alignment film are required to be good not only in the initial characteristics, but also after a long time exposure at a high temperature. Characteristic. [PRIOR ART DOCUMENT] [Patent Document 1] Japanese Laid-Open Patent Publication No. Hei No. Hei. No. Hei. No. Hei. No. Hei. Japanese Laid-Open Patent Publication No. JP-A No. Hei. No. Hei. No. Hei. [Explanation of the Invention] [Resolution of the Invention] 201030055 An object of the present invention is to provide a liquid crystal alignment treatment agent which is less likely to cause precipitation when a weak solvent is mixed in a coating liquid of a liquid crystal alignment treatment agent, and has a liquid crystal The characteristic that the pretilt angle becomes large, even if the liquid crystal is aligned in the vertical direction at a low use ratio, a voltage retention ratio can be obtained, and the residual accumulated by the DC voltage even after exposure for a long time at a high temperature can be obtained. The charge is moderated by a fast liquid crystal alignment film. Further, an object of the present invention is to provide a liquid crystal display element which is highly resistant to long-term use in an environment of excessively severe use by using the liquid crystal alignment agent.

本發明者欲達到上述目的進行詳細硏究結果,發現可 達成此之新穎液晶配向處理劑。本發明係以該見解爲準者 ,具有以下要旨。 (1) 一種液晶配向處理劑,其特徵爲將含有下述式 〔1〕所示二胺化合物(A)、下述式〔2〕所示二胺化合 物(B)、分子内具有羧基之二胺化合物的二胺化合物(C )之二胺成分、與四羧酸二酐進行反應所得之共聚物者;The inventors of the present invention have conducted detailed investigations to achieve the above object, and have found that a novel liquid crystal alignment treatment agent can be achieved. The present invention is based on this finding and has the following gist. (1) A liquid crystal alignment treatment agent comprising a diamine compound (A) represented by the following formula [1], a diamine compound (B) represented by the following formula [2], and a carboxyl group in the molecule. a diamine component of the amine compound diamine compound (C) and a copolymer obtained by reacting with a tetracarboxylic dianhydride;

(式〔1〕中,P爲〇或1的整數,X!爲伸苯基,χ2爲伸苯基 或伸環己基,X3爲伸環己基,X4爲碳數3〜12的烷基、碳 數3〜12的氟烷基、碳數3〜12的烷氧基' 或碳數3〜12的 氟烷氧基。式〔2〕中,丫1爲-0-、-NH-、-N(CH3)-、 -CONH-、-NHCO-、-CH20-、-OCO·、-CON(CH3)-、或(In the formula [1], P is an integer of 〇 or 1, X! is a phenyl group, χ2 is a phenyl or cyclohexyl group, X3 is a cyclohexylene group, and X4 is an alkyl group having a carbon number of 3 to 12, carbon. a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms or a fluoroalkoxy group having 3 to 12 carbon atoms. In the formula [2], 丫1 is -0-, -NH-, -N (CH3)-, -CONH-, -NHCO-, -CH20-, -OCO·, -CON(CH3)-, or

-8- 201030055 -N(CH3)CO-,Υ2爲單鍵、碳數1〜20的脂肪族烴基、非芳 香族環式烴基、或芳香族烴基,Υ3爲單鍵、-〇-、-ΝΗ-、 -N(CH3)-、-CONH-、-NHCO-、-COO-、-OCO-、 -CON(CH3)-、-N(CH3)CO-、或- 〇(CH2)m-(tn爲 1 〜5的整數 ),Y4爲含氮芳香族雜環,η爲1〜4的整數。) (2)如上述(1)所記載之液晶配向處理劑,其中前 述二胺化合物(Α)爲下述式〔1’〕所示二胺化合物(Α·-8- 201030055 -N(CH3)CO-, Υ2 is a single bond, an aliphatic hydrocarbon group having 1 to 20 carbon atoms, a non-aromatic cyclic hydrocarbon group, or an aromatic hydrocarbon group, and Υ3 is a single bond, -〇-, -ΝΗ -, -N(CH3)-, -CONH-, -NHCO-, -COO-, -OCO-, -CON(CH3)-, -N(CH3)CO-, or - 〇(CH2)m-(tn An integer of 1 to 5), Y4 is a nitrogen-containing aromatic heterocyclic ring, and η is an integer of 1 to 4. (2) The liquid crystal alignment treatment agent according to the above (1), wherein the diamine compound (Α) is a diamine compound represented by the following formula [1'] (Α·

[化2][Chemical 2]

及χ4與前述式〔1〕同義。 (3 )如上述(1 )所記載之液晶配向處理劑,其中前 述二胺化合物(Α)爲下述式〔Γ’〕所示二胺化合物(Α1And χ4 is synonymous with the above formula [1]. (3) The liquid crystal alignment treatment agent according to the above (1), wherein the diamine compound (Α) is a diamine compound represented by the following formula [Γ'] (Α1)

[化3] [Γ] (式〔1’’〕中’ x’’^l,4-伸苯基或1,4-伸環己基,又',2爲 碳數3〜12的烷基、碳數3〜12的氟烷基、碳數3〜12的烷 氧基、或碳數3〜12的氟烷氧基。) (4 )如上述(2 )所記載之液晶配向處理劑,其中二 胺化合物(A')爲下述式〔1,a〕所示二胺化合物。 -9- 201030055 [化4][化3] [Γ] (in the formula [1''] 'x''^l, 4-phenylene or 1,4-cyclohexylene, and ', 2 is an alkyl group having a carbon number of 3 to 12, A fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. (4) The liquid crystal alignment treatment agent according to the above (2), wherein The diamine compound (A') is a diamine compound represented by the following formula [1, a]. -9- 201030055 [化4]

X5 ,X5,

(式〔l'a〕中,X5爲碳數3〜12的烷基、碳數3〜12的氟烷 基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基,I,4-伸環己基之順-反式異構性各爲反式異構物。) (5)如上述(2)所記載之液晶配向處理劑,其中二 胺化合物(Α’)爲下述式〔i'b〕所示二胺化合物。 [化5](In the formula [l'a], X5 is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. The cis-trans isomer of the thiol group, the cis-trans isomer is a trans isomer. (5) The liquid crystal alignment treatment agent according to the above (2), wherein the diamine compound (Α') It is a diamine compound represented by the following formula [i'b]. [Chemical 5]

(式〔l'b〕中,χ6爲碳數3〜12的烷基、碳數3〜12的氟 院基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基, 1,4-伸環己基的順-反式異構性爲反式異構物。) (6 )如上述(3 )所記載之液晶配向處理劑,其中二 胺化合物(Α”)爲下述式〔r,a〕所示二胺化合物。 -10- 201030055 [化6](In the formula [l'b], χ6 is an alkyl group having 3 to 12 carbon atoms, a fluorine-based group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. The cis-trans isomer of the 1,4-cyclohexylene group is a trans isomer. (6) The liquid crystal alignment treatment agent according to the above (3), wherein the diamine compound (Α) is A diamine compound represented by the following formula [r, a]. -10- 201030055 [Chemical 6]

Χ··3Χ··3

Era] (式〔l’’a〕中,X’’3爲碳數3〜12的烷基、碳數3〜12的氟 院基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基, ® 丨,4-伸環己基的順_反式異構性各爲反式異構物)。 (7)如上述(3)所記載之液晶配向處理劑,其中二 胺化合物(A'')爲下述式〔〗,,b〕所示二胺化合物。Era] (In the formula [l''a], X''3 is an alkyl group having 3 to 12 carbon atoms, a fluorine-based group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a carbon number of 3 The cis-trans isomers of -12 fluoroalkoxy, ® 丨, 4-cyclohexylene are each a trans isomer). (7) The liquid crystal alignment treatment agent according to the above (3), wherein the diamine compound (A'') is a diamine compound represented by the following formula [], b].

[化7][Chemistry 7]

(式〔l''b〕中’ X’’4爲碳數3〜12的烷基、碳數3〜12的氟 烷基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基, 1,4-伸環己基的順-反式異構性爲反式異構物)。 (8 )如上述(2 )〜(7 )中任一項所記載之液晶配 向處理劑’其中式〔2〕中之γ^·〇_、·ΝΗ_、_c〇NH_、 -NHCO-、-CON(CH3)-、或 _CH2〇_。 (9 )如上述(2 )〜(8 )中任一項所記載之液晶配 向處理劑’其中式〔2〕中之Y2爲單鍵、碳數1〜$的直鏈 -11 - 201030055 或分支院基、或苯環。 (10)如上述(2)〜(9)中任一項所記載之液晶配 向處理劑’其中式〔2〕中之γ3爲單鍵、-Ο-、-CONH-、 -NHCO-、_COO_、-oco-、或-〇((:1^2)„1-(111爲1〜5的整數 )° (11 )如上述(2 )〜(1 〇 )中任〜項所記載之液晶 配向處理劑,其中式〔2〕中之Y4爲吡咯環、咪唑環 '吡 哩環、吡陡環、或嘴陡環。 參 (1 2 )如上述(2 )〜(1 1 )中任一項所記載之液晶 配向處理劑’其中式〔2〕中之η爲1〜3的整數。 (1 3 )如上述(2 )〜(7 )中任一項所記載之液晶配 向處理劑,其中式〔2〕中之Υι爲- 〇-、-ΝΗ-、-CONH-、 -NHCO-、-CON(CH3)-、或-CH20-,Y2 爲碳數 i〜5的直鏈 或分支烷基,Y3爲單鍵,Y4爲吡咯環、咪唑環、卩比唑環、 吡啶環、或嘧啶環,η爲1〜3的整數。(In the formula [l''b], 'X''4 is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a carbon number of 3 to 12 The fluoroalkoxy group, the cis-trans isomer of 1,4-cyclohexylene is a trans isomer). (8) The liquid crystal alignment treatment agent according to any one of the above (2) to (7), wherein γ^·〇·, ΝΗ_, _c〇NH_, -NHCO-, -CON in the formula [2] (CH3)-, or _CH2〇_. (9) The liquid crystal alignment treatment agent according to any one of the above (2) to (8) wherein the Y2 in the formula [2] is a single bond, and the carbon number is 1 to $ linear -11 - 201030055 or a branch Hospital base, or benzene ring. (10) The liquid crystal alignment treatment agent according to any one of the above (2) to (9) wherein γ3 in the formula [2] is a single bond, -Ο-, -CONH-, -NHCO-, _COO_, -oco-, or -〇((:1^2)„1-(111 is an integer of 1 to 5)° (11) The liquid crystal alignment treatment as described in any one of the above (2) to (1) The Y4 in the formula [2] is a pyrrole ring, an imidazole ring 'pyridinium ring, a pyridyl ring, or a mouth steep ring. The reference (1 2 ) is as described in any one of the above (2) to (1 1 ). In the liquid crystal alignment treatment agent of the above formula (2), the liquid crystal alignment treatment agent according to any one of the above (2) to (7), wherein 2] Υι is - 〇-, -ΝΗ-, -CONH-, -NHCO-, -CON(CH3)-, or -CH20-, Y2 is a linear or branched alkyl group having a carbon number of i~5, Y3 Is a single bond, and Y4 is a pyrrole ring, an imidazole ring, a pyridazole ring, a pyridine ring, or a pyrimidine ring, and η is an integer of 1 to 3.

〇4)如上述(2)〜(7)中任一項所記載之液晶配 向處理劑,其中式〔2〕中的Υ^-〇-、-ΝΗ-、-CONH.、 -NHCO-、-C〇N(CH3)_、或-CH20-,丫2爲苯環,丫3爲 、-CONH-、-NHC〇-、-C〇0_、〇c〇-、或-〇(CH2)m_ (爪爲 1〜5的整數),Y4爲啦略環、咪唑環、吡唑環、吡陡環、 或嘧啶環,η爲1的整數。 (15 )如上述( 配向處理劑,其中二 胺化合物。 2 )〜(1 4 )中任一項所記載之液晶 胺化含物(C)爲下述式〔3〕所示二 -12- [3] 201030055 [化8] (c〇〇H)k h2n〆 1、nh2 (式〔3〕中,Z】爲具有碳數6〜30的芳香族環之有機基, k爲1〜4的整數。) (1 6 )如上述(1 5 )所記載之液晶配向處理劑,其中 〔3〕的二胺化合物爲選自下述式〔3a〕、式〔3b〕、式 〔3〇〕、式〔3<1〕及式〔3e〕所成群之至少1種的二胺化 合物。The liquid crystal alignment treatment agent according to any one of the above aspects (2), wherein Υ^-〇-, -ΝΗ-, -CONH., -NHCO-, - in the formula [2] C〇N(CH3)_, or -CH20-, 丫2 is a benzene ring, 丫3 is, -CONH-, -NHC〇-, -C〇0_, 〇c〇-, or -〇(CH2)m_ ( The claw is an integer of 1 to 5), and Y4 is a Rachel ring, an imidazole ring, a pyrazole ring, a pyridyl ring, or a pyrimidine ring, and η is an integer of 1. (15) The liquid crystal amination content (C) according to any one of the above formula (3), wherein the liquid crystal amination content (C) according to any one of the above formulas (3) is a -12- [3] 201030055 [c8] (c〇〇H)k h2n〆1, nh2 (in the formula [3], Z] is an organic group having an aromatic ring having 6 to 30 carbon atoms, and k is 1 to 4 The liquid crystal alignment treatment agent according to the above (1), wherein the diamine compound of [3] is selected from the following formula [3a], formula [3b], and formula [3]. At least one type of diamine compound of the formula [3<1] and the formula [3e].

[化9][Chemistry 9]

[3e] (式〔3a〕中’ m丨爲ι〜4的整數。式〔孙〕中,匕爲[3e] (in the formula [3a], m丨 is an integer of ι~4. In the formula [孙], 匕

C(CH3)2- ' -CF2- ' -C(CF3)- ' -o-、-CO-、_NH_、N(CH3)、 -OCH 單鍵、-ch2.、_c2H4_、… CONH-、-NHCO-、-CH20-、 2-、-coo—、_oc〇·、_c〇N(CH3)、或 _n(cH3)c〇, m2及各表示0〜4的整數,且m2 + m3表示1〜4的整數。式 -13- 201030055 〔3c〕中,m4及m5各爲1〜5的整數。式〔3d〕中,Z3爲碳 數1〜5的直鏈或分支烷基,1116爲1〜5的整數。式〔3e〕中 ,Z4爲單鍵、-CH2-、-C2H4-、-C(CH3)2-、-CF2-、 -C(CF〇-、-Ο-、-CO-、-NH-、-N(CH3)-、-CONH-、 -NHCO-、-CH20-、-OCH2-、-COO-、-OCO-、-CON(CH3)-、或-N(CH3)CO-,m7爲1〜4的整數。) (1 7 )如上述(1 6 )所記載之液晶配向處理劑,其中 式〔3a〕中,1^爲1〜2的整數。 φ (1 8 )如上述(1 6 )所記載之液晶配向處理劑,其中 式〔3b〕中 ’ Z2爲單鍵、_(:112-、-(:2114-、-€((:113)2-、-0-、-CO-、-NH-、-N(CH3)-、-CONH-、-NHCO-、-COO-、 或- OCO-,m2及m3同時爲1的整數。 (1 9 )如上述(1 6 )所記載之液晶配向處理劑,其中 式〔3e〕中 ’ Z4爲單鍵、-CH2-、-Ο-、-CO-、-NH-、 -CONH-、-NHCO-、-CH2〇-、-〇CH2-、-COO-、或-OCO-, m7爲1〜2的整數。 參 (2〇 )如上述(2 )〜(1 9 )中任一項所記載之液晶 配向處理劑’其中二胺成分中,二胺化合物(A)對於二 胺化合物(C)之1莫耳而言爲〇5〜5〇莫耳,二胺化合物 (B)對於二胺化合物(C)之1莫耳而言爲〇 5〜1〇莫耳。 (2 1 )如上述(2 )〜(2〇 )中任一項所記載之液晶 配向處理劑’其中液晶配向處理劑中含有5〜7〇質量%之弱 溶劑。 (22 )如上述(2 )〜(2 1 )中任一項所記載之液晶 -14- 201030055 配向處理劑’其中液晶配向處理劑中之共聚物爲使聚 酸進行脫水閉環而得之聚醯亞胺。 (23) —種液晶配向膜,其特徵爲使用如上述 〜(22 )中任一項所記載之液晶配向處理劑所得者。 (24 ) —種液晶顯示元件,其特徵爲具有上述( 所記載之液晶配向膜者。 [發明之效果] 本發明的液晶配向處理劑可由比較簡便之方法得 作爲液晶配向膜時,具有使液晶之預傾角變大之特性 使以較少使用比率亦可將液晶於垂直方向進行配向。 又,於液晶配向處理劑的塗佈液中混合弱溶劑時 不容易產生析出,故塗佈於大型基板上時,亦可形成 液晶配向膜。 且,亦可得到電壓保持率高,且即使於高溫下長 φ 曝光後,經直流電壓所累積的殘留電荷之緩和快速之 配向膜。因此,具有由本發明之液晶配向處理劑所得 晶配向膜的液晶顯示元件,可適用於信賴性優良、大 下高精細之液晶電視上等。 [實施發明之形態] 以下對於本發明作詳細説明。 本發明爲含有將二胺化合物(A)、二胺化合物( 及二胺化合物(C)之二胺成分與四羧酸二酐進行反 醯胺 :2 ) 23 ) 到, ,即 ,因 均勻 時間 液晶 之液 畫面 應所 -15- 201030055 得之共聚物的液晶配向處理劑、使用該液晶配向處理劑所 得之液晶配向膜、進一步爲具有該液晶配向膜之液晶顯示 元件。 此時,二胺化合物(A)爲式〔1〕所示二胺化合物, 二胺化合物(B )爲式〔2〕所示二胺化合物’二胺化合物 (C)爲分子内具有羧基之二胺化合物。 本發明所使用的二胺化合物(A )爲,具有於側鏈上 具有使預傾角變大之特性的取代基之特定二胺(以下亦稱 爲特定二胺(A ))。 因此,使用該特定二胺(A)所得之液晶配向處理劑 爲,即使於特定二胺(A )爲較低使用比率下亦可使液晶 於垂直方向進行配向。又,藉由使該使用比率變少,聚合 物之有機溶劑溶解性會變大,即使於液晶配向處理劑之塗 佈液中混合弱溶劑時亦不容易產生析出現象。 本發明所使用的二胺化合物(B )(以下亦稱爲特定 二胺(B))爲側鏈上具有含氮芳香族雜環。該含氮芳香 族雜環因藉由該共軛結構可作爲電荷跳躍側之功能,故液 晶配向膜中,可促進電荷之移動。且,該含氮芳香族雜環 爲,與二胺化合物(C)(以下亦稱爲特定二胺(C))所 具有之羧基’以鹽形成或所謂氫鍵之靜電相互作用而結合 ,故羧基與含氮芳香族雜環之間會引起電荷移動。因此, 移動至含氮芳香族雜環部位的電荷可有效率地移動於共聚 物之分子内、分子間。 藉由上述’本發明的液晶配向處理劑作爲液晶配向膜 -16- 201030055 時,具有使液晶之預傾角變大之特性,即使於較少使用比 率下亦可使液晶於垂直方向進行配向。又,於液晶配向處 理劑之塗佈液中混合弱溶劑時,亦不容易產生析出。且, 可得到電壓保持率高且即使於高溫下長時間曝光後,經直 流電壓所累積之殘留電荷的緩和快速的液晶配向膜。 以下對於本發明所使用的化合物類作説明。C(CH3)2- '-CF2- '-C(CF3)- '-o-, -CO-, _NH_, N(CH3), -OCH single bond, -ch2., _c2H4_,... CONH-, -NHCO -, -CH20-, 2-, -coo-, _oc〇·, _c〇N(CH3), or _n(cH3)c〇, m2 and each represent an integer from 0 to 4, and m2 + m3 represents 1~ An integer of 4. Formula -13- 201030055 In [3c], m4 and m5 are each an integer of 1 to 5. In the formula [3d], Z3 is a linear or branched alkyl group having 1 to 5 carbon atoms, and 1116 is an integer of 1 to 5. In the formula [3e], Z4 is a single bond, -CH2-, -C2H4-, -C(CH3)2-, -CF2-, -C(CF〇-, -Ο-, -CO-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH20-, -OCH2-, -COO-, -OCO-, -CON(CH3)-, or -N(CH3)CO-, m7 is 1 (1) The liquid crystal alignment treatment agent according to the above (1), wherein, in the formula [3a], 1 is an integer of 1 to 2. Φ (1 8 ) The liquid crystal alignment treatment agent according to the above (16), wherein in the formula [3b], 'Z2 is a single bond, _(: 112-, -(:2114-, -€((:113)) 2-, -0-, -CO-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -COO-, or -OCO-, m2 and m3 are integers of 1 at the same time. (9) The liquid crystal alignment treatment agent according to the above (1), wherein in the formula [3e], 'Z4 is a single bond, -CH2-, -Ο-, -CO-, -NH-, -CONH-, -NHCO -, -CH2〇-, -〇CH2-, -COO-, or -OCO-, m7 is an integer of 1 to 2. The reference (2〇) is as described in any one of the above (2) to (1 9). The liquid crystal alignment treatment agent 'in the diamine component, the diamine compound (A) is 〇5 to 5 〇mol for 1 mol of the diamine compound (C), and the diamine compound (B) is for the diamine compound. (1) The liquid crystal alignment treatment agent described in any one of the above (2) to (2), wherein the liquid crystal alignment treatment agent is in the liquid crystal alignment treatment agent. (2) The liquid crystal-14-201030055 as described in any one of the above (2) to (2 1), wherein the alignment treatment agent The copolymer in the treatment agent is a polyimine obtained by dehydration ring closure of the polyacid. (23) A liquid crystal alignment film characterized by using the liquid crystal alignment according to any one of the above-mentioned (22). (24) A liquid crystal display device having the liquid crystal alignment film described above. [Effect of the Invention] The liquid crystal alignment treatment agent of the present invention can be obtained as a liquid crystal alignment film by a relatively simple method. In the case where the pretilt angle of the liquid crystal is increased, the liquid crystal can be aligned in the vertical direction at a low use ratio. Further, when the weak solvent is mixed in the coating liquid of the liquid crystal alignment treatment agent, precipitation is unlikely to occur. When applied to a large substrate, a liquid crystal alignment film can also be formed, and a high voltage holding ratio can be obtained, and even after exposure at a high temperature for a long φ exposure, the residual charge accumulated by the DC voltage is relaxed and the alignment film is quickly formed. Therefore, the liquid crystal display element having the crystal alignment film obtained by the liquid crystal alignment treatment agent of the present invention can be applied to a liquid crystal television having excellent reliability, large and high definition, and the like. BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be described in detail below. The present invention contains a ruthenium amine containing a diamine compound (A), a diamine compound (and a diamine component of the diamine compound (C) and a tetracarboxylic dianhydride: 2) 23), that is, a liquid crystal alignment treatment agent obtained by using a liquid crystal alignment treatment agent obtained by using a liquid crystal alignment treatment agent of a copolymer obtained by a liquid crystal screen of a uniform time, -15-201030055, and further having the liquid crystal alignment Liquid crystal display element of the film. In this case, the diamine compound (A) is a diamine compound represented by the formula [1], and the diamine compound (B) is a diamine compound represented by the formula [2]. The diamine compound (C) has a carboxyl group in the molecule. Amine compound. The diamine compound (A) used in the present invention is a specific diamine (hereinafter also referred to as a specific diamine (A)) having a substituent having a property of increasing the pretilt angle in the side chain. Therefore, the liquid crystal alignment agent obtained by using the specific diamine (A) can align the liquid crystal in the vertical direction even when the specific diamine (A) is at a lower use ratio. Further, by reducing the use ratio, the solubility of the organic solvent of the polymer is increased, and even when a weak solvent is mixed in the coating liquid of the liquid crystal alignment agent, precipitation is unlikely to occur. The diamine compound (B) (hereinafter also referred to as a specific diamine (B)) used in the present invention has a nitrogen-containing aromatic heterocyclic ring in a side chain. Since the nitrogen-containing aromatic heterocyclic ring functions as a charge jump side by the conjugated structure, the liquid crystal alignment film promotes the movement of charges. Further, the nitrogen-containing aromatic heterocyclic ring is bonded to the carboxyl group of the diamine compound (C) (hereinafter also referred to as a specific diamine (C)) by a salt interaction or a so-called hydrogen bond electrostatic interaction. A charge shift is caused between a carboxyl group and a nitrogen-containing aromatic heterocyclic ring. Therefore, the charge moved to the nitrogen-containing aromatic heterocyclic moiety can be efficiently moved in the intramolecular or intermolecular phase of the copolymer. When the liquid crystal alignment treatment agent of the present invention is used as the liquid crystal alignment film -16-201030055, the liquid crystal alignment angle is increased, and the liquid crystal can be aligned in the vertical direction even at a low usage ratio. Further, when a weak solvent is mixed in the coating liquid of the liquid crystal alignment agent, precipitation does not easily occur. Further, a liquid crystal alignment film having a high voltage holding ratio and a rapid relaxation of the residual electric charge accumulated by the DC voltage even after long-time exposure at a high temperature can be obtained. The compounds used in the present invention are explained below.

<二胺化合物(A ) > 本發明所使用的二胺化合物(A)爲下述式〔1〕所示 二胺化合物。 [化 10]<Diamine compound (A) > The diamine compound (A) used in the present invention is a diamine compound represented by the following formula [1]. [化10]

式〔1〕中,式〔1〕中,P爲0或1的整數,X!爲伸苯 基’較佳爲1,4-伸苯基,X2爲伸苯基,較佳爲1,4-伸苯基 '或伸環己基伸苯基,較佳爲1,4-伸環己基,X3爲伸環己 基伸苯基,較佳爲I,4-伸環己基。伸苯基及伸環己基、視 必要可具有取代基。X4爲碳數3〜12的烷基、碳數3〜12的 氣院基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基。 燒基、氟烷基、烷氧基、及氟烷氧基可爲直鏈狀或分 $狀’以直鏈狀爲佳,又亦可具有取代基。 〜胺化合物(A)中’以下述式〔1,〕所示二胺化合 物(A,)、或下述式〔1,,〕所示二胺化合物(A,,)爲佳。 -17- 201030055 [化11]In the formula [1], in the formula [1], P is an integer of 0 or 1, X! is a phenylene group, preferably a 1,4-phenylene group, and X2 is a phenylene group, preferably 1,4. - Stretching phenyl' or a cyclohexyl extended phenyl group, preferably 1,4-cyclohexylene, and X3 is a cyclohexyl extended phenyl group, preferably an I, 4-cyclohexylene group. The phenyl group and the cyclohexylene group may have a substituent. X4 is an alkyl group having 3 to 12 carbon atoms, a gas-base group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. The alkyl group, the fluoroalkyl group, the alkoxy group, and the fluoroalkoxy group may be linear or in a linear form, and may preferably have a linear form or a substituent. The amine compound (A) is preferably a diamine compound (A) having the following formula [1,] or a diamine compound (A,) represented by the following formula [1,]. -17- 201030055 [化11]

[化 12][化 12]

以下對於二胺化合物(A')及二胺化合物(A")作説 明。 <二胺化合物(A') > 本發明所使用的二胺化合物(A’)爲下述式〔1’〕所 示二胺化合物。 [化 13]Hereinafter, the diamine compound (A') and the diamine compound (A") will be described. <Diamine compound (A') > The diamine compound (A') used in the present invention is a diamine compound represented by the following formula [1']. [Chem. 13]

(式〔1’〕中,Χι、x2、x3、及又4與前述式〔1〕同義。 ) 式〔1'〕中的胺基所結合之苯環中之胺基的結合位置 並無限定。作爲具體例,可舉出對於側鏈之結合基( -CH2O-) ’本環上之2,3位置、2,4位置、2,5位置、2,6位 置、3,4位置、3,5位置。其中由合成聚醯胺酸時的反應性 觀點來看’以2,4位置、2,5位置、3,5位置爲佳。若再考慮 到二胺化合物合成之容易性,以2,4位置、或2,5位置爲佳 201030055 式〔1’〕的二胺化合物中,亦以下述式〔i,a〕及式〔 l'b〕所示二胺化合物因可於較少使用比率下使液晶之預傾 角變大的效果較大故較佳。特別爲式〔l,a〕所示二胺因該 效果優異,故更佳。 [化 14](In the formula [1'], Χι, x2, x3, and 4 are synonymous with the above formula [1]. The binding position of the amine group in the benzene ring to which the amine group in the formula [1'] is bonded is not limited. . Specific examples include a binding group for a side chain (-CH2O-) '2, 3 positions, 2, 4 positions, 2, 5 positions, 2, 6 positions, 3, 4 positions, 3 on the ring. 5 positions. Among them, from the viewpoint of reactivity in synthesizing polyamic acid, it is preferable to use 2, 4 position, 2, 5 position, and 3, 5 position. If the ease of synthesis of the diamine compound is further considered, the diamine compound of the formula [1'] in the 2,4 position or the 2,5 position is preferably the following formula [i, a] and formula [1] The diamine compound represented by 'b' is preferred because it has a large effect of increasing the pretilt angle of the liquid crystal at a low use ratio. Particularly, the diamine represented by the formula [l, a] is more preferable because it is excellent in the effect. [Chem. 14]

式〔l'a〕中之X5爲碳數3〜12的烷基、碳數3〜12的氟 烷基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基。其 中,X5以碳數3〜12的烷基或碳數3〜12的氟烷基爲佳,較 佳爲碳數3〜12的烷基,特佳爲碳數3〜7的烷基。且,式 〔1'a〕中之1,4-伸環己基之順-反式異構性以各反式異構 物爲佳。 ® [化 15]X5 in the formula [l'a] is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. . Among them, X5 is preferably an alkyl group having 3 to 12 carbon atoms or a fluoroalkyl group having 3 to 12 carbon atoms, more preferably an alkyl group having 3 to 12 carbon atoms, particularly preferably an alkyl group having 3 to 7 carbon atoms. Further, the cis-trans isomerism of the 1,4-cyclohexylene group in the formula [1'a] is preferably a trans-isomer. ® [Chem. 15]

式〔l’b〕中之X6爲碳數3〜12的烷基、碳數3〜12的 氟烷基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基。 其中亦以X4爲碳數3〜12的烷基或碳數3〜12的氟烷基爲佳 -19 - 201030055 ’較佳爲碳數3〜12的烷基,特佳爲碳數3〜7的烷基。且 ’式〔l’b〕中之1,4-伸環己基的順-反式異構性以反式異 構物爲佳。 本發明的式〔Γ〕所示二胺化合物之較佳具體例爲下 述式〔1、〕〜式〔l’f〕所示二胺化合物。且,下述式中 之X5〜X8各獨立爲碳數3〜12的烷基、碳數3〜12的氟烷基 、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基。其中亦 以X5〜X8各獨立爲碳數3〜12的烷基或碳數3〜12的氟烷基 爲佳,較佳爲碳數3〜12的烷基,特佳爲碳數3〜7的烷基 。又,下述式中之1,4-伸環己基的順-反式異構性各皆爲反 式異構物。 -20- 201030055X6 in the formula [l'b] is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. . Wherein X4 is an alkyl group having a carbon number of 3 to 12 or a fluoroalkyl group having a carbon number of 3 to 12, preferably -19 - 201030055 ', preferably an alkyl group having a carbon number of 3 to 12, particularly preferably a carbon number of 3 to 7. Alkyl. Further, the cis-trans isomerism of the 1,4-cyclohexylene group in the formula [l'b] is preferably a trans isomer. A preferred specific example of the diamine compound represented by the formula [Γ] of the present invention is a diamine compound represented by the following formula [1] to the formula [l'f]. Further, X5 to X8 in the following formula are each independently an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluorine having 3 to 12 carbon atoms. Alkoxy. Further, X5 to X8 are each independently an alkyl group having 3 to 12 carbon atoms or a fluoroalkyl group having 3 to 12 carbon atoms, preferably an alkyl group having 3 to 12 carbon atoms, particularly preferably having a carbon number of 3 to 7. Alkyl. Further, the cis-trans isomerism of the 1,4-cyclohexylene group in the following formula is each a trans isomer. -20- 201030055

[化 16][Chemistry 16]

製造式〔Γ〕所示二胺化合物之方法特無特別限定, 但作爲較佳方法可舉出以下方法。 [化Π]The method for producing the diamine compound of the formula [Γ] is not particularly limited, but a preferred method is as follows. [Π化]

-21 - 201030055 合成上述式〔l,g〕之二硝基化合物,係由以一般方法 將硝基還原變換爲胺基後得到。作爲還原二硝基化合物之 方法並無特別限制,一般將鈀-碳、氧化鉑、雷氏鎳、鉑 黑、铑-氧化鋁、硫化鉑碳等作爲觸媒使用,於乙酸乙酯 、甲苯、四氫呋喃、二噁烷、醇系等溶劑中,藉由氫氣、 肼、氯化氫等進行還原之方法。式〔l'g〕中之X!、χ2、 X3、及X4與式〔1〕所定義者相同。 式〔l'g〕之二硝基化合物可由下述式〔l'h〕所示含 有羥基之化合物與二硝基氯苯等之反應而得到。且,式〔 l'h〕中之Χι、Χ2、χ3、及x4與式〔1〕所定義者相同。 [化 18] ΗΟ-Χ广Χ2-Χ3-Χ4 [1Ή] 製造式〔l’h〕所示含有羥基之化合物之方法,可藉由 下述反應式(1)、或反應式(2)所示方法而製造,本發 明並未受到這些限定》 X2爲1,4_伸環己基時,可舉出反應式(1)之合成途徑 。反應式(1 )中之X,、X3、及X4與式〔1〕所定義者相同 ’ Ri表不甲基或苯甲基等保護基,R2表示]VIgBr、MgCl或 Li等。 作爲使用於脫水反應之試劑。可舉出鹽酸或硫酸等無 機酸類、P-甲苯磺酸等有機酸類、乙酸酐或三氟乙酸酐等 酸酐類等。 作爲還原反應,可使用將鈀(Pd )或鉑(Pt )等作爲 觸媒的氫化反應、或使用鐵、錫或鋅等金屬的接觸還原反 -22- 201030055 應等。 作爲脫保護基之反應,可舉出使用三溴化硼(BBr3 ) 之甲基的脫離反應、或使用Pd觸媒等之經氫化的脫苯甲基 化反應等。-21 - 201030055 The dinitro compound of the above formula [1, g] is synthesized by subjecting a nitro group to an amine group by a general method. The method for reducing the dinitro compound is not particularly limited, and generally, palladium-carbon, platinum oxide, nickel-plated nickel, platinum black, rhodium-alumina, and platinum sulfide carbon are used as a catalyst, and ethyl acetate and toluene are used. A method of reducing by hydrogen, helium, hydrogen chloride or the like in a solvent such as tetrahydrofuran, dioxane or an alcohol. X!, χ2, X3, and X4 in the formula [l'g] are the same as those defined in the formula [1]. The dinitro compound of the formula [l'g] can be obtained by reacting a compound having a hydroxyl group represented by the following formula [l'h] with dinitrochlorobenzene or the like. Further, Χι, Χ2, χ3, and x4 in the formula [ l'h] are the same as those defined in the formula [1]. ΗΟ-Χ广Χ 2-Χ3-Χ4 [1Ή] The method of producing a compound having a hydroxyl group represented by the formula [l'h] can be carried out by the following reaction formula (1) or reaction formula (2) The invention is produced by the method, and the present invention is not limited thereto. When X2 is 1,4_cyclohexylene, the synthetic route of the reaction formula (1) can be mentioned. X, X3, and X4 in the reaction formula (1) are the same as those defined in the formula [1]. ‘R represents a protecting group such as a methyl group or a benzyl group, and R2 represents a group VIgBr, MgCl or Li. As a reagent used in the dehydration reaction. Examples thereof include inorganic acids such as hydrochloric acid and sulfuric acid, organic acids such as P-toluenesulfonic acid, and acid anhydrides such as acetic anhydride or trifluoroacetic anhydride. As the reduction reaction, a hydrogenation reaction using palladium (Pd) or platinum (Pt) or the like as a catalyst or contact reduction using a metal such as iron, tin or zinc can be used. The reaction of the deprotection group may be a desorption reaction using a methyl group of boron tribromide (BBr3) or a debenzylation reaction using a hydrogenation such as a Pd catalyst.

[化 19][Chem. 19]

[Vh-a] Cl'h-c] 脫水[Vh-a] Cl'h-c] dehydration

還原 [fh-d]Restore [fh-d]

[l’h-β] 脫保護基[l'h-β] deprotection group

X4 Crh-f] 反應式⑴ X2爲1,4-伸苯基時,可舉出反應式(2)之合成途徑。 反應式(2)中之X^Xs、及X4與式〔1〕所定義者相同, 心表示甲基或苯甲基等保護基,T2表示鹵素原子、甲磺醯 氧基、苯磺醯氧基 '三氟甲磺醯氧基、B(OH)2、MgBr、 M gCl或Li等,T3表示鹵素原子、甲磺醯氧基、苯磺醯氧基 、三氟甲磺醯氧基、Β(ΟΗ)2、MgBr、MgCl或Li等。 作爲脫保護基之反應,可舉出使用ΒΒγ3的甲基之脫離 反應或使用Pd觸媒等藉由氫化之脫苯甲基化反應等。 -23- 201030055 [化 20] Τι/〇νχΓΤ2 [1'h-g]X4 Crh-f] Reaction Formula (1) When X2 is a 1,4-phenylene group, a synthetic route of the reaction formula (2) can be mentioned. X^Xs and X4 in the reaction formula (2) are the same as defined in the formula [1], the heart represents a protecting group such as a methyl group or a benzyl group, and T2 represents a halogen atom, a methanesulfonyloxy group, a benzenesulfonyloxy group. a 'trifluoromethanesulfonyloxy group, B(OH)2, MgBr, MGCl or Li, etc., T3 represents a halogen atom, a methanesulfonyloxy group, a benzenesulfonyloxy group, a trifluoromethanesulfonyloxy group, an anthracene (ΟΗ) 2, MgBr, MgCl or Li, and the like. The reaction of the deprotection group may be a desorption reaction using a methyl group of ΒΒγ3 or a debenzylation reaction by hydrogenation using a Pd catalyst or the like. -23- 201030055 [化 20] Τι/〇νχΓΤ2 [1'h-g]

Tl^cTXlTl^cTXl

Crh-i] xrX4 脫保護基 HO〆Crh-i] xrX4 deprotection group HO〆

x4 [Vh-j] χΓX4 [Vh-j] χΓ

反應式⑵ <二胺化合物(A’1 ) > 本發明所使用的二胺化合物(A,,)爲下述式〔1"〕所 示二胺化合物。 [化 21]Reaction Formula (2) <Diamine Compound (A'1) > The diamine compound (A,) used in the present invention is a diamine compound represented by the following formula [1". [Chem. 21]

式〔1”〕中,又”丨爲I,4-伸苯基或1,4-伸環己基。1,4-伸苯基及1,4-伸環己基視必要可具有取代基。χι’2爲碳數3 〜12的垸基、碳數3〜12的氟院基、碳數3〜12的院氧基、 或碳數3〜12的氟烷氧基。烷基、氟烷基、烷氧基、及氟 烷氧基可爲直鏈狀或分支狀,但以直鏈狀爲佳,亦可具有 取代基。 式〔Γ'〕中之胺基所結合的苯環中之胺基的結合位置 並無限定。作爲具體例,可舉出對於側鏈之結合基(-ο- α - 201030055 ),苯環上的2,3位置、2,4位置、2,5位置、2,6位置、3,4 位置、3,5位置。其中由合成聚醯胺酸時的反應性之觀點 來看’以2,4位置、2,5位置、3,5位置爲佳。若再考慮到二 胺化合物之合成的容易性,以2,4位置、或2,5位置爲佳。 式〔I1'〕的二胺化合物中,乂^爲1,4-反式-伸環己基 之下述式〔l,,a〕及式〔l,,b〕所示二胺化合物,於較少使 率下可使液晶的預傾角變大之效果較大故較佳。特別In the formula [1"], "丨" is I, 4-phenylene or 1,4-cyclohexylene. The 1,4-phenylene group and the 1,4-cyclohexylene group may have a substituent as necessary. Χι'2 is a fluorenyl group having 3 to 12 carbon atoms, a fluorine-based group having 3 to 12 carbon atoms, a tertiary oxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. The alkyl group, the fluoroalkyl group, the alkoxy group, and the fluoroalkoxy group may be linear or branched, but may be linear or may have a substituent. The binding position of the amine group in the benzene ring to which the amine group in the formula [Γ'] is bonded is not limited. Specific examples include a binding group for a side chain (-ο-α - 201030055), a 2, 3 position, a 2, 4 position, a 2, 5 position, a 2, 6 position, and a 3, 4 position on the benzene ring. , 3, 5 position. Among them, from the viewpoint of reactivity in synthesizing poly-proline, 'the position of 2, 4, 2, 5, and 3, 5 is preferable. In view of the ease of synthesis of the diamine compound, it is preferred to use a 2, 4 position or a 2, 5 position. In the diamine compound of the formula [I1'], the diamine compound represented by the following formula [l, a] and the formula [l, b] is a 1,4-trans-cyclohexylene group. It is preferable that the effect of increasing the pretilt angle of the liquid crystal at a small rate is large. particular

爲式〔l,’a〕所示二胺化合物之效果優異而更佳。 [化 22]The effect of the diamine compound represented by the formula [l, 'a] is excellent and more preferable. [化22]

式〔1" a〕中之X,'3爲碳數3〜12的烷基、碳數3〜12的 氟院基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基。 其中以X',3爲碳數3〜12的烷基或碳數3〜12的氟烷基爲佳 ’較佳爲碳數3〜12的烷基,特佳爲碳數3〜7的烷基。且 ’式〔l,,a〕中之1,4-伸環己基的順-反式異構性以各反式 異構物爲佳》 [化 23ϋX in the formula [1" a, '3 is an alkyl group having 3 to 12 carbon atoms, a fluorine-based group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or fluorine having a carbon number of 3 to 12 Alkoxy. Wherein X', 3 is an alkyl group having 3 to 12 carbon atoms or a fluoroalkyl group having 3 to 12 carbon atoms; preferably an alkyl group having 3 to 12 carbon atoms, particularly preferably an alkyl group having 3 to 7 carbon atoms. base. And the cis-trans isomerism of the 1,4-cyclohexylene group in the formula [l,, a] is preferably a trans-isomer.

-25- 201030055 氣院基、碳 其中以χΊ ,較佳爲碳 ,式〔l',b〕 構物爲佳。 本發明 述式〔1 ’’c〕 之 X,,5 〜X,,* 基、碳數3〜 亦以X''5 ~ > 烷基爲佳, 烷基。又, 爲反式異構 數3〜I2的烷氧基、或碳數3〜12的氟烷氧基。 爵碳數3〜12的烷基或碳數3〜12的氟烷基爲佳 數3〜12的烷基,特佳爲碳數3〜7的烷基。且 中之1,4-伸環己基的順-反式異構性以反式異 @式〔1"〕所示二胺化合物之較佳具體例爲下 至式〔l"f〕所示二胺化合物。且,下述式中 t各獨立爲碳數3〜12的烷基、碳數3〜12的氟烷 -12的烷氧基、或碳數3〜12的氟烷氧基。其中 各獨立爲碳數3〜12的烷基或碳數3〜12的氟 較佳爲碳數3〜12的烷基,特佳爲碳數3〜7的 下述式中之1,4-伸環己基的順-反式異構性各全 物。 -26- 201030055-25- 201030055 Gas base, carbon It is better to use χΊ, preferably carbon, formula [l', b]. The X, 5, X, and * groups of the formula [1 ''c] of the present invention, and the carbon number of 3 to X are preferably X''5 ~ > alkyl groups, and alkyl groups. Further, it is an alkoxy group having a trans isomer number of 3 to 12 or a fluoroalkoxy group having a carbon number of 3 to 12. The alkyl group having 3 to 12 carbon atoms or the fluoroalkyl group having 3 to 12 carbon atoms is preferably an alkyl group having 3 to 12 carbon atoms, particularly preferably an alkyl group having 3 to 7 carbon atoms. And the cis-trans isomerism of the 1,4-extended cyclohexyl group is as shown in the formula [1"f] in the preferred embodiment of the diamine compound represented by the trans-formula [1" Amine compound. Further, in the following formula, t each independently represents an alkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms of fluoroalkane-12, or a fluoroalkoxy group having 3 to 12 carbon atoms. The alkyl group independently having a carbon number of 3 to 12 or the fluorine having a carbon number of 3 to 12 is preferably an alkyl group having 3 to 12 carbon atoms, particularly preferably having a carbon number of 3 to 7 in the following formula: 1,4- The cis-trans isomerism of the cyclohexyl group is extended. -26- 201030055

[化 24][Chem. 24]

製造式〔1 ''〕所示二胺化合物之方法並無特別限定, 作爲較佳方法可舉出以下方法。 [化 25]The method for producing the diamine compound represented by the formula [1 ''] is not particularly limited, and a preferred method is as follows. [Chem. 25]

Crg] x"2 合成上述式〔r’g〕之二硝基化合物,以一般方法還 原硝基轉換成胺基而得到。還原二硝基化合物之方法並無 -27- 201030055 特別限制,一般將鈀-碳、氧化鉑、雷氏鎳、鉑黑、铑-氧 化鋁、硫化鉑碳等作爲觸媒使用,於乙酸乙酯、甲苯、四 氫呋喃、二噁烷、醇系等溶劑中,藉由氫氣、肼、氯化氫 等進行還原之方法。式〔l,,g〕中之X、、及X’'2與式〔1,, 〕所定義者相同。 式〔l’’g〕的二硝基化合物可由下述式〔l"h〕所示含 有羥基之化合物與二硝基氯苯等之反應得到。且,式〔 r'h〕中之X"】、及Χ·’2與式〔1"〕所定義者相同。Crg] x" 2 The dinitro compound of the above formula [r'g] is synthesized and converted into an amine group by a general method. The method for reducing the dinitro compound is not limited to -27-201030055. Generally, palladium-carbon, platinum oxide, nickel-plated nickel, platinum black, ruthenium-alumina, and platinum sulfide carbon are used as catalysts in ethyl acetate. A method of reducing by hydrogen, helium, hydrogen chloride or the like in a solvent such as toluene, tetrahydrofuran, dioxane or an alcohol. X, and X''2 in the formula [l, g] are the same as those defined in the formula [1,]. The dinitro compound of the formula [l''g] can be obtained by reacting a compound having a hydroxyl group represented by the following formula [1 " h] with dinitrochlorobenzene or the like. Further, X"] and Χ·'2 in the formula [r'h] are the same as those defined in the formula [1"].

製造式〔r'h〕所示含有羥基之化合物之方法,可由 下述反應式(1)或反應式(2)所示方法製造,但本發明 並未限定於此。 Χ"ι爲1,4-伸環己基時,可舉出反應式(1)之合成途 徑。反應式(1 )中之X"2與式〔1’’〕所定義者相同,1表 示甲基或苯甲基等之保護基,R2表示MgBr、MgCl或Li等 〇 作爲使用於脫水反應之試劑,可舉出鹽酸或硫酸等# 機酸類、P-甲苯磺酸等有機酸類、乙酸酐或三氟乙酸肝等 酸酐類等。 作爲還原反應,可舉出將鈀(Pd)或鈾(pt)等作爲 觸媒使用的氫化反應、或使用鐵、錫或幹等金屬之接觸還 原反應等。 -28- 201030055 作爲脫保護基之反應’可舉出使用三溴化硼(BBr3) 的甲基之脫離反應、或使用Pd觸媒等藉由氫化之脫苯甲基 化反應等。 [化 27]The method for producing a compound having a hydroxyl group represented by the formula [r'h] can be produced by the following reaction formula (1) or the reaction formula (2), but the present invention is not limited thereto. When Χ"ι is 1,4-cyclohexylene, the synthetic route of the reaction formula (1) can be mentioned. X"2 in the reaction formula (1) is the same as defined in the formula [1''], 1 represents a protecting group such as a methyl group or a benzyl group, and R2 represents a hydrazine such as MgBr, MgCl or Li as a dehydration reaction. Examples of the reagent include organic acids such as hydrochloric acid and sulfuric acid, organic acids such as P-toluenesulfonic acid, and acid anhydrides such as acetic anhydride or trifluoroacetic acid. The reduction reaction may be a hydrogenation reaction using palladium (Pd) or uranium (pt) or the like as a catalyst, or a contact reduction reaction using a metal such as iron, tin or dry. -28-201030055 The reaction of the deprotection group is a decarboxylation reaction using a methyl group of boron tribromide (BBr3) or a debenzylation reaction by hydrogenation using a Pd catalyst or the like. [化27]

反應式⑴ 又,|1爲1,4-伸苯基時,可舉出反應式(2)之合成途徑 。反應式(2)中之X"2與式〔1"〕所定義者相同’ h表示 甲基或苯甲基等保護基,T2表示鹵素原子、甲磺醯氧基、 苯磺醯氧基、三氟甲磺醯氧基、B(0H)2、MgBr、MgC1或 Li等,T3表示鹵素原子、甲磺醯氧基、苯磺醯氧基、三氟 甲磺醯氧基、B(OH)2、MgBr、MgCl或Li等。 作爲脫保護基之反應’可舉出使用ΒΒΓ3之甲基的脫離 反應或使用Pd觸媒等藉由氫化之脫苯甲基化反應等。 -29 - 201030055 [化 28]In the reaction formula (1), when |1 is a 1,4-phenylene group, the synthesis route of the reaction formula (2) can be mentioned. X"2 in the reaction formula (2) is the same as defined in the formula [1"], h represents a protecting group such as a methyl group or a benzyl group, and T2 represents a halogen atom, a methanesulfonyloxy group, a benzenesulfonyloxy group, Trifluoromethanesulfonyloxy, B(0H)2, MgBr, MgC1 or Li, etc., T3 represents a halogen atom, a methanesulfonyloxy group, a benzenesulfonyloxy group, a trifluoromethanesulfonyloxy group, and a B(OH) group. 2. MgBr, MgCl or Li, etc. The reaction of the deprotection group is exemplified by a desorption reaction using a methyl group of ruthenium 3 or a debenzylation reaction by hydrogenation using a Pd catalyst or the like. -29 - 201030055 [化 28]

<二胺化合物(B ) > 本發明所使用的二胺化合物(B)爲下述式〔2〕所示<Diamine compound (B) > The diamine compound (B) used in the present invention is represented by the following formula [2]

[化 29][化29]

[2][2]

式〔2〕中,丫】爲-〇-、-NH-、-N(CH3)-、-CONH-、 -NHCO-、-CH20-、-OCO-、-CON(CH3)-、或-N(CH3)CO- ,Y2爲單鍵、碳數1〜20的脂肪族烴基、非芳香族環式烴 基、或芳香族烴基’ Υ3爲單鍵、-Ο-、-ΝΗ-、-N(CH3)-、 -CONH·、-NHCO-、-COO-、-OCO-、-CON(CH3)-、 -N(CH3)CO-、或- 〇(CH2)m- ( m爲 1 〜5的整數)’ Y4 爲含氣 芳香族雜環,η爲1〜4的整數。 式〔2〕中之2個胺基(-ΝΗ2 )之結合位置並未限定。 具體可舉出對於側鏈之結合基(γι) ’苯環上之2,3位虞 -30- 201030055 、2,4位置、2,5位置、2,6位置、3,4位置、3,5位置。其中 ’由合成聚醯胺酸時的反應性之觀點來看,以2,4位置、 2,5位置、3,5位置爲佳。再考慮到合成二胺化合物時的容 易性’以2,4位置、或2,5位置爲更佳。 式〔2〕中,丫】爲-〇-、-NH-、-N(CH3)-、-CONH-、 -NHCO-、-CH2〇-、-OCO- ' -CON(CH3)-、或-N(CH3)C〇-。其中以-〇·、-NH-、-CONH-、-NHCO-、-CON(CH3)-、 -CH20-、或-OCO-容易合成二胺化合物故較佳。特佳爲、 -Ο- ' -NH- ' -CONH- ' -NHCO- ' -CON(CH3>- ' ^ -CH2〇-〇 式〔2〕中,Y2爲單鍵、碳數1〜20的脂肪族烴基、非 芳香族環式烴基、或芳香族烴基。碳數1〜20的脂肪族烴 基可爲直鏈狀、或分支狀、亦可具有不飽和鍵。較佳爲碳 數1〜10的脂肪族烴基。作爲非芳香族烴基之具體例,可 舉出環丙烷環、環丁烷環、環戊烷環、環己烷環、環庚烷 環、環辛烷環、環壬烷環、環癸烷環、環十一烷環、環十 二烷環、環十三烷環、環十四烷環、環十五烷環、環十六 烷環、環十七烷環、環十八烷環、環十九烷環、環二十院 環、三環二十院環、三環二十二烷環、雙環庚烷環、十氫 萘環、原菠烯環、金剛烷環等。 作爲芳香族烴基之具體例,可舉出苯環、萘環、四氫 萘環、奧環、茚環、芴環、蒽環、菲環、非那烯環等。 式〔2〕中作爲較佳Y2’可舉出單鍵、碳數丄〜^的直 鏈或分支伸烷基、碳數1〜10的不飽和伸烷基、環丙院環 201030055 、環丁烷環、環戊烷環、環己烷環、環庚烷環、原菠烯環 、金剛烷環、苯環、萘環、四氫萘環、芴環、蒽環,較佳 爲單鍵、碳數1〜10的直鏈或分支烷基、碳數1〜10的不飽 和烷基、環己烷環、原菠烯環、金剛烷環、苯環、萘環、 芴環、蒽環,更佳爲單鍵、碳數1〜10的直鏈或分支烷基 、環己烷環、苯環、萘環,特佳爲單鍵、碳數1〜5的直鏈 或分支烷基、苯環。 式〔2〕中,Y3 爲單鍵、-ο-、-NH-、-N(CH3)-、 -CONH-、-NHCO-、-COO-、-OCO-、-CON(CH3)_、 -N(CH3)CO-、或- 0(CH2)m-(m爲1〜5的整數),較佳爲單 鍵、-0-、-NH-、-CONH-、-NHCO·、-COO-、-OCO-、或 -0((^2)1„-(111爲1〜5的整數),更佳爲單鍵、-0-、-:^11-、-C Ο N Η -、- N H C Ο -、- C Ο 〇 - ' - 0 c Ο -、或-0 ( c Η 2 ) m - ( m 爲 1〜5的整數),特佳爲單鍵、-〇·、-CONH-、-NHCO-、 -C00-、-0C0-、或- 0(CH2)m-(m爲 1 〜5的整數)。 式〔2〕中,Y4爲含氮芳香族雜環,含有選自下述式 〔2a〕、式〔2b〕、及式〔2c〕所成群之至少1個結構的 含氮芳香族雜環。 [化 30] /N—Α·| [2a] [2b] [2c] (式〔2c〕中,Ai爲碳數1〜5的直鏈或分支烷基)。 作爲前述含氮芳香族雜環,具體可舉出吡咯環、咪唾 -32- 201030055 環、噁唑環、噻唑環、吡唑環、吡啶環、嘧啶環、喹啉( quinoline)環、吡唑啉環、異喹啉環、咔唑環、嘌呤環、 噻二唑環、噠嗪環、吡唑啉環、三嗪環、吡唑啉烷環、三 哩環、啦嗪環、苯甲咪唑環、苯並咪唑環、喹啉( chinoline)環、菲繞啉環、吲哚環、喹喔啉環、苯並噻唑 環、吩噻嗪環、螺二哩環、叱η定環等。 式〔2〕中,作爲較佳γ4,可舉出吡咯環、咪唑環、 噁唑環、噻唑環、吡唑環、吡啶環、嘧啶環、喹啉( quinoline)環、吡唑啉環、異喹啉環、咔唑環、嘌呤環、 噻二唑環、噠嗪環、吡唑啉環、三嗪環、吡唑啉烷環、三 唑環、吡嗪環、苯甲咪唑環、苯並咪唑環、喹啉( chinoline)環、菲繞啉環、吲哚環、喹喔啉環、苯並噻唑 環、吩噻嗪環、噁二唑環、吖啶環,較佳爲吡咯環、咪唑 環、吡唑環、吡啶環、嘧啶環、吡唑啉環、昨唑環、噠嗪 環、吡唑啉環' 三嗪環、吡唑啉烷環、三唑環、吡嗪環、 苯甲咪唑環、苯並咪唑環,更佳爲吡咯環、咪唑環、吡唑 環、卩it D定環、喃陡環、噠嗪環、三嗪環、三π坐環、耻嗪環 、苯甲咪唑環、苯並咪唑環,特佳爲吡咯環、咪唑環,吡 唑環、吡啶環、嘧啶環。 又,Y3結合於不與Y4所含之式〔2a〕、式〔2b〕、及 式〔2c〕鄰接的取代基爲佳。 式〔2〕中,η爲1〜4的整數,由與四羧酸二酐之反應 性的觀點來看,以1〜3爲佳。 式〔2〕中之較佳Υ!、Υ2、Υ3、Υ4、及η之組合爲,Υ! -33- 201030055 爲-Ο-、-NH-、-CONH-、-NHCO-、-CON(CH3)-、-CH2〇- 、或- OCO-’ Y2爲碳數l〜10的直鏈或分支烷基、碳數1〜 10的不飽和院基、環丙烷環、環丁烷環、環戊烷環、環己 烷環、環庚烷環、原菠烯環、金剛烷環、苯環、萘環、四 氫萘環、芴環、或蒽環,γ3爲單鍵、-〇-、-]^11-、-(:0>^- 、-NHCO-、-C〇〇_、-〇c〇_、或 _〇(CH2)m_(m爲 1 〜5的整 數)’Y4爲吡咯環、咪唑環、噁唑環、噻唑環、吡唑環、 口比陡環、嘧陡環、喹啉(quinoline)環、啦哩啉環、異喹 啉環、咔唑環、嘌呤環、噻二唑環、噠嗪環、吡唑啉環、 三嗪環、吡唑啉烷環、三唑環、吡嗪環、苯甲咪唑環、苯 並咪唑環、喹啉(chinoline )環、菲繞啉環、吲哚環、喹 喔啉環、苯並噻唑環、吩噻嗪環、噁二唑環、或吖啶環, η爲1〜2。 較佳爲式〔2〕中之L、γ2、Υ3、Υ4、及η的組合爲, Υι 爲-〇-、-NH-、-CONH-、-NHCO-、-CH20-、或-OCO-, Y2爲碳數1〜10的直鏈或分支烷基、碳數1〜10的不飽和院 基、環己院環、原疲稀環、金剛院環、苯環、萘環、苟環 、或蒽環,Υ3 爲單鍵、-〇-、-NH-、-CONH-、-NHCO-、 -COO-、-OCO-、或- 〇(CH2)m- (m爲 1 〜5的整數),Y4 爲 吡咯環、咪唑環、吡唑環 '吡啶環、嘧啶環、吡唑啉環、 咔唑環、噠嗪環、吡唑啉環、三嗪環、吡唑啉烷環、 環、吡嗪環、苯甲咪唑環、或苯並咪唑環’ η爲1〜2。 更佳之式〔2〕中之Υ,、Υ2、Υ3、Υ4、及η的組合爲, Υι 爲-Ο-、-NH-、-CONH …-NHCO-、-CON(CH3)-、 201030055 -CH20-、或- OCO-,γ2爲碳數1〜10的直鏈或分支烷基、 環己烷環、苯環、或萘環,γ3爲單鍵、-〇_、-C〇NH-、 -NHCO-、_C00_、-OCO-、或- 〇(CH2)m-(m爲 1 〜5的整數 ),丫4爲啦略環、咪唑環、吡唑環、吡啶環、嘧啶環、噠 嚷環、三曉環、三唑環、吡嗪環、苯甲咪唑環、或苯並咪 唑環,η爲1或2 °In the formula [2], 丫] is -〇-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH20-, -OCO-, -CON(CH3)-, or -N (CH3)CO-, Y2 is a single bond, an aliphatic hydrocarbon group having 1 to 20 carbon atoms, a non-aromatic cyclic hydrocarbon group, or an aromatic hydrocarbon group 'Υ3 is a single bond, -Ο-, -ΝΗ-, -N(CH3) )-, -CONH·, -NHCO-, -COO-, -OCO-, -CON(CH3)-, -N(CH3)CO-, or -〇(CH2)m- (m is an integer from 1 to 5) ) Y4 is a gas-containing aromatic heterocyclic ring, and η is an integer of 1 to 4. The binding position of the two amine groups (-ΝΗ2) in the formula [2] is not limited. Specifically, a binding group for a side chain (γι), 2, 3 positions on the benzene ring, -30-201030055, 2, 4 positions, 2, 5 positions, 2, 6 positions, 3, 4 positions, 3, 5 positions. Among them, the position of 2, 4 position, 2, 5 position, and 3, 5 is preferable from the viewpoint of reactivity in synthesizing polyamic acid. Further, it is considered that the ease of synthesizing the diamine compound is more preferably 2, 4 positions or 2, 5 positions. In the formula [2], 丫] is -〇-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH2〇-, -OCO- '-CON(CH3)-, or - N(CH3)C〇-. Among them, a diamine compound is preferably synthesized by -?, -NH-, -CONH-, -NHCO-, -CON(CH3)-, -CH20-, or -OCO-. Particularly preferred, -Ο- '-NH- ' -CONH- ' -NHCO- ' -CON(CH3>- ' ^ -CH2〇-〇[2], Y2 is a single bond, carbon number 1~20 An aliphatic hydrocarbon group, a non-aromatic cyclic hydrocarbon group or an aromatic hydrocarbon group. The aliphatic hydrocarbon group having 1 to 20 carbon atoms may be linear or branched, or may have an unsaturated bond. Preferably, the carbon number is 1 to 10. The aliphatic hydrocarbon group. Specific examples of the non-aromatic hydrocarbon group include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, and a cyclodecane ring. , cyclodecane ring, cycloundecane ring, cyclododecane ring, cyclotridecane ring, cyclotetradecane ring, cyclopentadecane ring, cyclohexadecane ring, cycloheptadecane ring, ring ten Octacyclo ring, cyclopentadecane ring, ring 20 yard ring, tricyclic 20th ring, tricyclotetracosane ring, bicycloheptane ring, decahydronaphthalene ring, raw spinel ring, adamantane ring, etc. Specific examples of the aromatic hydrocarbon group include a benzene ring, a naphthalene ring, a tetrahydronaphthalene ring, an anthracene ring, an anthracene ring, an anthracene ring, an anthracene ring, a phenanthrene ring, a phenalylene ring, and the like. Preferably, Y2' can be exemplified by a single bond, a carbon number ^~^ Or branched alkyl, unsaturated alkyl 1 to 10, cyclopropyl ring 201030055, cyclobutane ring, cyclopentane ring, cyclohexane ring, cycloheptane ring, raw spinel ring, diamond An alkane ring, a benzene ring, a naphthalene ring, a tetrahydronaphthalene ring, an anthracene ring, an anthracene ring, preferably a single bond, a linear or branched alkyl group having 1 to 10 carbon atoms, an unsaturated alkyl group having 1 to 10 carbon atoms, a cyclohexane ring, a raw spinylene ring, an adamantane ring, a benzene ring, a naphthalene ring, an anthracene ring, an anthracene ring, more preferably a single bond, a linear or branched alkyl group having a carbon number of 1 to 10, a cyclohexane ring, a benzene ring or a naphthalene ring, particularly preferably a single bond, a linear or branched alkyl group having a carbon number of 1 to 5, or a benzene ring. In the formula [2], Y3 is a single bond, -ο-, -NH-, -N ( CH3)-, -CONH-, -NHCO-, -COO-, -OCO-, -CON(CH3)_, -N(CH3)CO-, or -0(CH2)m-(m is 1~5 Integer), preferably a single bond, -0-, -NH-, -CONH-, -NHCO·, -COO-, -OCO-, or -0((^2)1„-(111 is 1~5 Integer), more preferably a single bond, -0-, -:^11-, -C Ο N Η -, - NHC Ο -, - C Ο 〇- ' - 0 c Ο -, or -0 ( c Η 2) m - ( m is an integer from 1 to 5), particularly preferably a single bond, -〇·, -CONH- -NHCO-, -C00-, -0C0-, or - 0(CH2)m- (m is an integer of 1 to 5). In the formula [2], Y4 is a nitrogen-containing aromatic heterocyclic ring, and is selected from the group consisting of the following A nitrogen-containing aromatic heterocyclic ring having at least one structure of the group of the formula [2a], the formula [2b], and the formula [2c]. [Chemical Formula 30] /N-Α·| [2a] [2b] [2c] (In the formula [2c], Ai is a linear or branched alkyl group having 1 to 5 carbon atoms). Specific examples of the nitrogen-containing aromatic heterocyclic ring include a pyrrole ring, a pyrene-32-201030055 ring, an oxazole ring, a thiazole ring, a pyrazole ring, a pyridine ring, a pyrimidine ring, a quinoline ring, and a pyrazole. Phytol ring, isoquinoline ring, indazole ring, anthracene ring, thiadiazole ring, pyridazine ring, pyrazoline ring, triazine ring, pyrazolidine ring, triterpene ring, oxazine ring, benzazole Ring, benzimidazole ring, chinoline ring, phenanthroline ring, anthracene ring, quinoxaline ring, benzothiazole ring, phenothiazine ring, spirobifluorene ring, 叱η ring and the like. In the formula [2], preferred examples of γ4 include a pyrrole ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyrazole ring, a pyridine ring, a pyrimidine ring, a quinoline ring, a pyrazoline ring, and a different form. Quinoline ring, indazole ring, anthracene ring, thiadiazole ring, pyridazine ring, pyrazoline ring, triazine ring, pyrazolin ring, triazole ring, pyrazine ring, benzimidazole ring, benzo Imidazole ring, chinoline ring, phenanthroline ring, anthracene ring, quinoxaline ring, benzothiazole ring, phenothiazine ring, oxadiazole ring, acridine ring, preferably pyrrole ring, imidazole Ring, pyrazole ring, pyridine ring, pyrimidine ring, pyrazoline ring, azole ring, pyridazine ring, pyrazoline ring 'triazine ring, pyrazolidine ring, triazole ring, pyrazine ring, benzophenone Imidazole ring, benzimidazole ring, more preferably pyrrole ring, imidazole ring, pyrazole ring, 卩it D ring, mute ring, azine ring, triazine ring, tris(s) ring, azoazine ring, benzene The imidazole ring and the benzimidazole ring are particularly preferably a pyrrole ring, an imidazole ring, a pyrazole ring, a pyridine ring or a pyrimidine ring. Further, Y3 is bonded to a substituent which is not adjacent to the formula [2a], the formula [2b], and the formula [2c] contained in Y4. In the formula [2], η is an integer of from 1 to 4, and from the viewpoint of reactivity with tetracarboxylic dianhydride, it is preferably from 1 to 3. The combination of the preferred Υ!, Υ2, Υ3, Υ4, and η in the formula [2] is Υ! -33- 201030055 is -Ο-, -NH-, -CONH-, -NHCO-, -CON(CH3 )-, -CH2〇-, or - OCO-' Y2 is a linear or branched alkyl group having a carbon number of 1 to 10, an unsaturated mechanical group having a carbon number of 1 to 10, a cyclopropane ring, a cyclobutane ring, and a cyclopentane. An alkane ring, a cyclohexane ring, a cycloheptane ring, a raw spinylene ring, an adamantane ring, a benzene ring, a naphthalene ring, a tetrahydronaphthalene ring, an anthracene ring, or an anthracene ring, γ3 is a single bond, -〇-, - ]^11-, -(:0>^-, -NHCO-, -C〇〇_, -〇c〇_, or _〇(CH2)m_(m is an integer from 1 to 5) 'Y4 is a pyrrole ring , imidazole ring, oxazole ring, thiazole ring, pyrazole ring, oral ratio steep ring, pyrimidine ring, quinoline ring, porphyrin ring, isoquinoline ring, indazole ring, anthracene ring, thiadipine Oxazole ring, pyridazine ring, pyrazoline ring, triazine ring, pyrazolidine ring, triazole ring, pyrazine ring, benzimidazole ring, benzimidazole ring, quinoline ring, phenanthroline a ring, an anthracene ring, a quinoxaline ring, a benzothiazole ring, a phenothiazine ring, an oxadiazole ring, or an acridine ring, and η is 1 to 2. Preferably, it is in the formula [2]. The combination of L, γ2, Υ3, Υ4, and η is, Υι is -〇-, -NH-, -CONH-, -NHCO-, -CH20-, or -OCO-, and Y2 is a straight carbon number of 1 to 10. Chain or branched alkyl, unsaturated 1 to 10 carbon, ring ring, original weak ring, diamond ring, benzene ring, naphthalene ring, anthracene ring, or anthracene ring, Υ 3 is a single bond, - 〇-, -NH-, -CONH-, -NHCO-, -COO-, -OCO-, or - 〇(CH2)m- (m is an integer from 1 to 5), Y4 is a pyrrole ring, an imidazole ring, a pyrene An azole ring 'pyridine ring, pyrimidine ring, pyrazoline ring, oxazole ring, pyridazine ring, pyrazoline ring, triazine ring, pyrazolidine ring, ring, pyrazine ring, benzimidazole ring, or benzene And the imidazole ring 'η is 1 to 2. More preferably, the combination of Υ, Υ2, Υ3, Υ4, and η in the formula [2] is, Υι is -Ο-, -NH-, -CONH ...-NHCO-, -CON(CH3)-, 201030055 -CH20-, or - OCO-, γ2 is a linear or branched alkyl group having a carbon number of 1 to 10, a cyclohexane ring, a benzene ring, or a naphthalene ring, and γ3 is a single bond, - 〇_, -C〇NH-, -NHCO-, _C00_, -OCO-, or - 〇(CH2)m- (m is an integer from 1 to 5), 丫4 is a Raleigh ring, an imidazole ring, a pyrazole ring Pyridine ring, pyrimidine , Pyridazine ring cried, Xiao three ring, a triazole ring, a pyrazine ring, an imidazole ring benzyl, or benzimidazole ring, [eta] is 1 or 2 °

特佳式〔2〕中之γι、γ2、Υ3、Υ4、及η的組合爲’ Yi 爲-◦·、-NH-、-C〇NH-、-NHCO-、-CON(CH3)_、或 -ch2o-,Y2爲單鍵、碳數1〜5的直鏈或分支烷基、苯環, γ3 爲單鍵、_ 〇 -、- C Ο Ν Η -、- N H C Ο -、- C Ο 〇 -、- 〇 c 〇 -、或 -0(CH2)m- 爲1〜5的整數)’ Υ4爲啦略環、咪哩環、口比 嗖環、吡啶環、或嘧陡環,η爲1〜3。 最好式〔2〕中之γι、Υ2、Υ3、Υ4、及η的組合爲下述 表1〜表8所示。The combination of γι, γ2, Υ3, Υ4, and η in the special formula [2] is ' Yi is -◦·, -NH-, -C〇NH-, -NHCO-, -CON(CH3)_, or -ch2o-, Y2 is a single bond, a linear or branched alkyl group having a carbon number of 1 to 5, a benzene ring, γ3 is a single bond, _ 〇-, -C Ο Ν Η -, - NHC Ο -, - C Ο 〇 -, - 〇c 〇-, or -0(CH2)m- is an integer from 1 to 5)' Υ4 is a slightly ring, a oxime ring, a 嗖 ring, a pyridine ring, or a pyrimidine ring, η is 1 ~3. Preferably, the combination of γι, Υ2, Υ3, Υ4, and η in the formula [2] is as shown in the following Tables 1 to 8.

-35- 201030055 [表η Υι Υ2 Υ3 Υ4 A-1 -Ο- 碳數1〜5的直鏈或分支烷基 單鍵 吡咯環 A-2 -Ο- 碳數1〜5的直鏈或分支院基 單鍵 咪唑環 A-3 -ο- 碳數1〜5的直鏈或分支烷基 單鍵 吡唑環 A-4 -ο- 碳數1〜5的直鏈或分支烷基 單鍵 咖定環 A-5 -0- 碳數1〜5的直鏈或分支烷基 單鍵 嘧啶環 A-6 -ΝΗ- 碳數1〜5的直鏈或分支烷基 單鍵 吡咯環 A-7 -ΝΗ- 碳數1〜5的直鏈或分支烷基 單鍵 咪唑環 A-8 -ΝΗ- 碳數1〜5的直鏈或分支烷基 單鍵 吡唑環 A-9 -ΝΗ- 碳數1〜5的直鏈或分支烷基 單鍵 耻陡環 A-10 -ΝΗ- 碳數1〜5的直鏈或分支烷基 單鍵 嘧啶環 A-11 -CONH- 碳數1〜5的直鏈或分支烷基 單鍵 吡略環 A-12 -CONH- 碳數1~5的直鏈或分支烷基 單鍵 咪唑環 A-13 -CONH- 碳數1〜5的直鏈或分支烷基 單鍵 吡唑環 A-14 -CONH- 碳數1〜5的直鏈或分支烷基 單鍵 口比陡環 A-15 -CONH- 碳數1〜5的直鏈或分支烷基 單鍵 嘧啶環 A-16 -NHCO- 碳數1〜5的直鏈或分支烷基 單鍵 吡咯環 A-17 -NHCO- 碳數1~5的直鏈或分支烷基 單鍵 咪唑環 A-18 -NHCO- 碳數1〜5的直鏈或分支烷基 單鍵 吡唑環 A-19 -NHCO- 碳數1〜5的直鏈或分支烷基 單鍵 _ 吡啶環 A-20 -NHCO- 碳數1〜5的直鏈或分支烷基 單鍵 嘧啶環 表2] Υι Y2 γ3 Υ4 Α-21 -ch2o- 碳數1~5的直鏈或分支烷基 單鍵 吡咯環 Α-22 -ch2o- 碳數1〜5的直鏈或分支烷基 單鍵 咪唑環 Α-23 -ch2o- 碳數1〜5的直鏈或分支烷基 單鍵 吡唑環 Α-24 -ch2o- 碳數1〜5的直鏈或分支烷基 單鍵 吡啶環 Α-25 -ch2o- 碳數1~5的直鏈或分支烷基 單鍵 嘧啶環 Α-26 -con(ch3)- 碳數1〜5的直鏈或分支烷基 單鍵 吡咯環 Α-27 -CON(CH3)- 碳數1〜5的直鏈或分支烷基 單鍵 咪唑環 Α-28 -con(ch3)- 碳數1~5的直鏈或分支烷基 單鍵 吡唑環 Α-29 -con(ch3)- 碳數1〜5的直鏈或分支烷基 單鍵 啦症環 Α-30 -CON(CH3)- 碳數1〜5的直鏈或分支烷基 單鍵 嘧陡環 201030055 [表3] Yi Y2 Y3 Y4 A-31 -0- 苯環 吡咯環 A-32 -0- 苯環 咪唑環 A-33 -0- 苯環 吡唑環 A-34 -0- 苯環 吡陡環 A-35 -0- 苯環 -C0NH- 嘧啶環 A-36 -0- 苯環 -CONH- 吡咯環 A-37 -0- 苯環 -C0NH- 咪唑環 A-38 -0- 苯環 -C0NH- 吡唑環 A-39 -0 苯環 -NHC0- 吡啶環 A-40 -0- 苯環 -NHC0- 嘧聢環 A-41 -0- 苯環 -NHCO- 吡咯環 A-42 苯環 -NHC0- 咪唑環 A-43 苯環 -COO- 吡唑環 A-44 苯環 -COO- 吡啶環 A-45 苯環 -COO- 嘧啶環 A-46 -0- 苯環 -COO- 吡咯環 A-47 苯環 -0C0- 咪唑環 A-48 苯環 -OCO- 吡嗖環 A-49 -0- 苯環 -OCO- 吡陡環 A-50 -o- 苯環 -OCO- 嘧啶環 A-51 -0- 苯環 -0-(CH2)m- (m:l~5 之整數) 吡咯環 A-52 -0- 苯環 -0-(CH2)m- (m:l〜5 之整數) 咪唑環 A-53 -0- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 吡唑環 A-54 -o- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 吡症環 A-55 -NH- 苯環 -0- 吡咯環 A-56 -NH- 苯環 咪唑環 A-57 -NH- 苯環 -0- 吡唑環 A-58 -NH- 苯環 -0- 吡啶環 A-59 -NH- 苯環 -CONH- 嘧啶環 A-60 -NH- 苯環 -CONH- 吡咯環 -37- 201030055 表4]-35- 201030055 [Table η Υι Υ2 Υ3 Υ4 A-1 -Ο- Linear or branched alkyl single bond pyrrole ring A-2 -Ο - Carbon number 1~5 straight chain or branch Single-bonded imidazole ring A-3 -ο- straight or branched alkyl single bond pyrazole ring A-4 -ο- carbon number 1~5 straight or branched alkyl single bond Ring A-5 -0- straight or branched alkyl single bond pyrimidine ring A-6 -ΝΗ - carbon number 1~5 straight or branched alkyl single bond pyrrole ring A-7 -ΝΗ - a linear or branched alkyl single bond of a carbon number of 1 to 5, an imidazole ring A-8 - fluorene - a linear or branched alkyl group having a carbon number of 1 to 5, a pyrazole ring A-9 - ΝΗ - a carbon number of 1 5 linear or branched alkyl single bond shaky steep ring A-10 - ΝΗ - carbon number 1 to 5 linear or branched alkyl single bond pyrimidine ring A-11 -CONH- carbon number 1 to 5 linear or Branched alkyl single bond pyridine ring A-12 -CONH- linear or branched alkyl single bond imidazole ring A-13 -CONH- straight or branched alkyl single bond having 1 to 5 carbon atoms Pyrazole ring A-14 -CONH- a straight or branched alkyl single bond having a carbon number of 1 to 5 than a steep ring A-15 -CONH- a straight or branched alkyl single bond having 1 to 5 carbon atoms Pyrimidine ring A-16 -NHCO- straight or branched alkyl single bond pyrrole ring A-17 -NHCO- having a carbon number of 1 to 5 straight or branched alkyl single bond imidazole ring A-18 - NHCO- linear or branched alkyl single bond pyrazole ring A-19 -NHCO- having a carbon number of 1 to 5, straight or branched alkyl single bond having 1 to 5 carbon atoms _ pyridine ring A-20 -NHCO- carbon number 1 to 5 linear or branched alkyl single bond pyrimidine ring 2] Υι Y2 γ3 Υ4 Α-21 -ch2o- straight or branched alkyl single bond pyrrole Α-22 -ch2o- carbon having 1 to 5 carbon atoms 1 to 5 linear or branched alkyl single bond imidazole ring Α-23 -ch2o- straight or branched alkyl single bond pyrazole ring Α-24 -ch2o- carbon number 1 to 5 Linear or branched alkyl single bond pyridine ring Α-25 -ch2o- straight or branched alkyl single bond pyrimidine Α-26 -con(ch3)- carbon number 1~5 straight chain or Branched alkyl single bond pyrrole ring Α-27 -CON(CH3)- straight or branched alkyl single bond imidazole ring Α-28 -con(ch3) - carbon number 1~5 linear or Branched alkyl single bond pyrazole ring Α-29 -con(ch3)- linear or branched alkyl single bond having a carbon number of 1 to 5 ring Α-30 -CON(CH3)- carbon number 1 ~5 linear or branched alkyl single bond pyrimidine ring 201030055 [Table 3] Yi Y2 Y3 Y4 A-31 -0- phenylcyclopyrrole ring A-32 -0- phenylcycloimidazole ring A-33 -0- benzene Cyclopyrazole ring A-34 -0- phenylcyclopyrrolidine ring A-35 -0- phenyl ring-C0NH-pyrimidine ring A-36 -0- benzene ring-CONH- pyrrole ring A-37 -0- benzene ring- C0NH- Imidazole ring A-38 -0- phenyl ring-C0NH-pyrazole ring A-39 -0 benzene ring-NHC0- pyridine ring A-40 -0- benzene ring-NHC0- pyridinium ring A-41 -0- Benzene ring-NHCO-pyrrole ring A-42 benzene ring-NHC0- imidazole ring A-43 benzene ring-COO-pyrazole ring A-44 benzene ring-COO- pyridine ring A-45 benzene ring-COO-pyrimidine ring A- 46 -0- phenyl ring-COO-pyrrole ring A-47 benzene ring-0C0- imidazole ring A-48 benzene ring-OCO- pyridinium ring A-49 -0- benzene ring-OCO- pyridyl ring A-50 - O- phenyl ring-OCO-pyrimidine ring A-51 -0- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) pyrrole ring A-52 -0-benzene ring-0-(CH2) M- (m: an integer of 1 to 5) imidazole ring A-53 -0-benzene ring-0-(CH2)m- (m: an integer of 1 to 5) pyrazole ring A-54-o-benzene ring- 0-(CH2)m- (m: an integer from 1 to 5) Pyridinium ring A-55 -NH-benzene ring-0-pyrrole ring A-56 -NH-benzene ring Azole ring A-57 -NH- phenyl ring-0-pyrazole ring A-58 -NH- phenyl ring-0-pyridine ring A-59 -NH-benzene ring-CONH-pyrimidine ring A-60 -NH-benzene ring -CONH- Pyrrole ring-37- 201030055 Table 4]

Yi Y2 γ3 Y4 A-61 -NH- 苯環 -CONH- 咪嗤環 A-62 -NH- 苯環 -CONH- 吡嗤環 A-63 -NH- 苯環 -NHCO- 吡_ A-64 -NH- 苯環 -NHCO- 嘧啶環 A-65 -NH- 苯環 -NHCO- 吡咯環 A-66 -NH- 苯環 -NHCO- 咪哩環 A-67 -NH- 苯環 -COO- 啦哩環 A-68 -NH- 苯環 -COO- 吡啶環 A-69 -NH- 苯環 -COO- 嘧啶環 A-70 -NH- 苯環 -COO- 吡咯環 A-71 -NH- 苯環 -OCO- 咪唑環 A-72 -NH- 苯環 -OCO- 吡嗤環 A-73 -NH- 苯環 -OCO- 吡啶環 A-74 -NH- 賴 -OCO- 暗症環 A-75 -NH- 苯環 -0-(CH2)m- (m:l~5 之整數) 吡咯環 A-76 -NH- 苯環 -0-(CH2)m- (m:l~5 之整數) 咪唑環 A-77 -NH- 苯環 -0-(CH2)m- (m: 1 〜5 之整數) 吡唑環 A-78 -NH- 苯環 -0-(CH2)m- (m: 1 〜5 之整數) 口比陡環 201030055 [表5] Yi Y2 Y3 Y4 A-79 -CONH- 苯環 吡咯環 A-80 -CONH- 苯環 -0- 咪唑環 A-81 -CONH- 苯環 吡唑環 A-82 -CONH- 苯環 -0- 吡陡環 A-83 -CONH- 苯環 -CONH- 嘧啶環 A-84 -CONH- 苯環 -CONH- 吡咯環 A-85 -CONH- 苯環 -CONH- 咪唑環 A-86 -CONH- 苯環 -CONH- 吡嗤環 A-87 -CONH- 苯環 -NHCO- 吡啶環 A-88 -CONH- 苯環 -NHCO- 嘧啶環 A-89 -CONH- 苯環 -NHCO- 吡咯環 A-90 -CONH- 苯環 -NHCO- 咪唑環 A-91 -CONH- 苯環 -COO- 吡唑環 A-92 -CONH- 苯環 -COO- 吡_ A-93 -CONH- 苯環 -COO- 嘧啶環 A-94 -CONH- 苯環 -COO- 吡咯環 A-95 -CONH- 苯環 -OCO- 咪唑環 A-96 -CONH- 苯環 -OCO- 吡唑環 A-97 -CONH- 苯環 -OCO- 吡啶環 A-98 -CONH- 苯環 -OCO- 嘧啶環 A-99 -CONH- 苯環 -0-(CH2)m- (m:l〜5 之整數) 吡咯環 A-100 -CONH- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 咪唑環 A-101 -CONH- 苯環 -0-(CH2)m- 之整數) 吡唑環 A-102 -CONH- 苯環 -0-(CH2)m- (m: 1~5 之整數) 吡啶環 A-103 -NHCO- 苯環 吡咯環 A-104 -NHCO- 苯環 咪唑環 A-105 -NHCO- 苯環 吡唑環 A-106 -NHCO- 苯環 吡π定環 A-107 -NHCO- 苯環 -CONH- 嘧_ A-108 -NHCO- 苯環 -CONH- 吡咯環 A-109 -NHCO- 本壞 -CONH- 咪唑環 A-110 -NHCO- 苯環 -CONH- 吡唑環 -39- 201030055 [表6]Yi Y2 γ3 Y4 A-61 -NH- phenyl ring-CONH- oxime ring A-62 -NH- benzene ring-CONH- pyridinium ring A-63 -NH- benzene ring-NHCO- pyridine _ A-64 -NH - Benzene ring-NHCO-pyrimidine ring A-65 -NH- phenyl ring-NHCO- pyrrole ring A-66 -NH- benzene ring-NHCO- oxime ring A-67 -NH- benzene ring-COO- 哩 ring A -68 -NH-benzene ring-COO-pyridine ring A-69 -NH-benzene ring-COO-pyrimidine ring A-70 -NH-benzene ring-COO-pyrrole ring A-71 -NH-benzene ring-OCO-imidazole Ring A-72 -NH- phenyl ring-OCO-pyridinium ring A-73 -NH-benzene ring-OCO-pyridine ring A-74 -NH- Lai-OCO- circadian ring A-75 -NH- benzene ring- 0-(CH2)m- (m: an integer of 1 to 5) pyrrole ring A-76 -NH-benzene ring-0-(CH2)m- (m: an integer of 1 to 5) imidazole ring A-77-NH - Benzene ring-0-(CH2)m- (m: an integer of 1 to 5) Pyrazole ring A-78 -NH- phenyl ring-0-(CH2)m- (m: an integer of 1 to 5) Steep ring 201030055 [Table 5] Yi Y2 Y3 Y4 A-79 -CONH- Phenylcyclopyrrole ring A-80 -CONH- Benzene ring-0- Imidazole ring A-81 -CONH- Phenylpyrazole ring A-82 -CONH - Benzene ring-0-pyrrole ring A-83 -CONH- phenyl ring-CONH-pyrimidine ring A-84 -CONH- phenyl ring-CONH- pyrrole ring A-85 -CONH- phenyl ring-CONH- Azole ring A-86 -CONH- phenyl ring-CONH- pyridinium ring A-87 -CONH- benzene ring-NHCO- pyridine ring A-88 -CONH- phenyl ring-NHCO-pyrimidine ring A-89 -CONH- benzene ring -NHCO- Pyrrole ring A-90 -CONH- Benzene ring-NHCO- Imidazole ring A-91 -CONH- Benzene ring-COO- Pyrazole ring A-92 -CONH- Benzene ring-COO-pyridyl A-93 -CONH - Benzene ring-COO-pyrimidine ring A-94 -CONH- phenyl ring-COO-pyrrole ring A-95 -CONH- benzene ring-OCO- imidazole ring A-96 -CONH- benzene ring-OCO-pyrazole ring A- 97 -CONH- phenyl ring-OCO- pyridine ring A-98 -CONH- benzene ring-OCO-pyrimidine ring A-99 -CONH- phenyl ring-0-(CH2)m- (m: an integer of 1~5) pyrrole Ring A-100 -CONH- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) imidazole ring A-101 -CONH- phenyl ring-0-(CH2)m- an integer) pyrazole ring A-102 -CONH- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) pyridine ring A-103 -NHCO- phenylcyclopyrrole ring A-104 -NHCO- phenylcycloimidazole ring A-105 -NHCO- phenylcyclopyrazole ring A-106 -NHCO- phenylcyclopyridinium π ring A-107 -NHCO- phenyl ring-CONH- pyridine _ A-108 -NHCO- phenyl ring-CONH- pyrrole ring A-109 - NHCO- Ben Bad-CONH- Imidazole Ring A-110 -NHCO- Benzene Ring-CONH- Pyrazole Ring-3 9- 201030055 [Table 6]

Yl Y2 Y3 Y4 A-lll -NHCO- 苯環 -NHCO- 吡陡環 A-112 -NHCO- 苯環 -NHCO- 嘧啶環 A-113 -NHCO- 苯環 -NHCO- 吡咯環 A-114 -NHCO- 苯環 -NHCO- 咪唑環 A-115 -NHCO- 苯環 -COO- 吡唑環 A-116 -NHCO- 賴 -COO- 吡陡環 A-117 -NHCO- 苯環 -COO- 嘧_ A-118 -NHCO- 賴 -COO- 吡咯環 A-119 -NHCO- 苯環 -OCO- 咪唑環 A-120 -NHCO- 苯環 -OCO- 吡唑環 A-121 -NHCO- 苯環 -OCO- 耻陡環 A-122 -NHCO- 苯環 -OCO- 嘧啶環 A-123 -NHCO- 苯環 -0-(CH2)m- (m: 1~5 之整數) 吡咯環 A-124 -NHCO- 苯環 -0-(CH2)m- (m:l~5 之整數) 咪哩環 A-125 -NHCO- 苯環 -0-(CH2)m- (m: 1~5 之整數) 吡唑環 A-126 -NHCO- 苯環 -0-(CH2)m- (m: 1~5 之整數) 口比陡環 201030055 [表7]Yl Y2 Y3 Y4 A-lll -NHCO- phenyl ring-NHCO- pyridyl ring A-112 -NHCO- benzene ring-NHCO- pyrimidine ring A-113 -NHCO- benzene ring-NHCO- pyrrole ring A-114 -NHCO- Benzene ring-NHCO-imidazole ring A-115 -NHCO- benzene ring-COO-pyrazole ring A-116 -NHCO- Lai-COO- pyridox ring A-117 -NHCO- benzene ring-COO- pyridine _ A-118 -NHCO- Lai-COO- Pyrrole ring A-119 -NHCO- Benzene ring-OCO- Imidazole ring A-120 -NHCO- Benzene ring-OCO- Pyrazole ring A-121 -NHCO- Benzene ring-OCO- Shame steep ring A-122 -NHCO- phenyl ring-OCO-pyrimidine ring A-123 -NHCO- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) pyrrole ring A-124 -NHCO-benzene ring-0 -(CH2)m- (m: an integer from 1 to 5) oxime ring A-125 -NHCO- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) pyrazole ring A-126 - NHCO- phenyl ring-0-(CH2)m- (m: an integer from 1 to 5) mouth to steep ring 201030055 [Table 7]

Yi Y2 Y3 Y4 A-127 -ch2o- 苯環 吡咯環 A-128 -ch2o- 苯環 -0- 咪唑環 A-129 -ch2o- 苯環 -0- 吡哩環 A-130. -ch2o- 苯環 -0- 吡啶環 A-131 -ch2o- 苯環 -CONH- 啼π定環 A-132 -ch2o- 苯環 -CONH- 吡咯環 A-133 -ch2o- 苯環 -CONH- 咪唑環 A-134 -ch2o- 苯環 -CONH- 吡唑環 A-135 -ch2o- 苯環 -NHCO- 耻陡環 A-136 -ch2o- 苯環 -NHCO- 嘧啶環 A-137 -ch2o- 苯環 -NHCO- 吡咯環 A-138 -ch2o- 苯環 -NHCO- 咪唑環 A-139 -ch2o- 苯環 -COO- 吡唑環 A-140 -ch2o- 苯環 -COO- 啦口定環 A-141 -ch2o- 苯環 -COO- 嘧啶環 A-142 -ch2o- 苯環 -COO- 吡咯環 A-143 -ch2o- 苯環 -OCO- 咪哩環 A-144 -ch2o- 苯環 -OCO- 吡唑環 A-145 -ch2o- 苯環 -OCO- 口比D定環 A-146 -ch2o- 苯環 -OCO- 喃陡環 A-147 -ch2o- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 吡略環 A-148 -ch2o- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 咪唑環 A-149 -ch2o- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 吡唑環 A-150 -ch2o- 苯環 -0-(CH2)m- (m:l 〜5 之整數) 口ϋ陡環 A-151 -CON(CH3)- 苯環 -0- 吡咯環 A-152 -CON(CH3)- 苯環 咪唑環 A-153 -con(ch3)- 苯環 吡唑環 A-154 -CON(CH3)- 苯環 口比淀環 A-155 -CON(CH3)- 苯環 -CONH- 唆淀環 201030055 表8] Υι Y2 Ys Y4 A-156 -CON(CH3)- 苯環 -CONH- 吡咯環 A-157 -CON(CH3)- 苯環 -CONH- 咪唑環 A-158 -CON(CH3)- 苯環 -CONH- 吡唑環 A-159 -CON(CH3)- 苯環 -NHCO- 吡啶環 A-160 -CON(CH3)- 苯環 -NHCO- 嘧陡環 A-161 -CON(CH3)- 苯環 -NHCO- 吡咯環 A-162 -CON(CH3)- 苯環 -NHCO- 咪唑環 A-163 -CON(CH3)- 苯環 -COO- 吡唑環 A-164 -CON(CH3)- 苯環 -COO- 吡症環 A-165 -CON(CH3)- 苯環 -COO- 嘧啶環 A-166 -CON(CH3)- 苯環 -COO- 吡咯環 A-167 -CON(CH3)- 苯環 -OCO- 咪唑環 A-168 -CON(CH3)- 苯環 -OCO- 吡唑環 A-169 -CON(CH3)- 苯環 -OCO- 口比陡環 A-170 -CON(CH3)- 苯環 -OCO- 嘧陡環 A-171 -CON(CH3)- 苯環 •0-(CH2)m- (m: 1〜5 之整數) 吡咯環 A-172 -CON(CH3)- 苯環 •0-(CH2)m- (m:l~5 之整數) 咪唑環 A-173 -CON(CH3)- 苯環 -0-(CH2)m- (m:l〜5 之整數) 吡唑環 A-174 -CON(CH3)- 苯環 -0-(CH2)m- (m: 1 〜5 之整數) 吡啶環Yi Y2 Y3 Y4 A-127 -ch2o- phenylcyclopyrrole ring A-128 -ch2o- phenyl ring-0- imidazole ring A-129 -ch2o- phenyl ring-0-pyridinium ring A-130. -ch2o- benzene ring -0- pyridine ring A-131 -ch2o-benzene ring-CONH- 啼π-ring ring A-132 -ch2o-benzene ring-CONH- pyrrole ring A-133 -ch2o-benzene ring-CONH-imidazole ring A-134 - Ch2o- phenyl ring-CONH-pyrazole ring A-135 -ch2o- benzene ring-NHCO- shame steep ring A-136 -ch2o- benzene ring-NHCO-pyrimidine ring A-137 -ch2o- benzene ring-NHCO- pyrrole ring A-138 -ch2o- phenyl ring-NHCO- imidazole ring A-139 -ch2o- benzene ring-COO-pyrazole ring A-140 -ch2o- benzene ring-COO- 啦口定环 A-141 -ch2o- benzene ring -COO-pyrimidine ring A-142 -ch2o- phenyl ring-COO- pyrrole ring A-143 -ch2o- phenyl ring-OCO- oxime ring A-144 -ch2o- phenyl ring-OCO-pyrazole ring A-145 - Ch2o- benzene ring-OCO- port ratio D ring A-146 -ch2o- benzene ring-OCO- squirrel ring A-147 -ch2o- benzene ring-0-(CH2)m- (m: l 〜5 integer Pyridine ring A-148 -ch2o-benzene ring-0-(CH2)m- (m: an integer of 1 to 5) imidazole ring A-149 -ch2o-benzene ring-0-(CH2)m- (m: l an integer of ~5) pyrazole ring A-150 -ch2o-benzene ring-0-(CH2)m- (m:l 〜5 Number of ϋ ϋ steep ring A-151 -CON(CH3)- phenyl ring-0-pyrrole ring A-152 -CON(CH3)- phenylcycloimidazole ring A-153 -con(ch3)- phenylcyclopyrazole ring A -154 -CON(CH3)- phenyl ring mouth ring A-155 -CON(CH3)-benzene ring-CONH- 唆周环201030055 Table 8] Υι Y2 Ys Y4 A-156 -CON(CH3)- benzene ring -CONH-pyrrole A-157 -CON(CH3)-benzene ring-CONH-imidazole ring A-158 -CON(CH3)-benzene ring-CONH-pyrazole ring A-159 -CON(CH3)-benzene ring- NHCO-pyridine ring A-160-CON(CH3)-benzene ring-NHCO- pyrimidine ring A-161 -CON(CH3)-benzene ring-NHCO- pyrrole ring A-162 -CON(CH3)-benzene ring-NHCO - Imidazole ring A-163 -CON(CH3)-benzene ring-COO-pyrazole ring A-164 -CON(CH3)-benzene ring-COO-pyridyl ring A-165-CON(CH3)-benzene ring-COO - Pyrimidine ring A-166 -CON(CH3)-benzene ring-COO-pyrrole ring A-167 -CON(CH3)-benzene ring-OCO-imidazole ring A-168 -CON(CH3)-benzene ring-OCO-pyridyl Azole ring A-169 -CON(CH3)-benzene ring-OCO- port ratio steep ring A-170 -CON(CH3)-benzene ring-OCO-pyrimidine ring A-171 -CON(CH3)-benzene ring•0 -(CH2)m- (m: an integer from 1 to 5) Pyrrole ring A-172 -CON(CH3)-benzene ring•0-(CH2)m- (m: an integer of 1 to 5) Azole ring A-173 -CON(CH3)-benzene ring-0-(CH2)m- (m: an integer from 1 to 5) Pyrazole ring A-174 -CON(CH3)-benzene ring-0-(CH2) M- (m: an integer from 1 to 5) pyridine ring

製造本發明的式〔2〕所示二胺化合物之方法並無特 別限定,作爲較佳方法可舉出以下方法。 [化 31]The method for producing the diamine compound of the formula [2] of the present invention is not particularly limited, and a preferred method is as follows. [化31]

o2n 合成上述式〔2d〕所示二硝基化合物,以一般方法還 原硝基轉換成胺基而得到。還原二硝基化合物之方法,並 無特別限制,一般將鈀-碳、氧化鉑、雷氏鎳、鉑黑、铑- -42- 201030055 氧化鋁、硫化鉑碳等作爲觸媒使用,於乙酸乙酯、甲苯、 四氫呋喃、二噁烷、醇系等溶劑中,藉由氫氣、肼、氯化 氫等進行還原之方法。式〔2d〕中的Υ,、Υ2、Υ3、Υ4、及 η與式〔2〕之定義同意義》 式〔2d〕的二硝基化合物,介著Υ3,使¥2及Υ4結合, 其後使二硝基部介著Υ!結合之方法、將二硝基部介著連結 部丫】,使Υ2結合,其後介著Υ3與Υ4結合之方法等。 丫!爲-0-(醚鍵)、-ΝΗ-(胺鍵)、-N(CH3)-(甲基 化胺鍵)、-CONH-(醯胺鍵)、-NHCO-(反式醯胺鍵) 、-CH20-(伸甲基醚鍵)、-OCO-(反式酯鍵)、 -CON(CH3)- ( N-甲基化醯胺鍵)、或-N(CH3)CO- ( N -甲 基化反式醯胺鍵)等結合基,這些結合基一般可藉由有機 合成的手法形成。 例如,可舉出Y i爲醚、或伸甲基醚鍵之情況,與對應 之含有二硝基之鹵素衍生物,與含有γ2、γ3及¥4之羥基衍 生物於鹼存在下進行反應的方法、或含有二硝基之羥基衍 生物、與含有Υ2、Υ3及Υ4之鹵素取代衍生物於鹼存在下進 行反應的方法。 胺鍵之情況,可舉出所對應之含有二硝基之鹵素衍生 物、與含有γ2、γ3及γ4之胺基取代衍生物於鹼存在下進行 反應之方法。 酯鍵之情況,可舉出所對應之含有二硝基之酸氯化物 體、與含有Υ2、γ3及Υ4之羥基取代衍生物於鹼存在下進行 反應之方法。 -43- 201030055 反式醋鍵的情況,可舉出所對應之含有一硝基之經基 衍生物、與含有γ2、γ3及Υ4之酸氯化物體於驗存在下進行 反應之方法。 醯胺鍵的情況,可舉出所對應含有二硝基之酸氯化物 體、與含有Υ2、Υ3及Υ4之胺基取代體於鹸存在下進行反應 之方法。 反式醯胺鍵的情況,可舉出所對應含有二硝基之胺基 取代體、與含有γ2、γ3及Υ4之酸氯化物體於鹼存在下進行 反應之方法。 含有二硝基之鹵素衍生物及含有二硝基之衍生物的具 體例,可舉出3,5_二硝基氯苯、2,4-二硝基氯苯、2,4-二硝 基氟苯、3,5-二硝基安息香酸氯化物、3,5-二硝基安息香 酸、2,4-二硝基安息香酸氯化物、2,4-二硝基安息香酸、 3,5-二硝基苯甲基氯化物、2,4-二硝基苯甲基氯化物、3,5-二硝基苯甲基醇、2,4-二硝基苯甲基醇、2,4-二硝基苯胺 、3,5-二硝基苯胺、2,6-二硝基苯胺、2,4-二硝基酚、2,5-二硝基酚、2,6-二硝基酚、2,4-二硝基苯基乙酸等。 含有二硝基之鹵素衍生物及含有二硝基之衍生物,若 考慮到原料之取得性、反應之觀點時,可選擇一種或複數 種使用。 <二胺化合物(C ) > 本發明所使用的二胺化合物(C)爲分子内具有羧基 之二胺化合物。該具體結構並無特別限定,但較佳爲式〔 -44 - [3] 201030055 3〕所示化合物。 [化 32] (C00H)k η2ν 、νη2 式〔3〕中,Ζ!爲具有碳數6〜30的芳香族環之有機基 ,让爲1〜4的整數。O2n The dinitro compound represented by the above formula [2d] is synthesized, and the nitro group is converted into an amine group by a general method. The method for reducing the dinitro compound is not particularly limited, and generally, palladium-carbon, platinum oxide, nickel nickel, platinum black, ruthenium--42-201030055 alumina, platinum sulfide carbon, or the like is used as a catalyst. A method in which a solvent such as an ester, toluene, tetrahydrofuran, dioxane or an alcohol is reduced by hydrogen, helium, hydrogen chloride or the like. The dinitro compounds of the formula [2d] in the formula [2d], Υ, Υ2, Υ3, Υ4, and η have the same meaning as the definition of the formula [2], and the combination of 23 and ¥4, The method of combining the dinitro group with the dinitro moiety, the bonding of the dinitro moiety, the bonding of the indole 2, and the subsequent bonding of the crucible 3 and the crucible 4 are carried out. Hey! Is -0-(ether bond), -ΝΗ-(amine bond), -N(CH3)-(methylated amine bond), -CONH-(melamine bond), -NHCO- (trans-guanamine bond) , -CH20- (methyl ether bond), -OCO- (trans ester bond), -CON(CH3)- (N-methylated guanamine bond), or -N(CH3)CO- (N - A binding group such as a methylated trans-amine bond, which is generally formed by an organic synthesis method. For example, when Y i is an ether or a methyl ether bond, a corresponding halogen derivative containing a dinitro group and a hydroxy derivative containing γ 2 , γ 3 and ¥ 4 are reacted in the presence of a base. A method, or a method comprising reacting a hydroxy derivative of a dinitro group with a halogen-substituted derivative containing hydrazine 2, hydrazine 3 and hydrazine 4 in the presence of a base. The case of the amine bond may be a method in which a corresponding halogen derivative containing a dinitro group and an amine-substituted derivative containing γ2, γ3 and γ4 are reacted in the presence of a base. The ester bond may be a method in which a corresponding dinitro acid chloride-containing acid and a hydroxy-substituted derivative containing ruthenium 2, γ3 and ruthenium 4 are reacted in the presence of a base. -43- 201030055 In the case of the trans acetal bond, a corresponding one of a nitro group-containing derivative and an acid chlorided object containing γ2, γ3 and Υ4 may be reacted in the presence of the test. The case of the guanamine bond may be a method in which a corresponding dinitro acid chloride is contained and an amine substituent containing ruthenium 2, iridium 3 and ruthenium 4 is reacted in the presence of ruthenium. The case of the trans-amine bond may be a method in which an amine group-containing substituent containing a dinitro group and an acid chloride-containing object containing γ2, γ3 and Υ4 are reacted in the presence of a base. Specific examples of the dinitro group-containing halogen derivative and the dinitro group-containing derivative include 3,5-dinitrochlorobenzene, 2,4-dinitrochlorobenzene, and 2,4-dinitro group. Fluorobenzene, 3,5-dinitrobenzoic acid chloride, 3,5-dinitrobenzoic acid, 2,4-dinitrobenzoic acid chloride, 2,4-dinitrobenzoic acid, 3,5 -dinitrobenzyl chloride, 2,4-dinitrobenzyl chloride, 3,5-dinitrobenzyl alcohol, 2,4-dinitrobenzyl alcohol, 2,4 -dinitroaniline, 3,5-dinitroaniline, 2,6-dinitroaniline, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol , 2,4-dinitrophenylacetic acid, and the like. The halogen derivative containing a dinitro group and the derivative containing a dinitro group may be used singly or in combination in consideration of the viewpoint of the availability of the raw material and the reaction. <Diamine compound (C) > The diamine compound (C) used in the present invention is a diamine compound having a carboxyl group in the molecule. The specific structure is not particularly limited, but a compound of the formula [-44 - [3] 201030055 3] is preferred. (C00H)k η2ν, νη2 In the formula [3], Ζ! is an organic group having an aromatic ring having 6 to 30 carbon atoms, and is an integer of 1 to 4.

若將式〔3〕所示化合物具體表示時,可舉出下述式 〔3a〕、式〔3b〕、式〔3c〕、式〔3d〕及式〔3e〕之二 胺化合物。 [化 33]When the compound of the formula [3] is specifically represented, a diamine compound of the following formula [3a], formula [3b], formula [3c], formula [3d] and formula [3e] can be given. [化33]

(CH2)m4COOH Η2Ντ>Γ〇~ΝΗ2 (CH2)m5COOH(CH2)m4COOH Η2Ντ>Γ〇~ΝΗ2 (CH2)m5COOH

(CH2)m6COOH(CH2)m6COOH

之3 [3d]3 [3d]

[3c] H2N-ΟΟΌ, (COOHJm? [3e] 式〔3a〕中,1111爲1〜4的整數。 式〔3b〕中,Z2爲單鍵、-(:112-、-(:2114-、-(:((:113)2-、-CF2-、-C(CF3)-、-0-、-C0-、-NH-、-N(CH3)-、-C0NH-、-NHCO-、-CH20-、-OCH2-、-COO-、-OCO-、-CON(CH3)-、或-N(CH3)CO-,m2及m3各表示0〜4的整數,且m2 + m3表 -45- 201030055 示1〜4的整數。 式〔3c〕中,m4及m5各爲1〜5的整數。 式〔3d〕中,Z3爲碳數1〜5的直鏈或分支烷基,nu爲 1〜5的整數。 式〔3e〕中,Z4 爲單鍵、-(:112-、-(:2114-、-(:((:113)2-、-CF2-、-C(CF3)-、-Ο-、-CO-、-NH-、-N(CH3)-、 -CONH-、-NHCO-、-CH2〇-、-OCH2-、-COO-、-OCO-、 -CON(CH3)-、或-N(CH3)CO-,m7爲 1 〜4的整數。 m 上述式〔3a〕、式〔3b〕、式〔3c〕、式〔3d〕及式 、 〔3e〕之二胺化合物中,較佳爲式〔3〇中,m丨爲1〜2的 整數之結構,式〔3b〕中,Z2爲單鍵、-CH2-、-C2H4-、 -C(CH3)2-、-Ο-、-CO-、-NH-、-N(CH3)-、-CONH-、 -NHCO-、-COO-、或- OCO-,m2及m3同時爲1的整數之結 構,式〔3e〕中,Z4爲單鍵、-CH2-、-〇-、-CO-、-NH-、 -CONH-、-NHCO-、-CH20-、-OCH2-、-COO-、或-OCO-,m7爲1〜2的整數之結構。 作爲二胺化合物(C)之具體例,可舉出下述式〔3f 〕至式〔3n〕、及式〔3p〕的化合物。 -46- 201030055[3c] H2N-ΟΟΌ, (COOHJm? [3e] In the formula [3a], 1111 is an integer of 1 to 4. In the formula [3b], Z2 is a single bond, -(:112-, -(:2114-, -(:((:113)2-, -CF2-, -C(CF3)-, -0-, -C0-, -NH-, -N(CH3)-, -C0NH-, -NHCO-, - CH20-, -OCH2-, -COO-, -OCO-, -CON(CH3)-, or -N(CH3)CO-, m2 and m3 each represent an integer from 0 to 4, and m2 + m3 is -45- 201030055 is an integer of 1 to 4. In the formula [3c], m4 and m5 are each an integer of 1 to 5. In the formula [3d], Z3 is a linear or branched alkyl group having 1 to 5 carbon atoms, and nu is 1 to 5. An integer of 5. In the formula [3e], Z4 is a single bond, -(:112-, -(:2114-, -(:((:113)2-, -CF2-, -C(CF3)-, - Ο-, -CO-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH2〇-, -OCH2-, -COO-, -OCO-, -CON(CH3)-, Or -N(CH3)CO-, m7 is an integer of 1 to 4. m In the above formula [3a], formula [3b], formula [3c], formula [3d], and the diamine compound of the formula [3e], Preferably, in the formula [3, m丨 is an integer of 1 to 2, and in the formula [3b], Z2 is a single bond, -CH2-, -C2H4-, -C(CH3)2-, -Ο- , -CO-, -NH-, -N(CH3)-, -CONH-, - NHCO-, -COO-, or -OCO-, m2 and m3 are both an integer integer structure, and in the formula [3e], Z4 is a single bond, -CH2-, -〇-, -CO-, -NH-, -CONH-, -NHCO-, -CH20-, -OCH2-, -COO-, or -OCO-, m7 is a structure of an integer of 1 to 2. Specific examples of the diamine compound (C) include a compound of the formula [3f] to the formula [3n], and the formula [3p]. -46- 201030055

[化 34][34]

[化 35][化35]

式〔3η〕中,:^爲單鍵、-CH2-、-Ο-、-CO-、In the formula [3η], :^ is a single bond, -CH2-, -Ο-, -CO-,

-NH -47- 201030055 、-CONH-、-NHCO-、_CH20-、 o 式〔3p〕中,B2爲單鍵、 ' -CONH- ' -NHCO- ' -CH2〇- ' -OCH2-、-COO-、或-OCO- -CH2-、-0-、-CO- ' -NH--OCH2-、-COO-、或-OCO- <其他二胺化合物> 本發明中,以不損害本發明之效果的限制下’可將二 胺化合物(A)、二胺化合物(B)、二胺化合物(C)以 〇 外之二胺化合物作爲二胺成分倂用。該具體例可舉出以下 Ρ-伸苯基二胺' 2,3,5,6-四甲基_ρ_伸苯基二胺、2,5_二 甲基-Ρ-伸苯基二胺、m_伸苯基二胺、2,4_二甲基_m伸苯 基一胺、2,5-二胺甲苯、2,6_二胺甲苯、2,5•二胺酚、2,4· 二胺酚、3,5-二胺酚、3,5_二胺苯甲基醇、2,[二胺苯甲基 醇、4,6-一胺間苯二酚、4,4’_二胺聯苯基、3,3,-二甲基_ 4,4 -一胺聯苯基、3,3、二甲氧基_4,4,_二胺聯苯基、3,3,_ —羥基-4,4 胺聯苯基、3,3,_二氟_4,4,聯苯基、3,3,-三 氟甲基-4,4,-二胺聯苯基、3,4,_二胺聯苯基、3,3,_二胺聯 苯基、2,2’-二胺聯苯基、2,3,_二胺聯苯基、4,4,_二胺二 本基甲烷、3,3,-二胺二苯基甲烷、3,4,_二胺二苯基甲烷、 2,2’-二胺二苯基甲烷、2,3’·二胺二苯基甲烷、4,4,_二胺 二苯基醚、3,3,-二胺二苯基醚、3,4,_二胺二苯基醚、 2,2’-二胺二苯基醚、2,3,_二胺二苯基醚、4,4,_磺醯基二 -48 - 201030055 苯胺' 3,3’-磺醯基二苯胺、雙(4_胺基苯基)矽烷 3-胺基苯基)矽烷、二甲基-雙(4-胺基苯基)矽烷 基-雙(3-胺基苯基)矽烷、4,4’-硫二苯胺、3,3’-胺、4,4 ’ -二胺二苯基胺、3,3 ’ -二胺二苯基胺、3… 二苯基胺、2,2’-二胺二苯基胺、2,3’-二胺二苯基胺 基(4,4’-二胺二苯基)胺、N-甲基(3,3’-二胺二苯 、N -甲基(3,4’-二胺二苯基)胺、N -甲基(2,2’-二 基)胺、N-甲基(2,3’-二胺二苯基)胺、4,4’-二胺 酮、3,3’-二胺二苯甲酮、3,4’-二胺二苯甲酮、1,4-、2,2’-二胺二苯甲酮、2,3’-二胺二苯甲酮、1,5-二 1,6-二胺萘、1,7-二胺萘、1,8-二胺萘、2,5-二胺萘 胺萘、2,7-二胺萘、2,8-二胺萘、1,2-雙(4-胺基苯 烷、1,2-雙(3-胺基苯基)乙烷、1,3-雙(4_胺基苯 烷、1,3-雙(3-胺基苯基)丙烷、I,4-雙(4胺基苯 烷、1,4-雙(3-胺基苯基)丁烷、雙(3,5-二乙基-苯基)甲烷、1,4-雙(4-胺基苯氧基)苯、1,3-雙( 苯氧基)苯、1,4-雙(4-胺基苯基)苯、1,3-雙(4-基)苯、1,4-雙(4-胺基苯甲基)苯、1,3-雙(4-胺 基)苯、4,4’-〔 1,4-伸苯基雙(伸甲基)〕二苯胺 〔1,3-伸苯基雙(伸甲基)〕二苯胺、3,4’-〔 1,4-雙(伸甲基)〕二苯胺、3,4’-〔 1,3-伸苯基雙(伸 〕二苯胺、3,3’-〔 1,4-伸苯基雙(伸甲基)〕二 3,3’-〔 1,3-伸苯基雙(伸甲基)〕二苯胺、1,4-伸 〔(4-胺基苯基)甲酮〕、1,4-伸苯基雙〔(3-胺 、雙( 、二甲 硫二苯 t,-二胺 、N-甲 基)胺 胺二苯 二苯甲 二胺萘 胺萘、 、2,6 二 基)乙 基)丙 基)丁 _4_胺基 4-胺基 胺基苯 基苯氧 、4,4,- 伸苯基 甲基) 苯胺、 苯基雙 基苯基 -49- 201030055 )甲酮〕、1,3-伸苯基雙〔(4-胺基苯基)甲酮〕、1,3-伸苯基雙〔(3-胺基苯基)甲酮〕、I,4-伸苯基雙(4-胺 基苯甲酸酯)、1,4-伸苯基雙(3-胺基苯甲酸酯)、1,3-伸苯基雙(4-胺基苯甲酸酯)、1,3-伸苯基雙(3-胺基苯 甲酸酯)、雙(4_胺基苯基)對苯二甲酸酯、雙(3-胺基 苯基)對苯二甲酸酯、雙(4-胺基苯基)間苯二甲酸酯、 雙(3-胺基苯基)間苯二甲酸酯、Ν,Ν’·( 1,4-伸苯基)雙 (4-胺基苯甲醯胺)、1;^-(1,3-伸苯基)雙(4-胺基苯 甲醯胺)、Ν,Ν’- ( 1,4-伸苯基)雙(3-胺基苯甲醯胺)、 Ν,Ν’- ( 1,3-伸苯基)雙(3-胺基苯甲醯胺)、Ν,Ν’-雙( 4-胺基苯基)對苯二甲醯胺、Ν,Ν’-雙(3-胺基苯基)對苯 二甲醯胺、Ν,Ν’-雙(4-胺基苯基)間苯二甲醯胺、Ν,Ν’-雙(3-胺基苯基)間苯二甲醯胺、9,10-雙(4-胺基苯基) 蒽、4,4’-雙(4-胺基苯氧基)二苯基颯、2,2’-雙〔4-(4-胺基苯氧基)苯基〕丙烷、2,2’-雙〔4- (4-胺基苯氧基) 苯基〕六氟丙烷、2,2’-雙(4-胺基苯基)六氟丙烷、2,2’-雙(3-胺基苯基)六氟丙烷、2,2’-雙(3-胺基-4-甲基苯基 )六氟丙烷、2,2’-雙(4-胺基苯基)丙烷、2,2’-雙(3-胺 基苯基)丙烷、2,2’-雙(3-胺基-4-甲基苯基)丙烷、1,3-雙(4-胺基苯氧基)丙烷、1,3-雙(3-胺基苯氧基)丙烷 、I,4·雙(4_胺基苯氧基)丁烷、1,4_雙(3-胺基苯氧基) 丁烷、1,5-雙(4-胺基苯氧基)戊烷、1,5-雙(3-胺基苯氧 基)戊烷、1,6-雙(4-胺基苯氧基)己烷、1,6-雙(3-胺基 苯氧基)己烷、1,7-雙(4_胺基苯氧基)庚烷、1,7-(3-胺 -50- 201030055 基苯氧基)庚烷、1,8-雙(4-胺基苯氧基)辛烷、1,8-雙 (3-胺基苯氧基)辛烷、1,9-雙(4-胺基苯氧基)壬烷、 1,9-雙(3-胺基苯氧基)壬烷、1,10-(4-胺基苯氧基)癸 烷、1,10- (3-胺基苯氧基)癸烷、1,11-(4-胺基苯氧基) 十一烷、1,1卜(3-胺基苯氧基)十一烷' 1,12-( 4-胺基苯 氧基)十二烷、1,12-(3-胺基苯氧基)十二烷。雙(4-胺 基環己基)甲烷、雙(4-胺基-3-甲基環己基)甲烷、1,3-二胺丙烷、1,4-二胺丁烷、1,5-二胺戊烷、1,6-二胺己烷、 1,7-二胺庚烷、1,8-二胺辛烷、1,9-二胺壬烷、1,1〇-二胺 癸烷、1,1 1-二胺十一烷、1,12-二胺十二烷等。 又,二胺化合物(A)、二胺化合物(B )、二胺化合 物(C )以外,可使用側鏈具有烷基、含氟烷基、芳香環 、脂肪族環、雜環、以及彼等所成之大環狀取代體的之二 胺化合物。具體而言可舉出下述式〔DA 1〕〜式〔DA2 6〕 所示二胺。 φ [化 36]-NH -47- 201030055, -CONH-, -NHCO-, _CH20-, o In the formula [3p], B2 is a single bond, '-CONH- ' -NHCO- ' -CH2〇- ' -OCH2-, -COO -, or -OCO- -CH2-, -0-, -CO- '-NH--OCH2-, -COO-, or -OCO-<other diamine compound> In the present invention, without impairing the present invention Under the limitation of the effect, the diamine compound (A), the diamine compound (B), and the diamine compound (C) may be used as a diamine component as a diamine component. The specific examples include the following fluorene-phenylenediamine '2,3,5,6-tetramethyl-ρ-phenylenediamine, 2,5-dimethyl-anthracene-phenylenediamine , m_phenylene diamine, 2,4-dimethyl-m-phenyleneamine, 2,5-diamine toluene, 2,6-diamine toluene, 2,5•diamine phenol, 2, 4. Diamine phenol, 3,5-diamine phenol, 3,5-diaminobenzyl alcohol, 2, [diaminobenzyl alcohol, 4,6-monoamine resorcinol, 4,4' _Diamine biphenyl, 3,3,-dimethyl-4,4-aminobiphenyl, 3,3, dimethoxy-4,4,diamine biphenyl, 3,3, _-Hydroxy-4,4-aminobiphenyl, 3,3,-difluoro-4,4,biphenyl, 3,3,-trifluoromethyl-4,4,-diaminobiphenyl, 3 , 4, _ diaminobiphenyl, 3,3,-diamine biphenyl, 2,2'-diamine biphenyl, 2,3,-diamine biphenyl, 4,4,-diamine Dimethyl methane, 3,3,-diamine diphenylmethane, 3,4,-diamine diphenylmethane, 2,2'-diamine diphenylmethane, 2,3'.diamine diphenyl Methane, 4,4,-diamine diphenyl ether, 3,3,-diamine diphenyl ether, 3,4,-diamine diphenyl ether, 2,2'-diamine diphenyl ether , 2,3,-diamine diphenyl ether, 4,4, sulfonyl di-48 - 20 1030055 aniline '3,3'-sulfonyldiphenylamine, bis(4-aminophenyl)decane 3-aminophenyl)decane, dimethyl-bis(4-aminophenyl)decyl-double (3-aminophenyl)decane, 4,4'-thiodiphenylamine, 3,3'-amine, 4,4 '-diamine diphenylamine, 3,3 '-diamine diphenylamine, 3... Diphenylamine, 2,2'-diaminediphenylamine, 2,3'-diaminediphenylamino (4,4'-diaminediphenyl)amine, N-methyl ( 3,3'-diamine diphenyl, N-methyl(3,4'-diaminediphenyl)amine, N-methyl(2,2'-diyl)amine, N-methyl (2, 3'-Diaminediphenyl)amine, 4,4'-diamine, 3,3'-diamine benzophenone, 3,4'-diamine benzophenone, 1,4-, 2 , 2'-diamine benzophenone, 2,3'-diamine benzophenone, 1,5-di-1,6-diamine naphthalene, 1,7-diamine naphthalene, 1,8-diamine Naphthalene, 2,5-diamine naphthylamine naphthalene, 2,7-diamine naphthalene, 2,8-diamine naphthalene, 1,2-bis(4-aminophenylbenzene, 1,2-bis(3-amine) Phenyl) ethane, 1,3-bis(4-aminophenylbenzene, 1,3-bis(3-aminophenyl)propane, I,4-bis(4-aminophenylbenzene, 1,4 - bis(3-aminophenyl)butane, double 3,5-Diethyl-phenyl)methane, 1,4-bis(4-aminophenoxy)benzene, 1,3-bis(phenoxy)benzene, 1,4-bis(4-amine Phenyl)benzene, 1,3-bis(4-yl)benzene, 1,4-bis(4-aminobenzyl)benzene, 1,3-bis(4-amino)benzene, 4,4 '-[ 1,4-phenylene bis(methyl))diphenylamine [1,3-phenylene bis(methyl)]diphenylamine, 3,4'-[ 1,4-double Methyl)]diphenylamine, 3,4'-[1,3-phenylenebis(extended)diphenylamine, 3,3'-[1,4-phenylenebis(methyl)methyl]3, 3'-[1,3-phenylenebis(methyl)diphenylamine, 1,4-extended [(4-aminophenyl)methanone], 1,4-phenylene bis[(3) -amine, bis(, dimethylthiodiphenyl t,-diamine, N-methyl)amine amine diphenyldiphenyldiamine naphthylamine naphthalene, 2,6-diyl)ethyl)propyl)- 4_Amino 4-aminoaminophenylphenoxy, 4,4,-phenylphenylmethyl) phenylamine, phenylbisphenylphenyl-49-201030055) ketone], 1,3-phenylene Bis[(4-aminophenyl)methanone], 1,3-phenylene bis[(3-aminophenyl)methanone], I,4-phenylphenylbis(4-amine) Benzoate), 1,4-phenylene bis(3-aminobenzoate), 1,3-phenylene bis(4-aminobenzoate), 1,3-stretch Phenyl bis(3-aminobenzoate), bis(4-aminophenyl)terephthalate, bis(3-aminophenyl)terephthalate, bis(4- Aminophenyl)isophthalate, bis(3-aminophenyl)isophthalate, anthracene, Ν'·( 1,4-phenylene) bis(4-aminobenzoic acid) Indoleamine, 1;^-(1,3-phenylene)bis(4-aminobenzamide), hydrazine, Ν'-(1,4-phenylene)bis(3-aminobenzene) Methotrexate, hydrazine, Ν'- (1,3-phenylene) bis(3-aminobenzamide), hydrazine, Ν'-bis(4-aminophenyl)-p-benzoquinone Amine, hydrazine, Ν'-bis(3-aminophenyl)terephthalamide, hydrazine, Ν'-bis(4-aminophenyl)m-xylyleneamine, hydrazine, Ν'-double (3-aminophenyl)m-xylyleneamine, 9,10-bis(4-aminophenyl)anthracene, 4,4'-bis(4-aminophenoxy)diphenylanthracene, 2,2'-bis[4-(4-aminophenoxy)phenyl]propane, 2,2'-bis[4-(4-aminophenoxy)phenyl]hexafluoropropane, 2, 2'-double (4-Aminophenyl)hexafluoropropane, 2,2'-bis(3-aminophenyl)hexafluoropropane, 2,2'-bis(3-amino-4-methylphenyl)hexa Fluoropropane, 2,2'-bis(4-aminophenyl)propane, 2,2'-bis(3-aminophenyl)propane, 2,2'-bis(3-amino-4-methyl Phenyl)propane, 1,3-bis(4-aminophenoxy)propane, 1,3-bis(3-aminophenoxy)propane, I,4·bis(4-aminophenoxy) Butane, 1,4-bis(3-aminophenoxy)butane, 1,5-bis(4-aminophenoxy)pentane, 1,5-bis(3-aminobenzene Oxy)pentane, 1,6-bis(4-aminophenoxy)hexane, 1,6-bis(3-aminophenoxy)hexane, 1,7-bis(4-amino Phenoxy)heptane, 1,7-(3-amine-50-201030055-phenoxy)heptane, 1,8-bis(4-aminophenoxy)octane, 1,8-bis ( 3-aminophenoxy)octane, 1,9-bis(4-aminophenoxy)decane, 1,9-bis(3-aminophenoxy)decane, 1,10-( 4-aminophenoxy)decane, 1,10-(3-aminophenoxy)decane, 1,11-(4-aminophenoxy)undecane, 1,1 b (3 -aminophenoxy)undecane' 1,12-( 4- Aminophenoxy)dodecane, 1,12-(3-aminophenoxy)dodecane. Bis(4-Aminocyclohexyl)methane, bis(4-amino-3-methylcyclohexyl)methane, 1,3-diaminepropane, 1,4-diaminebutane, 1,5-diamine Pentane, 1,6-diaminehexane, 1,7-diamine heptane, 1,8-diamine octane, 1,9-diamine decane, 1,1 decane-diamine decane, 1 , 1 1-diamine undecane, 1,12-diamine dodecane, and the like. Further, in addition to the diamine compound (A), the diamine compound (B), and the diamine compound (C), a side chain may have an alkyl group, a fluorine-containing alkyl group, an aromatic ring, an aliphatic ring, a heterocyclic ring, and the like. The diamine compound of the large cyclic substituent formed. Specifically, a diamine represented by the following formula [DA 1 ] to formula [DA26] can be given. Φ [化36]

[DA3][DA3]

式〔DA1〕〜式〔DA5〕中,爲碳數1以上22以下的 201030055 烷基或碳數1以上22以下之含氟烷基。 [化 37]In the formula [DA1] to the formula [DA5], it is a 201030055 alkyl group having 1 or more and 22 or less carbon atoms or a fluorine-containing alkyl group having 1 or more and 22 or less carbon atoms. [化37]

[DA6] [DA7][DA6] [DA7]

[DA8] [DA9] 式〔DA6〕〜式〔DA9〕中,R2 表示-COO-、 、-CONH-、-NHCO- ' -CH2-、-0-、-CO-、或-NH- 示碳數1以上22以下的烷基或碳數1以上22以下之含 -OCO- ,R3表 氟烷基 [化 38][DA8] [DA9] In the formula [DA6]~[DA9], R2 represents -COO-, -CONH-, -NHCO-'-CH2-, -0-, -CO-, or -NH- represents carbon An alkyl group having 1 or more and 22 or less or a -OCO- having a carbon number of 1 or more and 22 or less, and a fluoroalkyl group of R3;

式〔DA10〕及式〔DA11〕中,R4 表示-Ο-、 -52- -och2- 201030055 、-CH20-、-COOCH2-、或-CH2OCO·,R5 爲碳數 1 以上 22 以 下的烷基、碳數1以上22以下的烷氧基、碳數1以上22以下 的含氟烷基或碳數1以上22以下的含有氟之烷氧基。 [化 39]In the formula [DA10] and the formula [DA11], R4 represents -Ο-, -52--och2-201030055, -CH20-, -COOCH2-, or -CH2OCO., and R5 is an alkyl group having 1 or more and 22 or less carbon atoms. An alkoxy group having 1 or more and 22 or less carbon atoms, a fluorine-containing alkyl group having 1 or more and 22 or less carbon atoms, or a fluorine-containing alkoxy group having 1 or more and 22 or less carbon atoms. [化39]

式〔DA12〕〜式〔DA14〕中,R6表示-⑶0-、·0^^- 、-CONH-、-NHCO-、-COOCH2-、_CH2〇C〇-、_CH2〇-、 -OCH2-、或-CH2-,r7爲碳數1以上22以下的院基、碳數1 以上22以下的烷氧基、碳數1以上22以下的含氟烷基或碳 數1以上22以下的含有氟之烷氧基。 [化 40]In the formula [DA12]~[DA14], R6 represents -(3)0-, ·0^^-, -CONH-, -NHCO-, -COOCH2-, _CH2〇C〇-, _CH2〇-, -OCH2-, or -CH2-, r7 is a hospital group having a carbon number of 1 or more and 22 or less, an alkoxy group having 1 or more and 22 or less carbon atoms, a fluorine-containing alkyl group having 1 or more and 22 or less carbon atoms, or a fluorine-containing alkane having 1 or more and 22 or less carbon atoms. Oxygen. [40]

式〔DA15〕及式〔DA16〕中 ’ R8 表系-C〇〇_、-〇C〇 -53- 201030055 、-CONH-、-NHCO-、-COOCH2-、-CH2OCO-、-CH20-、 -OCH2-、-CH2-、-0-、或-NH·,R9爲氟基、氰基、三氟甲 基、硝基、偶氮基、甲醯基、乙醯基、乙醯氧基、或羥基 [化 41] 〇In the formula [DA15] and the formula [DA16], the 'R8 expression system-C〇〇_, -〇C〇-53- 201030055, -CONH-, -NHCO-, -COOCH2-, -CH2OCO-, -CH20-, - OCH2-, -CH2-, -0-, or -NH., R9 is fluoro, cyano, trifluoromethyl, nitro, azo, methyl, ethyl, ethoxy, or Hydroxyl group

ch3 ch3Ch3 ch3

-54- 201030055-54- 201030055

[化 42] NH,[Chem. 42] NH,

-55- 201030055 [化 43]-55- 201030055 [Chem. 43]

[化 44] H2N—(CH^3[化44] H2N—(CH^3)

ch3 Si-·Ο· I ch3Ch3 Si-·Ο· I ch3

[DA27][DA27]

式〔DA27〕中,m爲1〜10的整數。 其他二胺化合物,可配合作爲液晶配向膜時的液晶配 向性、電壓保持特性、累積電荷等特性,使用1種類或混 合2種類以上。 <四羧酸二酐> 本發明所使用的四羧酸二酐並無特別限定。欲得到四 羧酸二酐之羧酸的具體例可舉出以下。 均苯四甲酸、2,3,6,7-萘四羧酸、1,2,5,6-萘四羧酸、 -56- 201030055 1,4,5,8-萘四羧酸、2,3,6,7-蒽四羧酸、1,2,5,6-蒽四羧酸、 3,3’,4,4’-聯苯基四羧酸、2,3,3’,4-聯苯基四羧酸、雙( 3.4- 二羧基苯基)醚、3,3’,4,4’-二苯甲酮四羧酸、雙( 3.4- 二羧基苯基)颯、雙(3,4-二羧基苯基)甲烷、2,2-雙 (3,4-二羧基苯基)丙烷、1,1,1,3,3,3-六氟-2,2-雙(3,4- 二羧基苯基)丙烷、雙(3,4-二羧基苯基)二甲基矽烷、 雙(3,4-二羧基苯基)二苯基矽烷、2,3,4,5-吡啶四羧酸、 2,6-雙(3,4-二羧基苯基)吡啶、3,3’,4,4’-二苯基颯四羧 酸、3,4,9,10-茈四羧酸、1,3-二苯基-1,2,3,4-環丁烷四羧 酸、氧基二酞四羧酸、1,2,3,4-環丁烷四羧酸、1,2,3,4-環 戊烷四羧酸、1,2,4,5-環己烷四羧酸、1,2,3,4-四甲基-1,2,3,4-環丁烷四羧酸、1,2-二甲基-1,2,3,4-環丁烷四羧酸 、1,3-二甲基-1,2,3,4-環丁烷四羧酸、1,2,3,4-環庚烷四羧 酸、2,3,4,5-四氫呋喃四羧酸、3,4-二羧基-1-環己基琥珀 酸、2,3,5-三羧基環戊基乙酸、3,4-二羧基-1,2,3,4-四氫-1-萘琥珀酸、雙環〔3,3,0〕辛烷-2,4,6,8-四羧酸、雙環〔 4,3,0〕壬烷-2,4,7,9-四羧酸、雙環〔4,4,0〕癸烷-2,4,7,9-四羧酸、雙環〔4,4,0〕癸烷-2,4,8,10-四羧酸、三環〔 6·3·0·0<2,6>〕十一烷-3,5,9,11-四羧酸、1,2,3,4-丁 烷四羧 酸、4- (2,5-二側氧基四氫呋喃-3-基)-1,2,3,4-四氫萘-1,2-二羧酸、雙環〔2,2,2〕辛-7-烯-2,3,5,6-四羧酸、5-( 2.5- 二側氧基四氫呋喃)-3-甲基-3-環己烷-1,2-二羧酸、 四環〔6,2,1,1,0,2,7〕十二-4,5,9,10-四羧酸、3,5,6-三羧基 原菠烷基-2: 3,5: 6二羧酸、1,2,4,5-環己烷四羧酸等。 -57- 201030055 四羧酸二酐可配合作爲液晶配向膜時的液晶配向性、 電壓保持特性、累積電荷等特性,使用1種類或併用2種類 以上。 <共聚物> 本發明的共聚物爲,含有二胺化合物(A)、二胺化 合物(B)、與二胺化合物(C)之二胺成分、與四羧酸二 酐進行反應所得之聚醯胺酸、及將該聚醯胺酸經脫水閉環 所得之聚醯亞胺。該聚醯胺酸及聚醯亞胺之任一皆可作爲 得到液晶配向膜之共聚物使用。 使用本發明之共聚物所得之液晶配向膜爲,上述二胺 成分中之二胺化合物(A)之含有比率越多,液晶之預傾 角越大。因此,對於二胺成分中二胺化合物(A)的含有 量對於二胺化合物(C )之1莫耳而言爲0.01〜99莫耳爲佳 。較佳爲〇」〜75莫耳,更佳爲0.5〜50莫耳。 又,使用本發明之共聚物所得之液晶配向膜爲,上述 二胺成分中之二胺化合物(B)的含有比率越多,電壓保 持率越高,且即使於高溫下經長時間曝光後,經直流電壓 所累積之殘留電荷的緩和變快。因此,二胺成分中之二胺 化合物(B)的含有量對於二胺化合物(C)之1莫耳而言 爲0.01〜99莫耳爲佳。較佳爲0.1〜50莫耳,更佳爲0.5〜 2〇莫耳,最佳爲0.5〜10莫耳。 藉由二胺成分與四羧酸二酐之反應,欲得到本發明之 聚醯胺酸時,可使用公知合成手法。一般爲將四羧酸二酐 -58- 201030055 與二胺於有機溶劑中進行反應的方法。 之反應於有機溶劑中比較容易進行,且 較佳。 作爲使用於二胺與四羧酸二酐之反 爲可溶解所生成之聚醯胺酸者即可,並 體例可舉出以下。 >1,>1-二甲基甲醯胺、>1,:^二甲基2 _ 吡咯烷酮、N-甲基己內醯胺、二甲基亞 吡啶、二甲基颯、六甲基亞碾、γ-丁內 氧基甲基戊醇、二戊烯、乙基戊基酮、 乙基酮、甲基異戊基酮、甲基異丙基酮 基賽路蘇、甲基賽路蘇乙酸酯、乙基賽 卡必醇、乙基卡必醇、乙二醇、乙二醇 單異丙基醚、乙二醇單丁基醚、丙二醇 、丙二醇單甲基醚、丙二醇-tert-丁基| φ 基醚、二乙二醇、二乙二醇單乙酸酯、 、二丙二醇單乙酸酯單甲基醚、二丙二 二醇單乙基醚、二丙二醇單乙酸酯單乙 丙基醚、二丙二醇單乙酸酯單丙基醚、 基乙酸酯、三丙二醇甲基醚、3-甲基-3-丙基醚、乙基異丁基醚、二異丁烯、戊 酸酯、丁基醚、二異丁基酮、甲基環己 基醚、二噁烷、η-己烷、η-戊烷、η-辛 己酮、碳酸乙烯酯、碳酸丙烯酯、乳酸 四羧酸二酐與二胺 不會產生副產物故 應的有機溶劑,僅 無特別限定。該具 1醯胺、Ν-甲基-2-砸、四甲基尿素、 酯、異丙基醇、甲 甲基壬基酮、甲基 、甲基賽路蘇、乙 路蘇乙酸酯、丁基 單乙酸酯、乙二醇 、丙二醇單乙酸酯 魅、二丙二醇單甲 二乙二醇二甲基醚 醇單甲基醚、二丙 基醚、二丙二醇單 3-甲基-3-甲氧基丁 甲氧基丁醇、二異 基乙酸酯、丁基丁 烯、丙基醚、二己 烷、二乙基醚、環 甲酯、乳酸乙酯、 -59- 201030055 乙酸甲酯、乙酸乙酯、乙酸η-丁酯、乙酸丙二醇單乙基醚 、丙酮酸甲酯、丙酮酸乙酯、3-甲氧基丙酸甲酯、3-乙氧 基丙酸甲基乙酯、3 -甲氧基丙酸乙酯、3-乙氧基丙酸、3-甲氧基丙酸、3-甲氧基丙酸丙酯、3-甲氧基丙酸丁酯、二 甘二甲醚、4-羥基-4 -甲基-2-戊酮等。這些可單獨使用、 或混合使用。且,即使爲不溶解聚醯胺酸之溶劑,於所生 成之聚醯胺酸不會析出之範圍內,亦可混合於上述溶劑中 使用。 又,有機溶劑中之水分會阻礙聚合反應,且成爲水解 所生成之聚醯胺酸的原因,故有機溶劑使用經脫水乾燥者 爲佳。 將二胺成分與四羧酸二酐於有機溶劑中進行反應時, 攪拌分散或溶解二胺成分於有機溶劑之溶液,直接將四羧 酸二酐、或於有機溶劑中分散或溶解而添加的方法、相反 地將四羧酸二酐分散或溶解於有機溶劑之溶液中添加二胺 成分的方法、交互添加四羧酸二酐與二胺成分的方法等可 舉出,這些方法皆可使用。又,四羧酸二酐或二胺成分由 複數種化合物所成時,亦可於預先混合之狀態下進行反應 、或各別依序進行反應,進一步可將各別反應之低分子量 體進行混合反應而作爲高分子量體。 此時的聚合溫度可任意選自-20〜150°C之溫度,但較 佳爲-5〜l〇〇°C之範圍。又,反應可於任意濃度下進行,但 濃度過低時,難得到高分子量之聚合物,濃度過高時,反 應液之黏性過高而無法均勻地攪拌,故二胺成分與四羧酸 -60- 201030055 二酐之合計對於反應溶液全體(1 〇〇質量% )而言,較佳爲 1〜5 0質量°/〇,更佳爲5〜3 〇質量%。反應初期於高濃度下 進行,其後可追加有機溶劑。 聚酿胺酸的聚合反應中,四羧酸二酐之合計莫耳數、 與二胺成分之合計莫耳數比以〇.8〜1.2爲佳。與一般之聚 縮合反應同樣地’該莫耳比越接近〗.〇,所生成之聚醯胺 酸的分子量越大。 本發明的聚醯亞胺爲將前述聚醯胺酸經脫水閉環後所 得之聚醯亞胺’可作爲欲得到液晶配向膜之共聚物使用。 本發明的聚醯亞胺中,醯胺酸基之脫水閉環率(亞胺 化率)無需爲100%之必要,可配合用途或目的作任意調整 。作爲將聚醯胺酸進行亞胺化之方法,可舉出將聚醯胺酸 之溶液直接加熱的熱亞胺化、於聚醯胺酸之溶液中添加觸 媒使其觸媒亞胺化等。將聚醯胺酸於溶液中進行熱亞胺化 時的溫度爲1〇〇〜400 °C,較佳爲120〜250 °C,將經亞胺化 反應所生成之水除去至系統外下進行的方法爲佳。 聚醯胺酸的觸媒亞胺化爲’可於聚醯胺酸之溶液中, 添加鹼性觸媒與酸酐’於-20〜250°C,較佳爲0〜180°C下 進行攪拌。鹼性觸媒之量爲醯胺酸基之〇·5〜30莫耳倍’ 較佳爲2〜20莫耳倍,酸酐之量爲醯胺酸基之1〜50莫耳倍 ’較佳爲3〜30莫耳倍。 作爲鹼性觸媒可舉出吡啶、三乙基胺、三甲基胺、三 丁基胺、三辛基胺等,其中亦以吡啶於進行反應上持有適 度鹼性而較佳。 -61 - 201030055 作爲酸酐,可舉出乙酸酐、偏苯三酸酐、均苯四甲酸 酐等,其中亦以使用乙酸酐時可使反應終了後之純化容易 進行故較佳。 經觸媒亞胺化之亞胺化率,可藉由調節觸媒量與反應 溫度、反應時間而控制。 由聚醯胺酸或聚醯亞胺之反應溶液回收所生成之聚醯 胺酸或聚醯亞胺時,將反應溶液投入於弱溶劑中使其沈澱 即可。作爲沈澱所使用的弱溶劑,可舉出甲醇、丙酮、己 烷、丁基賽路蘇、庚烷、甲基乙基酮、甲基異丁基酮、乙 醇、甲苯、苯、水等。投入弱溶劑中使其沈澱的聚合物經 過濾並回收後,可於常壓或減壓下進行常溫或加熱後乾燥 。又,將沈澱回收之共聚物於有機溶劑中再溶解,將再沈 澱回收之操作重複2〜10次時,可使共聚物中之雜質變少 。作爲此時的弱溶劑,例如可舉出醇類、酮類、烴類等, 使用選自彼等中的3種類以上之弱溶劑時,可進一步提高 純化效率故較佳。 含於本發明的液晶配向處理劑之聚醯胺酸及聚醯亞胺 的分子量,考慮到所得塗膜之強度、及塗膜形成時之作業 性、塗膜之均勻性時,以 GPC ( Gel Permeation Chromatography )法所測定重量平均分子量時爲5,000〜1,000,000者爲佳 ,較佳爲 10,〇〇〇 〜150,000。 <液晶配向處理劑> 本發明的液晶配向處理劑爲欲形成液晶配向膜時的塗 -62- 201030055 液至 溶的 之物 劑聚 溶共 機之 有明 於發 解本 溶述 分上 成自 脂選 樹有。 之含分 膜爲成 被分脂 脂成樹 樹脂之 成樹物 形述聚 欲前共 , 肘 種 液於一 佈。少 此時,樹脂成分之含有量對於液晶配向處理劑全體( 100質量%)而言,以1〜20質量%爲佳,較佳爲3〜15質量 %,特佳爲3〜1 0質量%。 本發明中,前述樹脂成分可皆爲本發明之共聚物、或 亦可爲於本發明之共聚物中混合此以外之其他共聚物者。 此時,樹脂成分中之其他共聚物的含有量爲0.5〜15質量% ,較佳爲1〜1 〇質量%。 該其他共聚物,例如作爲與四羧酸二酐進行反應之二 胺成分,可舉出使用二胺化合物(A)、二胺化合物(B) 、二胺化合物(C)以外之二胺所得之聚醢胺酸或聚醯亞 胺等。 本發明的液晶配向處理劑所使用的有機溶劑爲,可溶 解上述樹脂成分的有機溶劑即可並無特別限定。 本發明的液晶配向處理劑可含有上述以外之成分。作 爲該例子,有可提高塗佈液晶配向處理劑時的膜厚均勻性 或表面平滑性之溶劑或化合物,進一步可提高液晶配向膜 與基板之密著性之化合物等。 作爲提高膜厚之均勻性或表面平滑性的溶劑之具體例 ,可舉出以下者。 例如可舉出異丙基醇、甲氧基甲基戊醇、甲基賽路蘇 、乙基賽路蘇、丁基賽路蘇、甲基賽路蘇乙酸酯、乙基賽 -63- 201030055 路蘇乙酸酯、丁基卡必醇、乙基卡必醇、乙基卡必醇乙酸 酯、乙二醇、乙二醇單乙酸酯、乙二醇單異丙基醚、乙二 醇單丁基醚、丙二醇、丙二醇單乙酸酯、丙二醇單甲基醚 、丙二醇-tert-丁基醚、二丙二醇單甲基醚、二乙二醇、 二乙二醇單乙酸酯、二乙二醇二甲基醚、二丙二醇單乙酸 酯單甲基醚、二丙二醇單甲基醚、二丙二醇單乙基醚、二 丙二醇單乙酸酯單乙基醚、二丙二醇單丙基醚、二丙二醇 單乙酸酯單丙基醚、3-甲基-3-甲氧基丁基乙酸酯、三丙二 醇甲基醚、3-甲基-3-甲氧基丁醇、二異丙基醚、乙基異丁 基醚、二異丁烯、戊基乙酸酯、丁基丁酸酯、丁基醚、二 異丁基酮、甲基環己烯、丙基醚、二己基醚、1-己醇、己 烷、η-戊烷、η-辛烷、二乙基醚、乳酸甲酯、乳酸乙酯、 乙酸甲酯、乙酸乙酯 '乙酸η-丁酯、乙酸丙二醇單乙基醚 、丙酮酸甲酯、丙酮酸乙酯、3-甲氧基丙酸甲酯、3-乙氧 基丙酸甲基乙酯、3-甲氧基丙酸乙酯、3-乙氧基丙酸、3-甲氧基丙酸、3-甲氧基丙酸丙酯、3-甲氧基丙酸丁酯、1-甲氧基-2-丙醇、1-乙氧基-2-丙醇、1-丁氧基-2-丙醇、1-苯氧基-2-丙醇、丙二醇單乙酸酯、丙二醇二乙酸酯、丙二 醇-1-單甲基醚-2-乙酸酯、丙二醇-1·單乙基醚-2-乙酸酯、 二丙二醇、2- (2-乙氧基丙氧基)丙醇、乳酸甲酯、乳酸 乙酯、乳酸η-丙基酯、乳酸η-丁基酯、乳酸異戊基酯等具 有低表面張力之溶劑等。 這些溶劑可使用1種類或混合複數種類後使用。使用 如上述之溶劑時,含於液晶配向處理劑之溶劑全體的5〜 -64 - 201030055 8 0質量%爲佳,較佳爲20〜60質量%。 作爲提高膜厚之均勻性或表面平滑性之化合物,可舉 出氟系界面活性劑、聚矽氧系界面活性劑、非離子系界面 活性劑等。 更具體爲,例如可舉出F-top EF301、EF303、EF352 (Tohkem Products 製))、美卡夫克 F171、F173、R-30 (大日本油墨公司製)、Fluorad FC430、FC431 (住友3M 公司製)、AsahiGuard AG710、沙福隆 S-3 82、SC101、 β SC102、 SC103、 SC104、 SC105、 SC106(旭硝子公司製) 等。這些界面活性劑之使用比率對於含於液晶配向處理劑 之樹脂成分1〇〇質量份而言,較佳爲0.01〜2質量份,更佳 爲0 _ 0 1〜1質量份。 作爲提高液晶配向膜與基板之密著性的化.合物之具體 例’可舉出以下所示官能性矽烷含有化合物 '含有環氧基 之化合物等。 • 例如可舉出3-胺基丙基三甲氧基矽烷、3-胺基丙基三 乙氧基砂院、2-胺基丙基三甲氧基砂垸、2-胺基丙基三乙 氧基矽烷、N- (2·胺基乙基)-3-胺基丙基三甲氧基矽烷、 N- (2-胺基乙基)-3-胺基丙基甲基二甲氧基矽烷、3-脲基 丙基三甲氧基矽烷、3-脲基丙基三乙氧基矽烷、N_乙氧基 羰基-3-胺基丙基三甲氧基矽烷、N-乙氧基羰基-3-胺基丙 基三乙氧基矽烷、N-三乙氧基甲矽烷基丙基三伸乙基三胺 、N -三甲氧基甲矽烷基丙基三伸乙基三胺、ι〇_三甲氧基 甲矽烷基-1,4,7-三氮雜癸烷、10_三乙氧基甲矽烷基-u,?- -65- 201030055 三氮雜癸烷、9-三甲氧基甲矽烷基-3,6-二氮雜壬基乙酸酯 、9-三乙氧基甲矽烷基-3,6-二氮雜壬基乙酸酯、N-苯甲 基-3-胺基丙基三甲氧基矽烷、N-苯甲基-3-胺基丙基三乙 氧基矽烷、N-苯基-3-胺基丙基三甲氧基矽烷、N-苯基-3-胺基丙基三乙氧基矽烷、N-雙(氧基伸乙基)-3-胺基丙 基三甲氧基矽烷、N-雙(氧基伸乙基)-3-胺基丙基三乙 氧基矽烷、乙二醇二縮水甘油醚、聚乙二醇二縮水甘油醚 、丙二醇二縮水甘油醚、三丙二醇二縮水甘油醚、聚丙二 醇二縮水甘油醚、新戊基甘醇二縮水甘油醚、1,6-己烷二 醇二縮水甘油醚、甘油二縮水甘油醚、2,2-二溴新戊基甘 醇二縮水甘油醚、1,3,5,6-四縮水甘油基-2,4-己烷二醇、 ]^少川’,1^’,-四縮水甘油基-111-二甲苯二胺、1,3-雙(>},>1-二 縮水甘油胺基甲基)環己烷、N,N,N’,N’,-四縮水甘油基-4 、4’-二胺二苯基甲烷等。 使用欲提高與基板之密著性的化合物時,對於含於液 晶配向處理劑之樹脂成分100質量份而言,以0.1〜30質量 份爲佳,較佳爲1〜20質量份。未達0.1質量份時,無法期 待密著性提高之效果,若比3 0質量份多時,液晶之配向性 會有變差之情況。 本發明的液晶配向處理劑中,除上述以外,若不損害 本發明效果之範圍內,可添加以變化液晶配向膜的介電率 或導電性等之電氣特性爲目的之介電體或導電物質,進一 步可添加以提高作爲液晶配向膜時的膜硬度或緻密度爲目 的之交聯性化合物。 -66- 201030055 <液晶配向膜•液晶顯示元件> 本發明的液晶配向處理劑於基板上進行塗佈、燒成後 ,以摩擦處理或光照射等進行配向處理、或於垂直配向用 途等無進行配向處理下可作爲液晶配向膜使用。此時,作 爲所使用的基板僅爲透明性高之基板即可,並無特別限定 ,可使用玻璃基板、或壓克力基板、聚碳酸酯基板等塑質 基板等。又,使用形成進行液晶驅動的ITO電極等之基板 ❹ 因可簡化製程之觀點來看爲佳。又,反射型液晶顯示元件 中僅爲單側之基板即可,亦可使用晶圓等不透明物質,此 時的電極亦可使用反射鋁等光的材料。 液晶配向處理劑之塗佈方法並無特別限定,但一般爲 工業上所使用的網板印刷、平版印刷、彈性印刷、噴墨印 刷等所進行的方法。作爲其他塗佈方法,亦可使用浸漬、 輥塗佈、縫隙塗佈、旋轉器等,可配合目的使用彼等。 ❹ 將液晶配向處理劑於基板上進行塗佈後的燒成,可藉 由加熱板等加熱手段以50〜300 °c,較佳爲80〜250 °c下蒸 發溶劑,形成塗膜。燒成後之塗膜厚度,若過厚時,對液 晶顯示元件之消費電力方面會不利,過薄時,液晶顯示元 件之信賴性會有降低之情況產生,故較佳爲5〜300nm,更 佳爲10〜100nm。將液晶成爲水平配向或傾斜配向時,進 行將燒成後之塗膜以摩擦或偏光紫外線照射等處理。 本發明的液晶顯示元件藉由上述手法由本發明之液晶 配向處理劑得到附有液晶配向膜之基板後,以公知方法製 -67- 201030055 作出液晶胞,成爲液晶顯示元件。 若舉出液晶胞製作之一例子,可舉出準備形成液晶配 向膜之1對基板,於單方基板之液晶配向膜上散佈間隔物 ,貼合另一方基板使液晶配向膜面成爲內側,將液晶進行 減壓注入而封止之方法、或於散佈間隔物之液晶配向膜面 滴入液晶後,貼合基板並進行封止之方法等。此時的間隔 物厚度,較佳爲1〜30μιη,更佳爲2〜ΙΟμιη。 如以上,使用本發明之液晶配向處理劑所製作之液晶 顯示元件成爲信賴性優異者,可利用於大畫面且高精細之 液晶電視等上。 【實施方式】 [實施例] 以下舉出實施例,對本發明作更詳細説明,但並非限 定於此且可被完全解釋者。 「聚醯胺酸、或聚醯亞胺之合成」 以下表示實施例所使用之化合物類的簡稱。 <四羧酸二酐> CBDA: 1,2,3,4-環丁烷四羧酸二酐 BODA :雙環〔3,3,0〕辛烷-2,4,6,8-四羧酸二酐 201030055 [化 45]In the formula [DA27], m is an integer of 1 to 10. Other diamine compounds may be used in combination with one type or two or more types in combination with characteristics such as liquid crystal alignment property, voltage holding property, and accumulated electric charge when used as a liquid crystal alignment film. <tetracarboxylic dianhydride> The tetracarboxylic dianhydride used in the present invention is not particularly limited. Specific examples of the carboxylic acid to obtain a tetracarboxylic dianhydride include the following. Pyromellitic acid, 2,3,6,7-naphthalenetetracarboxylic acid, 1,2,5,6-naphthalenetetracarboxylic acid, -56-201030055 1,4,5,8-naphthalenetetracarboxylic acid, 2, 3,6,7-decanetetracarboxylic acid, 1,2,5,6-nonanetetracarboxylic acid, 3,3',4,4'-biphenyltetracarboxylic acid, 2,3,3',4- Biphenyltetracarboxylic acid, bis(3.4-dicarboxyphenyl)ether, 3,3',4,4'-benzophenonetetracarboxylic acid, bis(3.4-dicarboxyphenyl)anthracene, bis(3) , 4-dicarboxyphenyl)methane, 2,2-bis(3,4-dicarboxyphenyl)propane, 1,1,1,3,3,3-hexafluoro-2,2-dual (3, 4-Dicarboxyphenyl)propane, bis(3,4-dicarboxyphenyl)dimethyloxane, bis(3,4-dicarboxyphenyl)diphenylnonane, 2,3,4,5-pyridine Tetracarboxylic acid, 2,6-bis(3,4-dicarboxyphenyl)pyridine, 3,3',4,4'-diphenylphosphonium tetracarboxylic acid, 3,4,9,10-decanetetracarboxylic acid Acid, 1,3-diphenyl-1,2,3,4-cyclobutanetetracarboxylic acid, oxydiinthylenetetracarboxylic acid, 1,2,3,4-cyclobutanetetracarboxylic acid, 1, 2,3,4-cyclopentanetetracarboxylic acid, 1,2,4,5-cyclohexanetetracarboxylic acid, 1,2,3,4-tetramethyl-1,2,3,4-cyclobutane Alkanetetracarboxylic acid, 1,2-dimethyl-1,2,3,4-cyclobutanetetracarboxylic acid, 1,3-dimethyl-1,2,3,4-cyclobutane IV Carboxylic acid, 1,2,3,4-cycloheptane tetracarboxylic acid, 2,3,4,5-tetrahydrofuran tetracarboxylic acid, 3,4-dicarboxy-1-cyclohexyl succinic acid, 2,3,5 -Tricarboxycyclopentyl acetic acid, 3,4-dicarboxy-1,2,3,4-tetrahydro-1-naphthalene succinic acid, bicyclo[3,3,0]octane-2,4,6,8 -tetracarboxylic acid, bicyclo[4,3,0]nonane-2,4,7,9-tetracarboxylic acid, bicyclo[4,4,0]nonane-2,4,7,9-tetracarboxylic acid Bicyclo[4,4,0]nonane-2,4,8,10-tetracarboxylic acid, tricyclo[6·3·0·0<2,6>]undecane-3,5,9, 11-tetracarboxylic acid, 1,2,3,4-butanetetracarboxylic acid, 4-(2,5-di-oxytetrahydrofuran-3-yl)-1,2,3,4-tetrahydronaphthalene- 1,2-dicarboxylic acid, bicyclo[2,2,2]oct-7-ene-2,3,5,6-tetracarboxylic acid, 5-(2.5-di-sided oxytetrahydrofuran)-3-methyl -3-cyclohexane-1,2-dicarboxylic acid, tetracyclo[6,2,1,1,0,2,7]dodec-4,5,9,10-tetracarboxylic acid, 3,5 , 6-tricarboxyfarbornyl-2: 3,5:6 dicarboxylic acid, 1,2,4,5-cyclohexanetetracarboxylic acid, and the like. -57- 201030055 The tetracarboxylic dianhydride can be used in combination with one type or two or more types in combination with liquid crystal alignment properties, voltage retention characteristics, and accumulated charges when used as a liquid crystal alignment film. <Copolymer> The copolymer of the present invention contains a diamine compound (A), a diamine compound (B), a diamine component of the diamine compound (C), and a tetracarboxylic dianhydride. Polylysine, and polyimine obtained by subjecting the polyamic acid to dehydration ring closure. Any of the polyamic acid and the polyimine can be used as a copolymer for obtaining a liquid crystal alignment film. In the liquid crystal alignment film obtained by using the copolymer of the present invention, the more the content ratio of the diamine compound (A) in the above diamine component, the larger the pretilt angle of the liquid crystal. Therefore, the content of the diamine compound (A) in the diamine component is preferably 0.01 to 99 moles per 1 mole of the diamine compound (C). It is preferably 〇"~75 m, more preferably 0.5~50 m. In the liquid crystal alignment film obtained by using the copolymer of the present invention, the higher the content ratio of the diamine compound (B) in the diamine component, the higher the voltage holding ratio, and even after exposure for a long time at a high temperature. The relaxation of the residual charge accumulated by the DC voltage becomes faster. Therefore, the content of the diamine compound (B) in the diamine component is preferably 0.01 to 99 moles per 1 mole of the diamine compound (C). It is preferably 0.1 to 50 m, more preferably 0.5 to 2 m, and most preferably 0.5 to 10 m. When the polyamine of the present invention is to be obtained by the reaction of a diamine component with a tetracarboxylic dianhydride, a known synthetic method can be used. It is generally a method of reacting tetracarboxylic dianhydride -58 to 201030055 with a diamine in an organic solvent. The reaction is relatively easy to carry out in an organic solvent, and is preferred. The polyamino acid produced by dissolving the diamine and the tetracarboxylic dianhydride may be used, and the following examples are mentioned. >1,>1-dimethylformamide, >1, :^ dimethyl 2 _pyrrolidone, N-methyl caprolactam, dimethyl pyridine, dimethyl hydrazine, hexa Kia Mill, γ-butoxymethylpentanol, dipentene, ethyl amyl ketone, ethyl ketone, methyl isoamyl ketone, methyl isopropyl ketone siroli, methyl race Lucas acetate, ethyl ceramide, ethyl carbitol, ethylene glycol, ethylene glycol monoisopropyl ether, ethylene glycol monobutyl ether, propylene glycol, propylene glycol monomethyl ether, propylene glycol - Tert-butyl | φ ether, diethylene glycol, diethylene glycol monoacetate, dipropylene glycol monoacetate monomethyl ether, dipropylene diethylene glycol monoethyl ether, dipropylene glycol monoacetic acid Ester monoethyl propyl ether, dipropylene glycol monoacetate monopropyl ether, hydroxy acetate, tripropylene glycol methyl ether, 3-methyl-3-propyl ether, ethyl isobutyl ether, diisobutylene, Valerate, butyl ether, diisobutyl ketone, methylcyclohexyl ether, dioxane, η-hexane, η-pentane, η-octyl ketone, ethylene carbonate, propylene carbonate, lactic acid The carboxylic acid dianhydride and the diamine do not produce by-products. Solvent, only not particularly limited. The amine, hydrazine-methyl-2-hydrazine, tetramethyl urea, ester, isopropyl alcohol, methyl decyl ketone, methyl, methyl stilbene, ethylene sulphate, Butyl monoacetate, ethylene glycol, propylene glycol monoacetate, dipropylene glycol monomethyl diethylene glycol dimethyl ether alcohol monomethyl ether, dipropyl ether, dipropylene glycol mono 3-methyl-3 -methoxybutoxybutanol, diisoacetate, butyl butene, propyl ether, dihexane, diethyl ether, cyclomethyl ester, ethyl lactate, -59- 201030055 Ester, ethyl acetate, η-butyl acetate, propylene glycol monoethyl ether acetate, methyl pyruvate, ethyl pyruvate, methyl 3-methoxypropionate, methyl ethyl 3-ethoxypropionate , 3-methoxypropionic acid ethyl ester, 3-ethoxypropionic acid, 3-methoxypropionic acid, 3-methoxypropionic acid propyl ester, 3-methoxypropionic acid butyl ester, digans Methyl ether, 4-hydroxy-4-methyl-2-pentanone, and the like. These can be used alone or in combination. Further, even if it is a solvent which does not dissolve the poly-proline, it may be used in the above solvent insofar as the produced polyamine does not precipitate. Further, since the water in the organic solvent hinders the polymerization reaction and becomes a cause of the polylysine produced by the hydrolysis, it is preferred that the organic solvent is dried by dehydration. When the diamine component and the tetracarboxylic dianhydride are reacted in an organic solvent, the solution of the diamine component in an organic solvent is stirred or dissolved, and the tetracarboxylic dianhydride or the organic solvent is directly dispersed or dissolved. In the method, a method in which a diamine component is added to a solution in which a tetracarboxylic dianhydride is dispersed or dissolved in an organic solvent, a method in which a tetracarboxylic dianhydride and a diamine component are alternately added, and the like can be mentioned, and these methods can be used. Further, when the tetracarboxylic dianhydride or the diamine component is formed of a plurality of compounds, the reaction may be carried out in a state of being mixed beforehand or separately, and the low molecular weight bodies of the respective reactions may be further mixed. The reaction is carried out as a high molecular weight body. The polymerization temperature at this time may be arbitrarily selected from the temperature of -20 to 150 ° C, but preferably in the range of -5 to 10 ° C. Further, the reaction can be carried out at any concentration. However, when the concentration is too low, it is difficult to obtain a polymer having a high molecular weight. When the concentration is too high, the viscosity of the reaction liquid is too high to be uniformly stirred, so the diamine component and the tetracarboxylic acid are -60-201030055 The total amount of the dianhydride is preferably from 1 to 50% by mass, more preferably from 5 to 3% by mass, based on the total amount of the reaction solution (1% by mass). The initial stage of the reaction is carried out at a high concentration, and then an organic solvent can be added. In the polymerization reaction of polyamic acid, the total molar ratio of the tetracarboxylic dianhydride to the molar ratio of the diamine component is preferably from 0.8 to 1.2. Similarly to the general polycondensation reaction, the closer the molar ratio is, the larger the molecular weight of the produced polyamine. The polyimine of the present invention is a polyimine obtained by subjecting the polyamic acid to dehydration ring closure, and can be used as a copolymer for obtaining a liquid crystal alignment film. In the polyimine of the present invention, the dehydration ring closure ratio (imidization ratio) of the proline group is not necessarily required to be 100%, and may be arbitrarily adjusted in accordance with the use or purpose. Examples of the method for imidizing polylysine include thermal imidization in which a solution of polylysine is directly heated, and addition of a catalyst to a solution of polyamic acid to imidize the catalyst. . The temperature at which the polyaminic acid is thermally imidized in the solution is from 1 to 400 ° C, preferably from 120 to 250 ° C, and the water formed by the imidization reaction is removed to the outside of the system. The method is better. The catalyst of poly-proline is imidized into a mixture of polyphthalic acid, and a basic catalyst and an acid anhydride are added at -20 to 250 ° C, preferably 0 to 180 ° C for stirring. The amount of the alkaline catalyst is 醯 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 3 to 30 moles. The basic catalyst may, for example, be pyridine, triethylamine, trimethylamine, tributylamine or trioctylamine. Among them, pyridine is preferably moderately alkaline in carrying out the reaction. -61 - 201030055 The acid anhydride may, for example, be acetic anhydride, trimellitic anhydride or pyromellitic anhydride. In the case where acetic anhydride is used, purification after completion of the reaction is easily carried out, which is preferred. The imidization ratio of the imidization of the catalyst can be controlled by adjusting the amount of the catalyst, the reaction temperature, and the reaction time. When the produced polyamine or polyimine is recovered from the reaction solution of polyglycolic acid or polyimine, the reaction solution may be placed in a weak solvent to precipitate. Examples of the weak solvent used for the precipitation include methanol, acetone, hexane, butyl sirolimus, heptane, methyl ethyl ketone, methyl isobutyl ketone, ethanol, toluene, benzene, water, and the like. The polymer precipitated in a weak solvent is filtered and recovered, and then dried at normal temperature or under reduced pressure under normal pressure or reduced pressure. Further, the precipitate-recovered copolymer is redissolved in an organic solvent, and the operation of re-precipitation recovery is repeated 2 to 10 times to reduce impurities in the copolymer. Examples of the weak solvent in this case include alcohols, ketones, and hydrocarbons. When three or more kinds of weak solvents selected from the group are used, the purification efficiency can be further improved, which is preferable. The molecular weight of the polyamic acid and the polyimine contained in the liquid crystal alignment agent of the present invention is GPC (GPC) in consideration of the strength of the obtained coating film, the workability at the time of formation of the coating film, and the uniformity of the coating film. The weight average molecular weight measured by the Permeation Chromatography method is preferably 5,000 to 1,000,000, preferably 10, 〇〇〇1 to 150,000. <Liquid Crystal Alignment Treatment Agent> The liquid crystal alignment treatment agent of the present invention is a coating agent for forming a liquid crystal alignment film, and the liquid to the solvent is dissolved in a solution. Choose a tree. The film containing the film is formed into a tree of resin, which is divided into a resin, and is formed into a tree. In this case, the content of the resin component is preferably 1 to 20% by mass, preferably 3 to 15% by mass, particularly preferably 3 to 10% by mass, based on the entire liquid crystal alignment agent (100% by mass). . In the present invention, the resin component may be either a copolymer of the present invention or a copolymer other than the copolymer of the present invention. In this case, the content of the other copolymer in the resin component is from 0.5 to 15% by mass, preferably from 1 to 1% by mass. The other copolymer is, for example, a diamine component which is reacted with a tetracarboxylic dianhydride, and is obtained by using a diamine compound (A), a diamine compound (B), or a diamine other than the diamine compound (C). Polylysine or polyimine. The organic solvent used in the liquid crystal alignment agent of the present invention is not particularly limited as long as it can dissolve the organic solvent of the resin component. The liquid crystal alignment agent of the present invention may contain components other than the above. In this example, there is a solvent or a compound which can improve the film thickness uniformity or surface smoothness when the liquid crystal alignment agent is applied, and a compound which can improve the adhesion between the liquid crystal alignment film and the substrate. Specific examples of the solvent for improving the uniformity of the film thickness or the surface smoothness include the following. For example, isopropyl alcohol, methoxymethylpentanol, methyl 赛苏苏, ethyl 赛赛苏, butyl 赛路苏, methyl sarbuta acetate, ethyl 赛-63- 201030055 Lucas acetate, butyl carbitol, ethyl carbitol, ethyl carbitol acetate, ethylene glycol, ethylene glycol monoacetate, ethylene glycol monoisopropyl ether, B Glycol monobutyl ether, propylene glycol, propylene glycol monoacetate, propylene glycol monomethyl ether, propylene glycol-tert-butyl ether, dipropylene glycol monomethyl ether, diethylene glycol, diethylene glycol monoacetate, Diethylene glycol dimethyl ether, dipropylene glycol monoacetate monomethyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether, dipropylene glycol monoacetate monoethyl ether, dipropylene glycol monopropyl Ether, dipropylene glycol monoacetate monopropyl ether, 3-methyl-3-methoxybutyl acetate, tripropylene glycol methyl ether, 3-methyl-3-methoxybutanol, diiso Propyl ether, ethyl isobutyl ether, diisobutylene, pentyl acetate, butyl butyrate, butyl ether, diisobutyl ketone, methyl cyclohexene, propyl ether, dihexyl ether, 1-hexanol, hexane, η- Pentane, η-octane, diethyl ether, methyl lactate, ethyl lactate, methyl acetate, ethyl acetate η-butyl acetate, propylene glycol monoethyl ether, methyl pyruvate, pyruvate Ester, methyl 3-methoxypropionate, methyl ethyl 3-ethoxypropionate, ethyl 3-methoxypropionate, 3-ethoxypropionic acid, 3-methoxypropionic acid, Propyl 3-methoxypropionate, butyl 3-methoxypropionate, 1-methoxy-2-propanol, 1-ethoxy-2-propanol, 1-butoxy-2- Propanol, 1-phenoxy-2-propanol, propylene glycol monoacetate, propylene glycol diacetate, propylene glycol-1-monomethyl ether-2-acetate, propylene glycol-1·monoethyl ether- 2-acetate, dipropylene glycol, 2-(2-ethoxypropoxy)propanol, methyl lactate, ethyl lactate, η-propyl lactate, η-butyl lactate, isoamyl lactate A solvent having a low surface tension such as an ester. These solvents can be used after using one type or a mixture of plural types. When the solvent is used, the solvent contained in the liquid crystal alignment agent is preferably 5 to -64 - 201030055 80% by mass, preferably 20 to 60% by mass. Examples of the compound for improving the uniformity of the film thickness or the surface smoothness include a fluorine-based surfactant, a polyfluorene-based surfactant, and a nonionic surfactant. More specifically, for example, F-top EF301, EF303, EF352 (manufactured by Tohkem Products), Mekkaf F171, F173, R-30 (manufactured by Dainippon Ink Co., Ltd.), Fluorad FC430, FC431 (Sumitomo 3M) System), AsahiGuard AG710, Shafulong S-3 82, SC101, β SC102, SC103, SC104, SC105, SC106 (made by Asahi Glass Co., Ltd.). The use ratio of the surfactant is preferably 0.01 to 2 parts by mass, more preferably 0 _ 0 1 to 1 part by mass, per part by mass of the resin component contained in the liquid crystal alignment agent. Specific examples of the compound which is used to improve the adhesion between the liquid crystal alignment film and the substrate include the following functional decane-containing compound 'epoxy group-containing compound and the like. • For example, 3-aminopropyltrimethoxydecane, 3-aminopropyltriethoxylate, 2-aminopropyltrimethoxysilylene, 2-aminopropyltriethoxylate Baseline, N-(2-aminoethyl)-3-aminopropyltrimethoxydecane, N-(2-aminoethyl)-3-aminopropylmethyldimethoxydecane, 3-ureidopropyltrimethoxydecane, 3-ureidopropyltriethoxydecane, N-ethoxycarbonyl-3-aminopropyltrimethoxydecane, N-ethoxycarbonyl-3- Aminopropyltriethoxydecane, N-triethoxycarbamidopropyltriethylamine, N-trimethoxymethylidenepropyltriethylamine, oxime-trimethoxy Methyl decyl-1,4,7-triazadecane, 10-triethoxymethane alkyl-u,? - -65- 201030055 Triazanonane, 9-trimethoxycarboxamido-3,6-diazaindolyl acetate, 9-triethoxycarbamimidin-3,6-diaza Mercaptoacetate, N-benzyl-3-aminopropyltrimethoxydecane, N-benzyl-3-aminopropyltriethoxydecane, N-phenyl-3-amine Propyltrimethoxydecane, N-phenyl-3-aminopropyltriethoxydecane, N-bis(oxyethylidene)-3-aminopropyltrimethoxydecane, N-bis(oxygen) Ethyl ethyl 3-aminopropyl triethoxy decane, ethylene glycol diglycidyl ether, polyethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, tripropylene glycol diglycidyl ether, polypropylene glycol Glycidyl ether, neopentyl glycol diglycidyl ether, 1,6-hexanediol diglycidyl ether, glycerol diglycidyl ether, 2,2-dibromoneopentyl glycol diglycidyl ether, 1 ,3,5,6-tetraglycidyl-2,4-hexanediol, ]^少川',1^',-tetraglycidyl-111-xylenediamine, 1,3-double ( >},>1-diglycidylaminomethyl)cyclohexane, N,N,N',N',-tetraglycidyl-4, 4'-Diamine diphenylmethane or the like. When the compound to be adhered to the substrate is used in an amount of 0.1 to 30 parts by mass, preferably 1 to 20 parts by mass, based on 100 parts by mass of the resin component contained in the liquid crystal alignment agent. When the amount is less than 0.1 part by mass, the effect of improving the adhesion cannot be expected, and if it is more than 30 parts by mass, the alignment of the liquid crystal may be deteriorated. In addition to the above, the liquid crystal alignment agent of the present invention may be added with a dielectric or a conductive material for the purpose of changing the electrical properties such as the dielectric constant or the conductivity of the liquid crystal alignment film, without impairing the effects of the present invention. Further, a crosslinkable compound for the purpose of improving film hardness or density when used as a liquid crystal alignment film can be further added. -66-201030055 <Liquid Crystal Alignment Film/Liquid Crystal Display Element> The liquid crystal alignment treatment agent of the present invention is applied to a substrate and fired, and then subjected to alignment treatment by rubbing treatment or light irradiation, or vertical alignment. It can be used as a liquid crystal alignment film without performing alignment treatment. In this case, the substrate to be used is not particularly limited as long as it is a substrate having high transparency, and a glass substrate, a plastic substrate such as an acrylic substrate or a polycarbonate substrate, or the like can be used. Further, it is preferable to use a substrate on which an ITO electrode or the like for liquid crystal driving is formed, because the process can be simplified. Further, the reflective liquid crystal display element may be a single-sided substrate, and an opaque substance such as a wafer may be used. In this case, a material that reflects light such as aluminum may be used as the electrode. The coating method of the liquid crystal alignment agent is not particularly limited, but is generally a method of screen printing, lithography, elastic printing, ink jet printing or the like which is used industrially. As another coating method, immersion, roll coating, slit coating, a rotator, or the like may be used, and they may be used in combination with the purpose.烧 After the liquid crystal alignment agent is applied onto the substrate, the solvent is evaporated by a heating means such as a hot plate at 50 to 300 ° C, preferably 80 to 250 ° C to form a coating film. When the thickness of the coating film after firing is too thick, it is disadvantageous in terms of power consumption of the liquid crystal display element. When the thickness is too thin, the reliability of the liquid crystal display element may be lowered. Therefore, it is preferably 5 to 300 nm. Good for 10~100nm. When the liquid crystal is horizontally aligned or obliquely aligned, the coating film after firing is treated by rubbing or polarized ultraviolet rays. In the liquid crystal display device of the present invention, a substrate having a liquid crystal alignment film is obtained from the liquid crystal alignment treatment agent of the present invention by the above-described method, and then a liquid crystal cell is produced by a known method, from 67 to 201030055, to form a liquid crystal display element. An example of the production of the liquid crystal cell is a pair of substrates on which a liquid crystal alignment film is to be formed, a spacer is spread on the liquid crystal alignment film of the single substrate, and the other substrate is bonded to the inside of the liquid crystal alignment film surface to form a liquid crystal. A method of sealing by pressure-reducing injection or a method of laminating a liquid crystal on a liquid crystal alignment film surface of a spacer, sealing the substrate, and sealing it. The spacer thickness at this time is preferably from 1 to 30 μm, more preferably from 2 to ΙΟμηη. As described above, the liquid crystal display device produced by using the liquid crystal alignment agent of the present invention is excellent in reliability, and can be used in a large-screen, high-definition liquid crystal television or the like. [Embodiment] [Embodiment] Hereinafter, the present invention will be described in more detail with reference to examples, but the invention is not limited thereto. "Synthesis of Polyamide or Polyimine" The abbreviations of the compounds used in the examples are shown below. <tetracarboxylic dianhydride> CBDA: 1,2,3,4-cyclobutanetetracarboxylic dianhydride BODA: bicyclo[3,3,0]octane-2,4,6,8-tetracarboxylic acid Acid dianhydride 201030055 [化45]

<二胺化合物(A’)> m-PBCH5DABz : 1,3-二胺-5- { 4-〔反式-4-(反式-4, Ο η-戊基環己基)環己基〕苯氧基甲基}苯 m-PBCH7DABz : 1,3-二胺-5- { 4-〔反式-4-(反式- 4-n-庚基環己基)環己基〕苯氧基甲基}苯 p-PBCH5DABz : 1,4-二胺-5- { 4-〔反式-4-(反式- 4-n-戊基環己基)環己基〕苯氧基甲基}苯 m-BPCH5DABz : 1,3 -二胺-5 - { 4 -〔 4 -(反式-4 - η-戊 基環己基)苯基〕苯氧基甲基}苯<Diamine compound (A')> m-PBCH5DABz : 1,3-diamine-5- {4-[trans-4-(trans-4, η η-pentylcyclohexyl)cyclohexyl] Phenoxymethyl}benzene m-PBCH7DABz : 1,3-diamine-5- { 4-[trans-4-(trans-4-n-heptylcyclohexyl)cyclohexyl]phenoxymethyl }Benzene p-PBCH5DABz : 1,4-diamine-5- { 4-[trans-4-(trans-4-n-pentylcyclohexyl)cyclohexyl]phenoxymethyl}benzene m-BPCH5DABz : 1,3 -diamine-5 - { 4 -[ 4 -(trans-4 - η-pentylcyclohexyl)phenyl]phenoxymethyl}benzene

-69 - 201030055 [化 46]-69 - 201030055 [Chem. 46]

NH <二胺化合物(A”)> 反式-4-n-戊 PBCH5DAB : 1,3 -二胺-4 - { 4 -〔反式-4 -( 基環己基)環己基〕苯氧基}苯 -70- 201030055 PBCH7DAB : 1,3 -二胺-4 - { 4 -〔反式-4 -(反式-4 - η-庚 基環己基)環己基〕苯氧基}苯 BPCH5DAB : 1,3 -二胺-4 - { 4 -〔 4 -(反式-4 - η-戊基環 己基)苯基〕苯氧基}苯 [化 47]NH <diamine compound (A")> trans-4-n-penta PBCH5DAB : 1,3 -diamine-4 - { 4 -[trans-4 -(cyclohexyl)cyclohexyl]phenoxy Benzene-70-201030055 PBCH7DAB : 1,3 -diamine-4 - { 4 -[trans-4 -(trans-4 - η-heptylcyclohexyl)cyclohexyl]phenoxy}benzene BPCH5DAB : 1,3 -diamine-4 - { 4 -[ 4 -(trans - 4 - η-pentylcyclohexyl)phenyl]phenoxy}benzene [47]

<二胺化合物(Β ) > G 二胺(Β1)〜二胺(Β12) -71 - 201030055 [化 48]<Diamine compound (Β) > G diamine (Β1)~diamine (Β12) -71 - 201030055 [Chem. 48]

[化 49][化49]

201030055 DBA : 3,5_二胺安息香酸 [化 50]201030055 DBA : 3,5-diamine benzoic acid [Chem. 50]

nh2 <其他二胺> φ p-PDA : P-伸苯基二胺 m-PBCH5DABEs : 3,5-二胺-{ 4-〔反式-4-(反式-4-n-戊基環己基)環己基〕苯基}苯甲酸酯 PBP5DABZ: 1,3 -二胺-4-〔 (4-n -戊基苯基)苯氧基 甲基〕苯 PCH7DAB : 1,3-二胺-4-〔4-(反式- 4-n-庚基環己基) 苯氧基〕苯 PBP5DAB : 1,3-二胺-4-〔( 4-n-戊基苯基)苯氧基〕 ❿苯 二胺(S 1 ) -73- 201030055 [化 51]Nh2 <other diamines> φ p-PDA : P-phenylenediamine m-PBCH5DABEs : 3,5-diamine-{ 4-[trans-4-(trans-4-n-pentyl) Cyclohexyl)cyclohexyl]phenyl}benzoate PBP5DABZ: 1,3 -diamine-4-[(4-n-pentylphenyl)phenoxymethyl]benzene PCH7DAB : 1,3-diamine 4-[4-(trans-4-n-heptylcyclohexyl)phenoxy]benzene PBP5DAB : 1,3-diamine-4-[(4-n-pentylphenyl)phenoxy] Indolediamine (S 1 ) -73- 201030055 [化51]

<有機溶劑> NMP : N-甲基-2-吡咯烷酮 BCS : 丁基賽路蘇 <聚醯胺酸、聚醯亞胺之分子量測定> 合成例中之聚醯亞胺的分子量爲使用昭和電工公司製 常溫凝膠滲透層析法(GPC)裝置(GPC-101) °Shodex 公司製管柱(KD-803、KD-805 )如以下進行測定。<Organic solvent> NMP: N-methyl-2-pyrrolidone BCS: butyl sirolimus <Measurement of molecular weight of poly phthalic acid, polyimine;> The molecular weight of the polyimine in the synthesis example is The room temperature gel permeation chromatography (GPC) apparatus (GPC-101) manufactured by Showa Denko Co., Ltd. was used to measure the column (KD-803, KD-805) manufactured by Shodex Co., Ltd. as follows.

管柱溫度:50°C 溶離液:N,N’-二甲基甲醯胺(作爲添加劑之溴化鋰· 水和物(LiBr · H20 )爲30 mmol/L、磷酸•無水結晶(〇 201030055 磷酸)爲30mmol/L、四氫呋喃(THF)爲l〇ml/L) 流速:1 .Oml/分鐘 做成校對曲線之標準試品:Tosoh公司製 TSK標準 聚環氧乙烷(分子量約900,000 ' 1 50,000、1〇〇,〇〇〇、 30,000 )、及 POLYMER LAB ORATORY公司製聚乙二醇 (分子量約 1 2,000、4,000、1,000 )。 <亞胺化率之測定> 合成例中之聚醯亞胺的亞胺化率如以下進行測定。將 聚醯亞胺粉末20mg放入於NMR取樣管(草野科學公司製 NMRSampling tube standard Φ 5)中,添加重氫化二甲基 亞颯(DMSO-d6,0.05%TMS (四甲基矽烷)混合品) 0.5 3ml,以超音波使其完全溶解。 將該溶液以日本電子DATUM公司製NMR測定器( JNW-ECA500 )測定500MHz之質子NMR。亞胺化率係以來 _ 自於亞胺化前後並無變化之結構的質子作爲基準質子而決Column temperature: 50 ° C Dissolution: N, N'-dimethylformamide (lithium bromide as an additive, water and substance (LiBr · H20) is 30 mmol / L, phosphoric acid • anhydrous crystals (〇201030055 phosphoric acid) 30 mmol/L, tetrahydrofuran (THF) l〇ml/L) Flow rate: 1.0 ml/min Standard proof of calibration curve: TSK standard polyethylene oxide manufactured by Tosoh Company (molecular weight about 900,000 '1 50,000, 1 〇〇, 〇〇〇, 30,000), and polyethylene glycol (molecular weight of about 1 2,000, 4,000, 1,000) manufactured by POLYMER LAB ORATORY. <Measurement of imidization ratio> The imidization ratio of the polyimine in the synthesis example was measured as follows. 20 mg of polyimine powder was placed in an NMR sampling tube (NMR Sampling tube standard Φ 5 manufactured by Kusano Scientific Co., Ltd.), and a mixture of hydrogenated dimethyl hydrazine (DMSO-d6, 0.05% TMS (tetramethyl decane) was added. ) 0.5 3ml, completely dissolved by ultrasound. This solution was measured for proton NMR at 500 MHz using a NMR measuring instrument (JNW-ECA500) manufactured by JEOL DATUM. Since the imidization rate has been _ protons from the structure that has not changed before and after imidization as the benchmark proton

W 定,使用該質子之波峰積算値、與來自自9.5至10. Oppm附 近所出現的醯胺酸之NH基的質子波峰積算値,藉由以下 式子求得。 亞胺化率(%) = (1-α· x/y)xl00 上述式中,X爲來字自醯胺酸之NH基的質子波峰積算 値,y爲來自基準質子之波峰積算値,a爲聚醯胺酸(亞胺 -75- 201030055 化率爲0% )時,對於醯胺酸之1個NH基質子的基準質子之 個數比率。 〈實施例1&gt; 將 BODA ( 3,50g, 14.0 mmol ) 、m-PBCH5DABz ( 1 .87g, 4.20 mmol )、二胺(Bl) ( 2.03g, 8.39 mmol )、 及 DBA(2.34g,15.4 mmol)於 NMP(20.8g)中進行混合 ,在80°C進行5小時反應後,力□入CBDA(2.74g,14.0mmol )與NMP ( 16.4g ),在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.1g)中加入NMP使聚醯胺酸的 含有量成爲6質量%而稀釋後,作爲亞胺化觸媒加入乙酸酐 (2.50g)、及吡啶(1.92g),在80°C進行4小時反應。將 該反應溶液投入於甲醇(3〇〇ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨’在1 00°C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 4 %,數 平均分子量爲18,500,重量平均分子量爲47,100。 於該聚醯亞胺粉末(3.〇〇g)加入NMP(19.5g)、及 B C S ( 2 7 · 5 g ),得到液晶配向處理劑〔1〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 &lt;液晶胞的製作&gt; 將上述所得之液晶配向處理劑〔1〕於3cmx4cm ITO附 201030055 有電極之基板的ITO面進行轉動塗佈,在80°c下進行5分鐘 ,在2 1 0°C之熱風循環式烤箱下進行1小時燒成,製作出膜 厚100nm之聚醯亞胺塗膜。 將該附有液晶配向膜之基板,於輥徑1 20mm、嫘縈布 之摩擦裝置上,以回轉數3〇〇rpm、輕進行速度20mm/sec、 壓入量0.3mm之條件下進行摩擦處理,得到附有液晶配向 膜之基板。 準備2片該附有液晶配向膜之基板,於該1片液晶配向 φ 膜面上散佈6ym之珠子間隔物後,自該上面塗上封劑。使 另1片的基板之液晶配向膜面作爲内側,貼合成摩擦方向 呈反方向後,製作出使封劑硬化之空胞。於該空胞藉由減 壓注入法,注入透明液晶,得到反平行配向之透明液晶胞 &lt;預傾角之評估&gt; 將上述所製作的液晶胞之預傾角,使用預傾角測定裝 置(ELSICON公司製模型:PAS-301 )於室溫下進行測定 。結果如表1 1所示。 又,未經摩擦處理以外,與上述同樣下所製作的液晶 胞藉由偏光顯微鏡觀察結果,確認出液晶呈均勻地垂直配 向。 &lt;電壓保持率之評估&gt; 於預傾角測定後之液晶胞,在80。(:之溫度下外加60μηι -77- 201030055 之4V電壓,測定16.67ms後及1 667ms後之電壓,將電壓之 保持程度作爲電壓保持率而計算。結果如表12所示。 &lt;殘留電荷的緩和評估&gt; 於電壓保持率測定後之液晶胞,外加3 0分鐘的直流電 壓10V,使其經1秒短路後,將於液晶胞内所產生的電位於 1 800秒間進行測定。再測定50秒後及1 000秒後之殘留電荷 。且,測定爲使用東陽Technica公司製6254型液晶物性評 估裝置。結果如表12所示。 &lt;高溫放置後之評估&gt; 將殘留電荷測定後之液晶胞,於設定爲1 00°C之高溫 槽中放置7天後,進行電壓保持率及殘留電荷之測定。結 果如後述之表12及表13。 &lt;實施例2&gt; 將 BODA ( 3.51g, 14.0 mmol ) 、m-PBCH5DABz ( 3.7 6 g, 8.42 mmol )、二胺(Bl) ( 1 . 3 6 g, 5.61 mmol )、 及 DBA(2.13g, 14.0 mmol)於 NMP(22_0g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.75g, 14.0 mmol )與NMP ( 17.6g ) ’在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.Og)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( -78- 201030055 4.32g )、及吡啶(3.35g ),於90°C進行3.5小時反應。將 該反應溶液投入於甲醇(3 00ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在l〇〇°C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 0%,數 平均分子量爲1 8,800,重量平均分子量爲48,900。 於該聚醯亞胺粉末(3.00g)加入NMP ( 22.0g )、及 BCS ( 25.0g ),得到液晶配向處理劑〔2〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔2〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表1 1所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例3&gt; 將 BODA ( 3.50g, 14.0 mmol ) 、m-PBCH5DABz ( 3.75g, 8.39 mmol)、二胺(B2) ( 2.8 7 g, 11.2 mmol) ' 及 DBA ( 1.28g,8.39 mmol)於 NMP ( 23.5g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.78g,14.2 mmol )與NMP ( 18.8g),在40°C進行6小時反應後得到聚醯胺 -79- 201030055 酸溶液。 於該聚醯胺酸溶液(25.1g)中加入NMP,稀釋至聚醯 胺酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐 (3.13g)、及吡啶(2.42g),在80°C進行4小時反應。將 該反應溶液投入於甲醇(3 50ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在1 0(TC進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲56%,數 平均分子量爲17,400,重量平均分子量爲46,600。 於該聚醯亞胺粉末(3.00g)加入NMP(21.2g)、及 BCS ( 25.8g ),得到液晶配向處理劑〔3〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如後述之表1 1所 示。且,未經摩擦處理以外,將與實施例1同樣所製作之 液晶胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地 垂直配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例4&gt; 將 BODA ( 3.4 8 g, 13.9 mmol ) 、m-PBCH5D ABz ( 3.7 3 g, 8.35 mmol )、二胺(B3) ( 0.7 5 g, 2.78 mmol)、 201030055 及 DBA(2.54g,16.7 mmol)於 NMP(22.0g)中進行混合 ,在80°(:進行5小時反應後,加入06〇八(2.738,13.9 111111〇1 )與NMP ( 17.7g),在4(TC進行6小時反應後得到聚醯胺 酸溶液。該聚醯胺酸溶液之數平均分子量爲24,100,重量 平均分子量爲57,200。 於所得之聚醯胺酸溶液(15.1g)中加入NMP ( l〇.2g )、及BCS ( 25.0g ),得到液晶配向處理劑〔4〕。於該 液晶配向處理劑中未見到混濁或析出等異常現象,確認樹 脂成分爲均勻地溶解。 使用所得之液晶配向處理劑〔4〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表11所示。且 ’未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又’使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表1 2及表1 3所示。 &lt;實施例5&gt; 將 BODA ( 3.50g, 14.0 mmol ) 、m-PBCH5DABz ( 1.87g, 4.20 mmol)、二胺(B4) ( 1.81g, 8.39 mmol)、 及 DBA (2.34g, 15.4 mmol)於 NMP (20.4g)中進行混合 ,在8〇°C進行5小時反應後,加入CBDA(2.74g,14.0mmol )與NMP ( i6.3g ),在4〇°C進行6小時反應後得到聚醯胺 -81 - 201030055 酸溶液。 於該聚醯胺酸溶液(25.1g)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 5.39g)、及吡啶(4.18g),於90°C進行3.5小時反應。將 該反應溶液投入於甲醇( 330ml)中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 7,500,重量平均分子量爲47,500。 於該聚醯亞胺粉末(3.10g)加入NMP(22.7g)、及 BCS ( 25.8g),得到液晶配向處理劑〔5〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔5〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表1 1所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所不。 &lt;實施例6&gt; 將 BODA ( 3.5 0g, 14.0 mmol ) 、m-PBCH5D ABz ( 1.87g,4.20 mmol )、二胺(B5) (0.60g,2.80 mmol )、 201030055 及 DBA(3.19g,21.0 mmol)於 NMP(19.8g)中進行混合 ,在80°C進行5小時反應後,加入CBDA(2.74g, I4.〇mmol )與NMP ( 15.6g ),在40°C進行6小時反應後得到聚酿胺 酸溶液。 於該聚醯胺酸溶液(20.lg)中加入NMP,稀釋聚酿胺 酸的含有量成爲6質量%後,加入作爲亞胺化觸媒之乙酸酐 (2.5 1 g )、及D比陡(1.93g),在80 °C進行4小時反應。將 該反應溶液投入於甲醇( 270ml)中,過據分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在l〇(TC進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲55%,數 平均分子量爲18,8 00,重量平均分子量爲48,3 00。 於該聚醯亞胺粉末(3.00g)加入NMP(22.1g)、及 BCS ( 25.0g ),得到液晶配向處理劑〔6〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔6〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表11所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 -83- 201030055 &lt;實施例7&gt; 將 BODA ( 3.5 0 g, 14.0 mmol ) 、m-PBCH5DABz ( 2.50g, 5.60 mmol )、二胺(B6 ) ( 1.20g, 5.60 mmol )、 及 DBA(2.55g, 16.8 mmol)於 NMP(20.7g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.74g,14.0 mmol )與NMP ( 16.6g ),在40 °C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐 (2.5 0 g )、吡啶(1 · 9 5 g ),在8 0 °C進行4小時反應。將該 反應溶液投入於甲醇(28 0ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 00°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 6 %,數平 均分子量爲17,800,重量平均分子量爲48,100。 於該聚醯亞胺粉末(3.21g)中加入NMP(26.1g)、 及BCS ( 24.1g),得到液晶配向處理劑〔7〕。於該液晶 配向處理劑中未見到混濁或析出等異常現象,確認樹脂成 分爲均勻地溶解。 使用所得之液晶配向處理劑〔7〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表1 1所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 -84- 201030055 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例8&gt; 將 BODA ( 3.5 1 g, 14.0 mmol ) 、m-PBCH5D ABz ( 2.5 1 g, 5.61 mmol )、二胺(B7) ( 1.2 8 g, 5.60 mmol )、 及 DBA(2.56g,16.8 mmol)於 NMP(20.9g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.75g, 14.0 mmol )與NMP ( 16.7g),在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(25.2g)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 5.398)、吡啶(4.182),於90°(:進行3.5小時反應。將該 反應溶液投入於甲醇(330ml)中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 0 〇 °C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲80%,數平 均分子量爲17,200’重量平均分子量爲47,100。 於該聚醯亞胺粉末(3.00g)加入NMP ( 19.5g)、及 B C S ( 2 7 · 5 g ) ’得到液晶配向處理劑〔8〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔8〕,與實施例1同樣地 製作出液晶胞’進行預傾角之評估。結果如表〗丨所示。且 ’未經摩擦處理以外’將與實施例1同樣所製作之液晶胞 -85- 201030055 以偏光顯微鏡進行觀察結果’確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例9&gt; 將 BODA ( 3.51g, 14.0 mmol ) 、m-PBCH5DABz ( 3.76g, 8.42 mmol )、二胺(B8) ( 0.6 4 g, 2.81 mmol)、 及 DBA(2_56g, 16_8 mmol)於 NMP(22.1g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.75g, 14.0 mmol )與NMP ( 17.6g),在40°C進行6小時反應後得到聚醯胺 酸溶液。該聚醯胺酸溶液之數平均分子量爲2〇, 9 00,重量 平均分子量爲50,900。 於所得之聚醯胺酸溶液(20.0g )中加入NMP ( 1 O.Og )及B C S ( 3 6 · 5 g ),得到液晶配向處理劑〔9〕。於該液 晶配向處理劑中未見到混濁或析出等異常現象,確認樹脂 成分爲均勻地溶解。 使用所得之液晶配向處理劑〔9〕,與實施例1同樣地 製作出液晶胞,進行預傾角之評估。結果如表1 1所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 -86- 201030055 '殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及袠13所示。 &lt;實施例1〇&gt; 將 BODA ( 3.5lg,14.0 mmol) 、m-PBCH5DABz ( 3.76g,8.42 mmol)、二胺(B9) ( 1.44g,5.61 mmol)、 及 DBA(2.13g,14_〇 mm〇i)於 NMP(22.6g)中進行混合 ’在80°C進行5小時反應後,加入cBDA(2.75g,14.0mmol )與NMP ( 18.1g ),在4(rc進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(25.0g)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 5.39g)、及吡啶(4.18g),於90°C進行3.5小時反應。將 該反應溶液投入於甲醇( 330ml)中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲79%,數 平均分子量爲18,100,重量平均分子量爲48,900。 於該聚醯亞胺粉末(3.01g)加入NMP(19.5g)、及 BCS ( 27.5g ),得到液晶配向處理劑〔1〇〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 0〕 ’與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外’將與實施例1同樣所製作之液晶 -87- 201030055 胞以偏光顯微鏡進行觀察結果’確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞’進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例11&gt; 將 BODA ( 3_48g,13.9 mmol ) 、m-PBCH5DABz ( 2.49g,5.56 mmol ) '二胺(BIO) ( 0.90g, 2.78 mmol ) 、及 DBA(2.96g, 19.5 mmol)於 NMP(20.8g)中進行混 合,在80°C進行5小時反應後,加入CBDA(2.73g,13.9 mmol)與NMP ( 16.7g),在4 0 °C進行6小時反應後得到聚 醯胺酸溶液。該聚醯胺酸溶液之數平均分子量爲23,500, 重量平均分子量爲5 5,800。 於所得之聚醯胺酸溶液(20.0g)加入NMP ( 13.3g ) 、及BCS(33.4g),得到向處理劑〔11〕。於該液晶配向 處理劑中未見到混濁或析出等異常現象,確認樹脂成分爲 均勻地溶解。 使用所得之液晶配向處理劑〔1 1〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表11所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 -88- 201030055 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例12&gt; 將 BODA ( 3.5 Og, 14.0 mmol ) 、m-PBCH5D ABz ( 3.75g, 8.39 mmol) —胺(Bll) ( 1.80g, 5.60 mmol ) 、及 DBA (2.13 g,14.0 mmol)於 NMP( 23.lg)中進行混 合,在80°C進行5小時反應後,加入CBDA ( 2.74g,14.0 mmol)與NMP ( I8.5g),在4 0 °C進行6小時反應後得到聚 醯胺酸溶液。 於該聚醯胺酸溶液(20. lg)中加入NMP使聚醯胺酸的 含有量成爲6質量%而稀釋後,加入作爲亞胺化觸媒之乙酸 酐(4.30g)、及吡啶(3.3 5g),於90°C進行3.5小時反應 。將該反應溶液投入於甲醇(3 00ml )中,過濾分離出所 得之沈澱物。將該沈澱物以甲醇洗淨,在1 00 °C進行減壓 乾燥後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲80% ,數平均分子量爲18,500,重量平均分子量爲48,9 00。 於該聚醯亞胺粉末(3.04g)加入NMP(19.5g)、及 BCS ( 27.5g),得到液晶配向處理劑〔1 2〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 2〕,與實施例i同樣 地製作出液晶胞’進行預傾角之評估。結果如表丨!所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 -89 - 201030055 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均句地垂直 配向。 又’使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例1 3 &gt; 將 BODA ( 3.50g, 14.0 mmol ) 、m-PBCH5DABz ( 3.75g,8.39 mmol )、二胺(B12 ) ( 2.58g, 8.39 mmol ) 、及 DBA(1.70g, 11.2 mmol )於 NMP(23.7g)中進行混 合’在80°C進行5小時反應後,加入CBDA(2.74g, 14.0 mmol )與NMP ( 19.0g ),在4 0 °C進行6小時反應後得到聚 醯胺酸溶液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐 (4.3 0 g )、及吡啶(3.3 5 g ),於9 0 °C進行3 · 5小時反應。 將該反應溶液投入於甲醇(2 80ml )中,過濾分離出所得 之沈澱物。將該沈澱物以甲醇洗淨,在100°C進行減壓乾 燥後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %, 數平均分子量爲17,800,重量平均分子量爲47,500。 於該聚醯亞胺粉末(3.21g)加入NMP(20.8g)、及 BCS ( 29.3g),得到液晶配向處理劑〔13〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 • 90 - 201030055 使用所得之液晶配向處理劑〔1 3〕,與實施例〗同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例14&gt; 將 BODA(3.51g,14.0 mmol ) 、m-PBCH7DABz ( 4.〇〇g, 8.42 mmol)、二胺(Bl) ( 1.36g, 5.6 1 mmol )、 及 DBA(2.13g, 14.0 mmol)於 NMP(22.8g)中進行混合 ,在80t進行5小時反應後,加入CBDA ( 2.75g, 14.0 mmol )與NMP ( 18.3g ),在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.2g )加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 4_30g )、及吡啶(3.33g ),於9(TC進行3.5小時反應。將 該反應溶液投入於甲醇(270ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲80%,數 平均分子量爲1 7,900,重量平均分子量爲47,3 00。 於該聚醯亞胺粉末(3.00g)加入NMP ( 19_5g)、及 -91 - 201030055 BCS ( 27.5g),得到液晶配向處理劑〔14〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 4〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表11所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例15&gt; 將 BODA ( 3.50g,14.0mol ) 、m - B P C Η 5 D A B z ( 3.9 8 g, 8.39 mmol)、二胺(Bl) (2.03g, 8.39 mmol)、及 DBA (1.70g,1 1.2 mmol )於 NMP (23.2g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA ( 2.74g,14.0 mmol )與 NMP ( 18.5g),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.29g )、及吡啶(3.35g),在80°C進行4小時反應。將該 反應溶液投入於甲醇(290ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 〇〇t進行減壓乾燥後 -92- 201030055 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲54% ,數平 均分子量爲17,8 00,重量平均分子量爲48,1 00。 於該聚醯亞胺粉末(3.50g)加入NMP(22.8g)、及 BCS ( 32.0g) ’得到液晶配向處理劑〔15〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 5〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。W, using the proton peak of the proton, and the proton peak of the NH group from the valeric acid present from 9.5 to 10. Oppm, the enthalpy is calculated by the following formula. Imidization rate (%) = (1-α· x/y)xl00 In the above formula, X is the proton peak product of the NH group of the proline, and y is the peak product from the reference proton, a The ratio of the number of reference protons to one NH proton of valeric acid when the polyamine acid (imine-75-201030055 conversion rate is 0%). <Example 1> BODA (3, 50 g, 14.0 mmol), m-PBCH5DABz (1.87 g, 4.20 mmol), diamine (Bl) (2.03 g, 8.39 mmol), and DBA (2.34 g, 15.4 mmol) After mixing in NMP (20.8 g), the reaction was carried out at 80 ° C for 5 hours, and then CBDA (2.74 g, 14.0 mmol) and NMP (16. 4 g) were introduced, and the reaction was carried out at 40 ° C for 6 hours to obtain polyfluorene. Amino acid solution. After adding NMP to the polyamic acid solution (20.1 g) to dilute the content of the polyproline to 6 mass%, acetic anhydride (2.50 g) and pyridine (1.92 g) were added as an imidization catalyst. The reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (3 ml), and the resulting precipitate was separated by filtration. The precipitate was washed with methanol to dryness under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 54%, a number average molecular weight of 18,500, and a weight average molecular weight of 47,100. NMP (19.5 g) and B C S (27 g 5 g) were added to the polyimine powder (3. g) to obtain a liquid crystal alignment treatment agent [1]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. &lt;Production of Liquid Crystal Cell&gt; The liquid crystal alignment treatment agent [1] obtained above was spin-coated on an ITO surface of a substrate having an electrode of 3 cm x 4 cm ITO attached 201030055, and was carried out at 80 ° C for 5 minutes at 2 1 0 ° The film was fired in a hot air circulating oven of C for 1 hour to prepare a polyimide film having a film thickness of 100 nm. The substrate with the liquid crystal alignment film was rubbed on a friction device having a roll diameter of 1 20 mm and a crepe cloth at a speed of 3 rpm, a light speed of 20 mm/sec, and a press-in amount of 0.3 mm. A substrate with a liquid crystal alignment film is obtained. Two sheets of the substrate having the liquid crystal alignment film were prepared, and a 6 μm bead spacer was spread on the surface of the liquid crystal alignment φ film, and then a sealing agent was applied thereto. The liquid crystal alignment film surface of the other substrate was set to the inner side, and the rubbing direction was reversed to form a hollow cell which hardened the sealing agent. In the empty cell, a transparent liquid crystal was injected by a vacuum injection method to obtain an anti-parallel alignment transparent liquid crystal cell. <Evaluation of the pretilt angle> The pretilt angle of the liquid crystal cell produced above was used, and a pretilt angle measuring device (ELSICON) was used. Model: PAS-301) was measured at room temperature. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as described above were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. &lt;Evaluation of voltage holding ratio&gt; The liquid crystal cell after the pretilt angle measurement was at 80. (At the temperature, a voltage of 4V of 60μηι -77-201030055 was applied, and the voltage after 16.67 ms and after 1 667 ms was measured, and the degree of voltage retention was calculated as the voltage holding ratio. The results are shown in Table 12. &lt;Residual charge Mitigation evaluation> The liquid crystal cell after the voltage holding rate measurement was applied with a DC voltage of 10 V for 30 minutes, and after short-circuiting for 1 second, the electricity generated in the liquid crystal cell was measured for 1 800 seconds. The residual charge was measured after the second and after 1 000 sec. The measurement was carried out using a 6254 liquid crystal physical property evaluation device manufactured by Toyo Technica Co., Ltd. The results are shown in Table 12. <Evaluation after high temperature placement> Liquid crystal after residual charge measurement The cells were placed in a high temperature bath set at 100 ° C for 7 days, and the voltage holding ratio and residual charge were measured. The results are shown in Table 12 and Table 13 which will be described later. <Example 2> BODA (3.51 g, 14.0 mmol), m-PBCH5DABz (3.76 g, 8.42 mmol), diamine (Bl) (1.36 g, 5.61 mmol), and DBA (2.13 g, 14.0 mmol) were mixed in NMP (22_0g). After 5 hours of reaction at 80 ° C, CBDA ( 2.75 g, 14.0 mmol) was added. And the NMP ( 17.6g ) ' is reacted at 40 ° C for 6 hours to obtain a poly-proline solution. NMP is added to the poly-proline solution (20.Og), and the content of the poly-proline is diluted. After 6 mass%, acetic anhydride (-78-201030055 4.32 g) and pyridine (3.35 g) were added as an imidization catalyst, and the reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (300 ml). The obtained precipitate was separated by filtration, and the precipitate was washed with methanol, and dried under reduced pressure at 10 ° C to obtain a polyimine powder. The imidization ratio of the polyimine was 80. %, the number average molecular weight was 1,800, and the weight average molecular weight was 48,900. NMP (22.0 g) and BCS (25.0 g) were added to the polyimine powder (3.00 g) to obtain a liquid crystal alignment treatment agent [2]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [2], liquid crystal cells were produced in the same manner as in Example 1, and pretilt angle was observed. Evaluation. The results are shown in Table 11. And, without friction treatment, will be The liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 1, the voltage holding ratio was evaluated and the residual charge was evaluated. And evaluation after high temperature placement. The results are shown in Table 12 and Table 13. &lt;Example 3&gt; BODA (3.50 g, 14.0 mmol), m-PBCH5DABz ( 3.75 g, 8.39 mmol), diamine (B2) (2.87 g, 11.2 mmol) and DBA ( 1.28 g, 8.39 mmol) After mixing in NMP (23.5 g) and reacting at 80 ° C for 5 hours, CBDA ( 2.78 g, 14.2 mmol) and NMP ( 18.8 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polyamine. 79- 201030055 Acid solution. After adding NMP to the polyamic acid solution (25.1 g) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (3.13 g) as an imidization catalyst and pyridine (2.42 g) were added. ), the reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (3 50 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried at a reduced pressure of 10 (TC) to give a polyimine powder. The imidization ratio of the polyimine was 56%, the number average molecular weight was 17,400, and the weight average molecular weight was 46,600. NMP (21.2 g) and BCS (25.8 g) were added to the polyimine powder (3.00 g) to obtain a liquid crystal alignment treatment agent [3]. No turbidity or precipitation was observed in the liquid crystal alignment treatment agent. An abnormality was observed, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [3], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11 below. The liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. The liquid crystal cell produced in the same manner as in Example 1 was used for voltage measurement. Evaluation of retention rate, evaluation of relaxation of residual charge, and evaluation after high temperature placement. The results are shown in Table 12 and Table 13. &lt;Example 4&gt; BODA (3.4 8 g, 13.9 mmol), m-PBCH5D ABz (3.7 3 g, 8.35 mmol ), Diamine (B3) (0.7 5 g, 2.78 mmol), 201030055 and DBA (2.54 g, 16.7 mmol) were mixed in NMP (22.0 g) at 80 ° (: after 5 hours of reaction, add 06〇8 ( 2.738, 13.9 111111〇1 ) and NMP ( 17.7g), a polyamine acid solution was obtained after 4 hours of reaction at 4 (TC). The polyaminic acid solution had a number average molecular weight of 24,100 and a weight average molecular weight of 57,200. NMP (1 g. 2 g) and BCS (25.0 g) were added to the obtained polyamidic acid solution (15.1 g) to obtain a liquid crystal alignment treatment agent [4]. No turbidity or precipitation was observed in the liquid crystal alignment treatment agent. The resin component was uniformly dissolved, and the liquid crystal cell was produced in the same manner as in Example 1 using the obtained liquid crystal alignment treatment agent [4], and the pretilt angle was evaluated. The results are shown in Table 11. The liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. The liquid crystal cell produced in the same manner as in Example 1 was used for voltage retention. Assessment, mitigation of residual charge And evaluation after high temperature standing. The results are shown in Table 1 2 and Table 13. [Example 5&gt; BODA (3.50 g, 14.0 mmol), m-PBCH5DABz (1.87 g, 4.20 mmol), diamine (B4) (1.81 g, 8.39 mmol), and DBA (2.34 g, 15.4 mmol) were mixed in NMP (20.4 g), and after 5 hours of reaction at 8 ° C, CBDA (2.74 g, 14.0 mmol) and NMP were added. (i6.3g), a 6-hour reaction at 4 ° C gave a polyamine-81 - 201030055 acid solution. After the NMP was added to the polyamic acid solution (25.1 g), and the content of the polyproline was 6 mass%, acetic anhydride (5.39 g) as an imidization catalyst and pyridine (4.18 g) were added. The reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (330 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 81%, a number average molecular weight of 17,500, and a weight average molecular weight of 47,500. NMP (22.7 g) and BCS (25.8 g) were added to the polyimine powder (3.10 g) to obtain a liquid crystal alignment treatment agent [5]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [5], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13. &lt;Example 6&gt; BODA (3.50 g, 14.0 mmol), m-PBCH5D ABz ( 1.87 g, 4.20 mmol), diamine (B5) (0.60 g, 2.80 mmol), 201030055 and DBA (3.19 g, 21.0 mmol) After mixing in NMP (19.8 g) and reacting at 80 ° C for 5 hours, CBDA (2.74 g, I4.〇mmol) and NMP (15.6 g) were added, and the mixture was reacted at 40 ° C for 6 hours to obtain a poly Alanine solution. After adding NMP to the polyamic acid solution (20.lg), the content of the diluted poly-araminic acid was 6% by mass, and acetic anhydride (2.5 1 g) as an imidization catalyst was added, and the D ratio was steep. (1.93 g), the reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (270 ml), and the obtained precipitate was separated. The precipitate was washed with methanol, and dried under reduced pressure to obtain a polyimine powder. The imidization ratio of the polyimine was 55%, and the number average molecular weight was 18,800. The average molecular weight is 48,300. In the polyimine powder (3.00 g), NMP (22.1 g) and BCS (25.0 g) are added to obtain a liquid crystal alignment treatment agent [6]. When an abnormal phenomenon such as turbidity or precipitation was observed, it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [6], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. The liquid crystal cell produced in the same manner as in Example 1 was used. Evaluation of voltage holding ratio, evaluation of residual charge relaxation, and evaluation after high temperature standing. The results are shown in Table 12 and Table 13. -83- 201030055 &lt;Example 7&gt; BODA (3.50 g, 14.0 mmol) m-PBCH5DABz ( 2.50g, 5.60 mmol , diamine (B6) (120g, 5.60 mmol), and DBA (2.55g, 16.8 mmol) were mixed in NMP (20.7 g), and after reacting at 80 ° C for 5 hours, CBDA ( 2.74 g, 14.0 mmol) and NMP (16.6 g) were reacted at 40 ° C for 6 hours to obtain a polyaminic acid solution. NMP was added to the polyamic acid solution (20.0 g) and diluted to the content of polyglycine. After 6% by mass, acetic anhydride (2.50 g) and pyridine (1·95 g) as an imidization catalyst were added, and the reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (28). In 0 ml), the obtained precipitate was separated by filtration, and the precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The imidization ratio of the polyimine was 5 6 %, the number average molecular weight was 17,800, and the weight average molecular weight was 48,100. NMP (26.1 g) and BCS (24.1 g) were added to the polyimine powder (3.21 g) to obtain a liquid crystal alignment treatment agent [7]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The obtained liquid crystal alignment treatment agent was used. [7] A liquid crystal cell was produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cell produced in the same manner as in Example 1 was polarized without rubbing treatment. Observation by a microscope confirmed that the liquid crystals were uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 1, the evaluation of the holding ratio of the voltage -84 - 201030055, the evaluation of the relaxation of the residual charge, and the evaluation after the high temperature standing were performed. The results are shown in Table 12 and Table 13. &lt;Example 8&gt; BODA (3.5 1 g, 14.0 mmol), m-PBCH5D ABz (2.5 1 g, 5.61 mmol), diamine (B7) (1.28 g, 5.60 mmol), and DBA (2.56 g, 16.8 mmol) was mixed in NMP (20.9 g), and after reacting at 80 ° C for 5 hours, CBDA ( 2.75 g, 14.0 mmol) and NMP (16.7 g) were added, and the mixture was reacted at 40 ° C for 6 hours to obtain a poly Proline solution. After adding NMP to the polyamic acid solution (25.2 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride ( 5.398) and pyridine (4.182) as an imidization catalyst were added to 90. °(: The reaction was carried out for 3.5 hours. The reaction solution was poured into methanol (330 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and dried under reduced pressure at 10 ° C to obtain a poly a quinone imine powder having an imidization ratio of 80% and a number average molecular weight of 17,200' weight average molecular weight of 47,100. The polyimine powder (3.00 g) is added with NMP (19. 5 g), and BCS (2 7 · 5 g ) 'The liquid crystal alignment treatment agent [8] was obtained. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The obtained liquid crystal alignment treatment agent was used. [8] The liquid crystal cell was produced in the same manner as in Example 1. The pretilt angle was evaluated. The results are shown in Table 且, and the liquid crystal cell-85 produced in the same manner as in Example 1 was used. - 201030055 Observed by polarized light microscope' The liquid crystal cells were uniformly aligned vertically. The evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high-temperature standing were carried out using the liquid crystal cell produced in the same manner as in Example 1. The results are shown in Table 12 and Table 13. &lt;Example 9&gt; BODA (3.51 g, 14.0 mmol), m-PBCH5DABz ( 3.76 g, 8.42 mmol), diamine (B8) (0.64 g, 2.81 mmol), and DBA (2_56 g, 16_8 mmol) After mixing in NMP (22.1 g) and reacting at 80 ° C for 5 hours, CBDA ( 2.75 g, 14.0 mmol) and NMP ( 17.6 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polydecylamine. The acid solution has a number average molecular weight of 2 〇, 9 00 and a weight average molecular weight of 50,900. NMP (1 O.Og) and BCS are added to the obtained polyglycine solution (20.0 g). 3 6 · 5 g ), the liquid crystal alignment treatment agent [9] was obtained. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The obtained liquid crystal alignment treatment agent [9] In the same manner as in Example 1, liquid crystal cells were produced and the pretilt angle was evaluated. The liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically as in Example 1 except that the rubbing treatment was carried out. The produced liquid crystal cells were subjected to voltage-86-201030055 'evacuation of residual charge and evaluation after high temperature placement. The results are shown in Tables 12 and 13. &lt;Example 1〇&gt; BODA (3.5 lg, 14.0 mmol), m-PBCH5DABz ( 3.76 g, 8.42 mmol), diamine (B9) (1.44 g, 5.61 mmol), and DBA (2.13 g, 14_) 〇mm〇i) was mixed in NMP (22.6 g). After reacting at 80 ° C for 5 hours, cBDA (2.75 g, 14.0 mmol) and NMP ( 18.1 g) were added, and after 4 hours of reaction at 4 (rc) The polyaminic acid solution was obtained. After the NMP was added to the polyamic acid solution (25.0 g), and the content of the polyproline was 6 mass%, acetic anhydride (5.39 g) as an imidization catalyst was added. And pyridine (4.18 g), the reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (330 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol at 100 ° C. The polyimine powder was obtained by drying under reduced pressure. The imidization ratio of the polyimine was 79%, the number average molecular weight was 18,100, and the weight average molecular weight was 48,900. The polyimine powder (3.01 g) was added. NMP (19.5 g) and BCS (27.5 g) obtained a liquid crystal alignment treatment agent [1]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent. It was confirmed that the resin component was uniformly dissolved. The liquid crystal cell was produced in the same manner as in Example 1 using the obtained liquid crystal alignment treatment agent [10], and the pretilt angle was evaluated. The results are shown in Table 11. The liquid crystal-87-201030055 produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 1 was used for voltage. Evaluation of retention rate, evaluation of relaxation of residual charge, and evaluation after high temperature placement. The results are shown in Table 12 and Table 13. &lt;Example 11&gt; BODA (3_48 g, 13.9 mmol), m-PBCH5DABz ( 2.49 g, 5.56) Methyl) (diamine (BIO) (0.90 g, 2.78 mmol), and DBA (2.96 g, 19.5 mmol) were mixed in NMP (20.8 g). After reacting at 80 ° C for 5 hours, CBDA (2.73 g) was added. , 13.9 mmol) and NMP (16. 7 g) were reacted at 40 ° C for 6 hours to obtain a polyaminic acid solution having a number average molecular weight of 23,500 and a weight average molecular weight of 5 5,800. Poly-proline solution (20.0g) added to NM P ( 13.3g ) and BCS (33.4g) were obtained as a treatment agent [11]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [1 1], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 1, the evaluation of the holding ratio of the voltage -88 - 201030055, the evaluation of the relaxation of the residual charge, and the evaluation after the high temperature standing were performed. The results are shown in Table 12 and Table 13. &lt;Example 12&gt; BODA (3.5 Og, 14.0 mmol), m-PBCH5D ABz ( 3.75 g, 8.39 mmol) -amine (Bll) ( 1.80 g, 5.60 mmol), and DBA (2.13 g, 14.0 mmol) The mixture was mixed in NMP (23 g), and after reacting at 80 ° C for 5 hours, CBDA ( 2.74 g, 14.0 mmol) and NMP (I8.5 g) were added, and the mixture was reacted at 40 ° C for 6 hours to obtain polyfluorene. Amino acid solution. After adding NMP to the polyamic acid solution (20. lg) to dilute the content of the polyproline to 6 mass%, acetic anhydride (4.30 g) as an imidization catalyst and pyridine (3.3) were added. 5 g), the reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (300 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyimine has an imidization ratio of 80%, a number average molecular weight of 18,500, and a weight average molecular weight of 48,900. NMP (19.5 g) and BCS (27.5 g) were added to the polyimine powder (3.04 g) to obtain a liquid crystal alignment treatment agent [1 2]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [1 2], liquid crystal cells were produced in the same manner as in Example i to evaluate the pretilt angle. The results are as shown! Shown. Further, the liquid crystal -89 - 201030055 produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was vertically aligned in a uniform sentence. Further, using the liquid crystal cell produced in the same manner as in Example 1, evaluation of voltage holding ratio, evaluation of relaxation of residual charge, and evaluation after high-temperature placement were performed. The results are shown in Table 12 and Table 13. &lt;Example 1 3 &gt; BODA ( 3.50 g, 14.0 mmol), m-PBCH5DABz ( 3.75 g, 8.39 mmol), diamine (B12) ( 2.58 g, 8.39 mmol), and DBA (1.70 g, 11.2 mmol) The mixture was mixed in NMP (23.7 g). After reacting at 80 ° C for 5 hours, CBDA (2.74 g, 14.0 mmol) and NMP (19.0 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polyfluorene. Amino acid solution. After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycine of 6 mass%, acetic anhydride (4.30 g) as an imidization catalyst, and pyridine (3.3) were added. 5 g ), 3 · 5 hours reaction at 90 ° C. The reaction solution was poured into methanol (2 80 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 81%, a number average molecular weight of 17,800, and a weight average molecular weight of 47,500. NMP (20.8 g) and BCS (29. 3 g) were added to the polyimine powder (3.21 g) to obtain a liquid crystal alignment treatment agent [13]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. • 90 - 201030055 Using the obtained liquid crystal alignment treatment agent [13], liquid crystal cells were produced in the same manner as in the examples, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13. &lt;Example 14&gt; BODA (3.51 g, 14.0 mmol), m-PBCH7DABz (4 g, 8.42 mmol), diamine (Bl) ( 1.36 g, 5.6 1 mmol), and DBA (2.13 g, 14.0 mmol) was mixed in NMP (22.8 g), and after reacting for 5 hours at 80 t, CBDA (2.75 g, 14.0 mmol) and NMP (1. 3 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polydecylamine. Acid solution. After adding NMP to the polyamic acid solution (20.2 g) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (4-30 g) and pyridine (3.33 g) as an imidization catalyst were added. The reaction was carried out at 9 (TC) for 3.5 hours. The reaction solution was poured into methanol (270 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and dried under reduced pressure at 100 ° C to obtain polyfluorene. The imine powder has an imidization ratio of 80%, a number average molecular weight of 17,900, and a weight average molecular weight of 47,300. The polyamidimide powder (3.00 g) is added to NMP (19_5 g). And -91 - 201030055 BCS (27.5g), the liquid crystal alignment agent [14] was obtained. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The alignment treatment agent [14] produced liquid crystal cells in the same manner as in Example 1, and evaluated the pretilt angle. The results are shown in Table 11. Further, the liquid crystal produced in the same manner as in Example 1 was used without the rubbing treatment. Observed by a polarizing microscope, confirmed The crystal cells were uniformly aligned vertically. The evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high-temperature standing were carried out using the liquid crystal cell produced in the same manner as in Example 1. The results are shown in Table 12 and Table 13. &lt;Example 15&gt; BODA (3.50 g, 14.0 mol), m-BPC Η 5 DAB z (3.98 g, 8.39 mmol), diamine (Bl) (2.03 g, 8.39 mmol), and DBA (1.70 g) , 1 1.2 mmol) was mixed in NMP (23.2 g), and after 5 hours of reaction at 8 ° C, CBDA ( 2.74 g, 14.0 mmol) and NMP ( 18.5 g) were added, and the reaction was carried out at 40 ° C for 6 hours. Then, a polyaminic acid solution was obtained. NMP was added to the polyamic acid solution (20.0 g), and the content of the poly-proline was 6 mass%, and acetic anhydride was added as an imidization catalyst ( 4.29 g). And pyridine (3.35 g), the reaction was carried out for 4 hours at 80 ° C. The reaction solution was poured into methanol (290 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol at 1 〇. 〇t was dried under reduced pressure -92-201030055 to obtain a polyimide pigment. The imidization ratio of the polyimine was 54%, number average The molecular weight was 17,8, and the weight average molecular weight was 48,100. To the polyimine powder (3.50 g), NMP (22.8 g) and BCS (32.0 g) were added to obtain a liquid crystal alignment treatment agent [15]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [15], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13.

&lt;實施例16&gt; 將 BODA ( 3.48g, 13.9 mmol ) 、p-PBCH5DABz ( 3.73g, 8.35 mmol )、二胺(Bl) (2.02g, 8.35 mmol )、 及 DBA(1.69g,11.1 mmol)於 NMP(22.7g)中進行混合 ,在80°C進行5小時反應後,加入CBDA ( 2.73g,13.9 mmol )與NMP ( 18_lg ),在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.5g)加入NMP ’稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( -93 - 201030055 4.358)、及吡啶(3.358),於90°〇進行3.5小時反應。將 該反應溶液投入於甲醇(2S 0ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在1〇〇 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲79%,數 平均分子量爲16,900,重量平均分子量爲46,800。 於該聚醯亞胺粉末(3.30g)加入NMP ( 22.7g )、及 BCS ( 25.8g),得到液晶配向處理劑〔16〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 6〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 〈比較例1 &gt; 將 BODA ( 3.51g,14.0 mmol ) 、PCH7DAB ( 1.60g, 4.21 mmol)、二胺(Bl) ( 2.04g, 8.42 mmol)、及 DBA (2.3 5 g, 15.4 mmol)於 NMP (20.3g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA ( 2.75g,14.0 mmol )與 NMP ( 16.3g),在40°C進行6小時反應後得到聚醯胺酸溶 201030055 液。 於該聚醯胺酸溶液(20.3g)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 2.50g )、及吡啶(1.94g ),在80°C進行4小時反應。將該 反應溶液投入於甲醇(28 0ml)中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1〇〇乞進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲54%,數平 均分子量爲1 7,000’重量平均分子量爲46,700。 於該聚醯亞胺粉末(3.30g)加入NMP(24.2g)、及 B C S ( 2 7 _ 5 g ),得到液晶配向處理劑〔丨7〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 7〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表1 2及表1 3所示。 &lt;比較例2 &gt; 將 BODA ( 3.50g,14.0 mmol ) 、PCH7DAB ( 5.31g,&lt;Example 16&gt; BODA (3.48 g, 13.9 mmol), p-PBCH5DABz (3.73 g, 8.35 mmol), diamine (Bl) (2.02 g, 8.35 mmol), and DBA (1.69 g, 11.1 mmol) were The mixture was mixed in NMP (22.7 g), and after reacting at 80 ° C for 5 hours, CBDA (2.73 g, 13.9 mmol) and NMP (18_lg) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain a polyaminic acid solution. After the polyacrylic acid solution (20.5 g) was added to NMP' diluted to a content of polyglycolic acid of 6 mass%, acetic anhydride (-93 - 201030055 4.358) as an imidization catalyst, and pyridine were added. 3.358), 3.5 hours reaction at 90 °. The reaction solution was poured into methanol (2 mL), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 ° C to obtain a polyimine powder. The polyimine had an imidization ratio of 79%, a number average molecular weight of 16,900, and a weight average molecular weight of 46,800. NMP (22.7 g) and BCS (25.8 g) were added to the polyimine powder (3.30 g) to obtain a liquid crystal alignment treatment agent [16]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [16], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13. <Comparative Example 1 &gt; BODA (3.51 g, 14.0 mmol), PCH7DAB ( 1.60 g, 4.21 mmol), diamine (Bl) (2.04 g, 8.42 mmol), and DBA (2.3 5 g, 15.4 mmol) in NMP (20.3 g) was mixed, and after reacting at 8 ° C for 5 hours, CBDA (2.75 g, 14.0 mmol) and NMP (16.3 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polylysine solution. 201030055 liquid. After adding NMP to the polyamic acid solution (20.3 g) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (2.50 g) as an imidization catalyst and pyridine (1.94 g) were added. The reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (280 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 Torr to give a polyimine powder. The polyamidimide had an imidization ratio of 54% and a number average molecular weight of 17,000. The weight average molecular weight was 46,700. To the polyimine powder (3.30 g), NMP (24.2 g) and B C S (27 g 5 g) were added to obtain a liquid crystal alignment treatment agent [丨7]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [17], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 1 2 and Table 13. &lt;Comparative Example 2 &gt; BODA (3.50 g, 14.0 mmol), PCH7DAB (5.31 g,

14.0 mmol )、二胺(Bl) ( 1.36g, 5.60 mmol )、及 DBA -95- 201030055 (l_28g,8.39 mmol)於 NMP(23.4g)中進行混合,在 80°C進行5小時反應後,加入CBDA(2,74g,14.0mmol)與 NMP ( 18.8g),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g )中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 2.48g) '及吡啶(1.94g),在80°C進行4小時反應。將該 反應溶液投入於甲醇(3 00ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在100°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 5%,數平 均分子量爲16,600,重量平均分子量爲46,100。 於該聚醯亞胺粉末(3.21g)加入NMP ( 23.5g )、及 BCS ( 26.7g),得到液晶配向處理劑〔18〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 8〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 201030055 &lt;比較例3 &gt; 將 BODA ( 3.50g,14.0 mmol ) 、m-PBCH5DABEs ( 3.87g, 8.39 mmol )、二胺(B1 ) ( 1.36g, 5.60 mmol)、 及 DBA(2.13g, 14.0 mmol)於 NMP(22.6g)中進行混合 ,在80°C進行5小時反應後,加入CBDA(2.74g, 14.0 mmol )與NMP ( 1 8.1 g ),在40°C進行6小時反應後得到聚醯胺 酸溶液。 於該聚醯胺酸溶液(20.0g)中加入NMP ’稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 2.51g)、及吡啶(1.95g),在80°C進行4小時反應。將該 反應溶液投入於甲醇(280ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 〇〇°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲54%,數平 均分子量爲1 7,400,重量平均分子量爲47,900。 於該聚醯亞胺粉末(3.01g)加入NMP(27.1g)、及 BCS ( 20.0g)後,引起樹脂成分之析出,無法得到液晶配 向處理劑。 因此,無法製作液晶胞。 &lt;比較例4 &gt; 將 BODA ( 3.49g,14.0 mmol ) 、PBP5DAB ( 3.54g, 8.37 mmol )、二胺(Bl) ( 1.35g, 5.58 mmol)、及 DBA (2.12g, 14_0 mmol)於 NMP(22.0g)中進行混合,在 80°C進行5小時反應後,加入CBDA(2.74g,14.0mmol)與 -97- 201030055 NMP ( 17.6g ),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g )中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 2.5 0g)、及吡啶(1.93g),在8 0°C進行4小時反應。將該 反應溶液投入於甲醇( 290ml)中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 〇〇°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲55 %,數平 均分子量爲16,400,重量平均分子量爲46,900。 於該聚醯亞胺粉末(3.20g)加入NMP ( 28.8g )、及 BCS ( 21.3g)後,引起樹脂成分之析出,無法得到液晶配 向處理劑。 因此,無法製作液晶胞。 &lt;比較例5 &gt; 將 BODA ( 3.48g,13.9 mmol ) 、PBCH5DAB ( 3.61g, 8.35 mmol )、二胺(Bl) ( 1.3 5 g, 5.56 mmol )、及 V· PDA(1.50g, 13.9 mmol)於 NMP(21.0g)中進行混合, 在8〇°C進行5小時反應後,加入CBDA(2.73g,13.9mmol) 與N MP ( 1 6 · 8 g ),在4 0 °C進行6小時反應後得到聚醯胺酸 溶液。 於該聚醯胺酸溶液(20.Og)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 2.48g)、及吡啶(1.94g),在80°C進行4小時反應。將該 -98- 201030055 反應溶液投入於甲醇(28 0ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 00 °C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲55%,數平 均分子量爲1 7,800,重量平均分子量爲48,1 00。 於該聚醯亞胺粉末(3.20g)加入NMP ( 22_ 1 g )、及 BCS ( 25.0g),得到液晶配向處理劑〔19〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔1 9〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均与地垂直 配向。 又,使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;比較例6&gt; 將 BODA ( 3.50g,14.0 mmol ) 、PBCH5DAB ( 3.63g, 8.39 mmol)、二胺(SI) ( 1 .35g, 5.60 mmol )、及 DBA (2.l3g, 14.0 mmol)於 NMP(22.2g)中進行混合,在 80t:進行5小時反應後,加入CBDA(2.74g, 14.0 mmo 1 )與 NMP ( 17.7g),在4〇°C進行6小時反應後得到聚醯胺酸溶 液。 -99 - 201030055 於該聚醯胺酸溶液(20.1g)中加入NMP使聚醯胺酸的 含有量成爲6質量%而稀釋後’加入作爲亞胺化觸媒之乙酸 酐(2 · 5 0 g )、及吡陡(1 · 9 5 g ) ’在8 0 °C進行4小時反應。 將該反應溶液投入於甲醇(2 90ml )中’過濾分離出所得 之沈澱物。將該沈澱物以甲醇洗淨,在1〇〇 °C進行減壓乾 燥後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲54% ’ 數平均分子量爲18,100,重量平均分子量爲47,800。 於該聚醯亞胺粉末(3.11g)加入NMP ( 2 2.7g )、及 BCS ( 25.8g),得到液晶配向處理劑〔20〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔20〕,與實施例1同樣 地製作出液晶胞,進行預傾角之評估。結果如表1 1所示。 且,未經摩擦處理以外,將與實施例1同樣所製作之液晶 胞以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直 配向。 又’使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表12及表13所示。 &lt;實施例21&gt; 將 BODA ( 3_51g, 14.0 mm〇l ) ' p B CH 5 D AB ( 1 _ 8 2 g, 4.21 mmol)、—胺(Bl) ( 2.04g, 8.42 mmol)、及 DBA (2.35g, 15.4 mmol)於 NMP(20.7g)中進行混合,在 -100- 201030055 8(TC進行5小時反應後,加入CBDA(2.75g,14.0mmol)與 NMP ( 1 6.6g ),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(2〇.〇g)中加入NMP’稀釋至聚醢 胺酸之含有量爲6質量%後’作爲亞胺化觸媒加入乙酸酐( 2.51g)、及吡啶(1.93g),在80°C進行4小時反應。將該 反應溶液投入於甲醇(28 0ml)中’過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨’在i〇〇°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 5 %,數平 均分子量爲19,100,重量平均分子量爲48,1 00。 於該聚醯亞胺粉末(3.01g)加入NMP(19.5g)、及 BCS ( 27.5g ),得到液晶配向處理劑〔21〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 &lt;液晶胞的製作&gt; 將上述所得之液晶配向處理劑〔21〕於3Cmx4Cm ITO 附有電極之基板的ITO面進行轉動塗佈,在80°C進行5分鐘 ’以2 1 (TC之熱風循環式烤箱進行1小時燒成,製作膜厚 100nm的聚醯亞胺塗膜。 於該附有液晶配向膜之基板,輥徑120mm、嫘縈布之 摩擦裝置,以回轉數3 OOrpm、輥進行速度20mm/sec、壓入 量0.3mm之條件下進行摩擦處理,得到附有液晶配向膜之 基板。 -101 - 201030055 準備2片該附有液晶配向膜之基板,於該1片液晶配向 膜面上散佈6 // m之珠子間隔物後,自該上面以封劑進行印 刷。使另1片的基板之液晶配向膜面作爲内側,貼合成摩 擦方向呈反方向後,製作出使封劑硬化之空胞。於該空胞 藉由減壓注入法,注入透明液晶,得到反平行配向之透明 液晶胞。 &lt;預傾角之評估&gt; 將上述所製作的液晶胞之預傾角,使用預傾角測定裝 置(ELSICON公司製模型:PAS-301 )於室溫下進行測定 。結果如表15所示。 又,未經摩擦處理以外,與上述同樣下所製作的液晶 胞藉由偏光顯微鏡觀察結果,確認出液晶呈均勻地垂直配 向。 &lt;電壓保持率之評估&gt; 於預傾角測定後之液晶胞,再8〇°C之溫度下外加60μιη 之4V電壓,測定16.67ms後及1667ms後之電壓’將電壓之 保持程度作爲電壓保持率而計算。結果如表1 6所示。 &lt;殘留電荷的緩和之評估&gt; 於電壓保持率測定後之液晶胞,外加30分鐘的直流電 壓1 0V,使其經1秒短路後,將於液晶胞内所產生的電位於 1 8 00秒間進行測定。再測定50秒後及1 000秒後之殘留電荷 -102- 201030055 。且,測定爲使用東陽Technica公司製6254型液晶物性評 估裝置。結果如表17所示。 &lt;高溫放置後之評估&gt; 將殘留電荷測定後之液晶胞,於設定爲1 〇(TC之高溫 槽中放置7天後,進行電壓保持率及殘留電荷之測定。結 果如表16及表17所示。 &lt;實施例22&gt; 將 BODA ( 3.49g,14.0 mmol ) 、PBCH5DAB ( 3.62g, 8.37 mmol )、二胺(Bl) ( 1 .35g, 5.58 mmol)、及 DBA (2.12g, 14.0 mmol )於 NMP (22_lg)中進行混合,在 80C進行5小時反應後,加入CBDA ( 2_74g,14.0 mmol)與 NMP ( 17.7g),在40°C進行6小時反應後得到聚醯胺酸溶 液。 φ 於該聚醯胺酸溶液(25.lg)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 5.4〇g )、及吡啶(4. 18g ),於90 °C進行3.5小時反應。將 該反應溶液投入於甲醇(3 3 0ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在1〇〇。(:進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 9,500,重量平均分子量爲49,5 00。 於該聚醯亞胺粉末(3.01g)加入NMP(22.0g)、及 BCS ( 25.lg) ’得到液晶配向處理劑〔22〕。於該液晶配 -103- 201030055 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解》 使用所得之液晶配向處理劑〔22〕,與實施例2 I同樣 地製作液晶胞’進行預傾角之評估。結果如表1 5所示。且 ’除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例23&gt; 將 BODA ( 3.55g,14.2 mmol ) 、PBCH5DAB ( 3.68g,14.0 mmol), diamine (Bl) ( 1.36 g, 5.60 mmol), and DBA-95-201030055 (1_28 g, 8.39 mmol) were mixed in NMP (23.4 g), and reacted at 80 ° C for 5 hours, then added CBDA (2, 74 g, 14.0 mmol) and NMP (18. 8 g) were reacted at 40 ° C for 6 hours to obtain a polyaminic acid solution. NMP was added to the polyamic acid solution (20.0 g), and the content of the polyamid acid was diluted to 6 mass%, and then acetic anhydride (2.48 g) and pyridine (1.94 g) were added as an imidization catalyst. The reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (300 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyimine had an imidization ratio of 55%, an average number average molecular weight of 16,600, and a weight average molecular weight of 46,100. NMP (23.5 g) and BCS (26.7 g) were added to the polyimine powder (3.21 g) to obtain a liquid crystal alignment treatment agent [18]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [18], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13. 201030055 &lt;Comparative Example 3 &gt; BODA (3.50 g, 14.0 mmol), m-PBCH5DABEs (3.87 g, 8.39 mmol), diamine (B1) ( 1.36 g, 5.60 mmol), and DBA (2.13 g, 14.0 mmol) After mixing in NMP (22.6 g) and reacting at 80 ° C for 5 hours, CBDA (2.74 g, 14.0 mmol) and NMP (1 8.1 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polyfluorene. Amino acid solution. After adding NMP' to the polyamic acid solution (20.0 g) to dilute to a content of polyglycolic acid of 6 mass%, acetic anhydride (2.51 g) and pyridine (1.95 g) were added as an imidization catalyst. The reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (280 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 54%, an average number average molecular weight of 17,400, and a weight average molecular weight of 47,900. After adding NMP (27.1 g) and BCS (20.0 g) to the polyimine powder (3.01 g), precipitation of the resin component was caused, and a liquid crystal alignment treatment agent could not be obtained. Therefore, it is impossible to produce a liquid crystal cell. &lt;Comparative Example 4 &gt; BODA (3.49 g, 14.0 mmol), PBP5DAB (3.54 g, 8.37 mmol), diamine (Bl) (1.35 g, 5.58 mmol), and DBA (2.12 g, 14_0 mmol) in NMP The mixture was mixed in (22.0 g), and after reacting at 80 ° C for 5 hours, CBDA (2.74 g, 14.0 mmol) and -97-201030055 NMP (1. 6 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polyfluorene. Amino acid solution. After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride (2.50 g) and pyridine (1.93 g) were added as an imidization catalyst. The reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (290 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 55 %, an average number average molecular weight of 16,400, and a weight average molecular weight of 46,900. After adding NMP (28.8 g) and BCS (21.3 g) to the polyimine powder (3.20 g), precipitation of a resin component was caused, and a liquid crystal alignment treatment agent could not be obtained. Therefore, it is impossible to produce a liquid crystal cell. &lt;Comparative Example 5 &gt; BODA (3.48 g, 13.9 mmol), PBCH5DAB (3.61 g, 8.35 mmol), diamine (Bl) (1.35 g, 5.56 mmol), and V·PDA (1.50 g, 13.9 mmol) The mixture was mixed in NMP (21.0 g), and after reacting at 8 ° C for 5 hours, CBDA (2.73 g, 13.9 mmol) and N MP (1 6 · 8 g) were added, and the mixture was reacted at 40 ° C for 6 hours. After the reaction, a polyaminic acid solution was obtained. After adding NMP to the polyamic acid solution (20. Og) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (2.48 g) and pyridine (1.94 g) were added as an imidization catalyst. ), the reaction was carried out at 80 ° C for 4 hours. The -98-201030055 reaction solution was poured into methanol (280 ml), and the resulting precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 55%, an average number average molecular weight of 17,800, and a weight average molecular weight of 48,100. NMP (22-1 g) and BCS (25.0 g) were added to the polyimine powder (3.20 g) to obtain a liquid crystal alignment treatment agent [19]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [19], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned with the ground. Further, the liquid crystal cells produced in the same manner as in Example 1 were used to evaluate the voltage holding ratio, the evaluation of the residual charge relaxation, and the evaluation after the high temperature standing. The results are shown in Table 12 and Table 13. &lt;Comparative Example 6&gt; BODA (3.50 g, 14.0 mmol), PBCH5DAB (3.63 g, 8.39 mmol), diamine (SI) (1.35 g, 5.60 mmol), and DBA (2.l3g, 14.0 mmol) were The mixture was mixed in NMP (22.2 g), and after reacting for 5 hours at 80 t, CBDA (2.74 g, 14.0 mmo 1 ) and NMP ( 17.7 g) were added, and the reaction was carried out at 4 ° C for 6 hours to obtain polylysine. Solution. -99 - 201030055 The NMP was added to the polyaminic acid solution (20.1 g) so that the content of the poly-proline was 6 mass%, and after dilution, 'acetic anhydride as an imidization catalyst was added (2 · 50 g ), and pyridox (1 · 9 5 g ) '4 hours reaction at 80 °C. The reaction solution was poured into methanol (2 90 ml), and the resulting precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 ° C to give a polyimine powder. The imidization ratio of the polyimine was 54%', the number average molecular weight was 18,100, and the weight average molecular weight was 47,800. NMP (2 2.7 g) and BCS (25.8 g) were added to the polyimine powder (3.11 g) to obtain a liquid crystal alignment treatment agent [20]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [20], liquid crystal cells were produced in the same manner as in Example 1, and the pretilt angle was evaluated. The results are shown in Table 11. Further, the liquid crystal cells produced in the same manner as in Example 1 were observed by a polarizing microscope, and it was confirmed that the liquid crystals were uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 1, evaluation of voltage holding ratio, evaluation of relaxation of residual charge, and evaluation after high-temperature placement were performed. The results are shown in Table 12 and Table 13. &lt;Example 21&gt; BODA (3_51 g, 14.0 mm〇l) ' p B CH 5 D AB (1 _ 8 2 g, 4.21 mmol), -amine (Bl) (2.04 g, 8.42 mmol), and DBA ( 2.35g, 15.4 mmol) was mixed in NMP (20.7 g), after -5 - 201030055 8 (TC was reacted for 5 hours, CBDA (2.75 g, 14.0 mmol) and NMP (1 6.6 g) were added at 40 ° After a reaction for 6 hours, a polyaminic acid solution was obtained. After the NMP' was added to the polyamic acid solution (2 〇.〇g), the content of the polyamid acid was diluted to 6% by mass. To the catalyst, acetic anhydride (2.51 g) and pyridine (1.93 g) were added, and the reaction was carried out for 4 hours at 80 ° C. The reaction solution was poured into methanol (280 ml), and the resulting precipitate was separated by filtration. The product was washed with methanol to obtain a polyimine powder after drying under reduced pressure at i ° ° C. The polyamidimide had an imidization ratio of 5 5 %, a number average molecular weight of 19,100, and a weight average molecular weight of 48. 00. Into the polyimine powder (3.01 g), NMP (19.5 g) and BCS (27.5 g) were added to obtain a liquid crystal alignment treatment agent [21]. No turbidity was observed in the liquid crystal alignment treatment agent. Analysis When the abnormality occurred, it was confirmed that the resin component was uniformly dissolved. &lt;Production of liquid crystal cell&gt; The liquid crystal alignment treatment agent [21] obtained above was spin-coated on the ITO surface of a substrate on which an electrode of 3 Cmx4Cm ITO was attached, and 80 °C was carried out for 5 minutes. The film was fired in a hot air circulating oven at TC for 1 hour to prepare a polyimide film having a thickness of 100 nm. The substrate having the liquid crystal alignment film was 120 mm in diameter. The rubbing device of the cloth was subjected to rubbing treatment under the conditions of a number of revolutions of 3 OO rpm, a roll speed of 20 mm/sec, and a press-in amount of 0.3 mm to obtain a substrate with a liquid crystal alignment film. -101 - 201030055 Preparation of 2 sheets of the liquid crystal The substrate of the alignment film is spread on the surface of the liquid crystal alignment film by 6/m, and then printed on the upper surface by a sealing agent. The liquid crystal alignment film surface of the other substrate is used as the inner side, and is laminated. After the rubbing direction is in the opposite direction, a hollow cell for hardening the sealing agent is prepared, and the transparent liquid crystal is injected into the empty cell by a vacuum injection method to obtain an anti-parallel aligned transparent liquid crystal cell. <Evaluation of pretilt angle> The liquid crystal produced above The pretilt angle was measured at room temperature using a pretilt angle measuring apparatus (Model: PAS-301, manufactured by ELSICON Co., Ltd.), and the results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as described above except for the rubbing treatment was used. The results of observation by a polarizing microscope confirmed that the liquid crystals were uniformly aligned vertically. &lt;Evaluation of voltage holding ratio&gt; The liquid crystal cell after the pretilt angle measurement was applied with a voltage of 4 V of 60 μm at a temperature of 8 ° C, and the voltage after 16.67 ms and after 1667 ms was measured as the voltage retention. Calculated by rate. The results are shown in Table 16. &lt;Evaluation of relaxation of residual charge&gt; After the voltage holding ratio was measured, the liquid crystal cell was applied with a DC voltage of 10 V for 30 minutes, and after being short-circuited for 1 second, the electricity generated in the liquid crystal cell was located at 1 800. The measurement was performed in seconds. The residual charge after 50 seconds and 1 000 seconds was measured again -102- 201030055. Further, it was measured to use a 6254 type liquid crystal property evaluation device manufactured by Dongyang Technica Co., Ltd. The results are shown in Table 17. &lt;Evaluation after high temperature placement&gt; The liquid crystal cell after the measurement of the residual charge was subjected to measurement for 1 day in a high temperature bath set to 1 Torr, and the voltage holding ratio and residual charge were measured. The results are shown in Table 16 and Table. &lt;Example 22&gt; BODA (3.49 g, 14.0 mmol), PBCH5DAB (3.62 g, 8.37 mmol), diamine (Bl) (1.35 g, 5.58 mmol), and DBA (2.12 g, 14.0) Methyl) was mixed in NMP (22_lg), and after reacting at 80 C for 5 hours, CBDA (2_74 g, 14.0 mmol) and NMP (17. 7 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain a polyaminic acid solution. φ was added to the polyacrylic acid solution (25.lg), and diluted to a content of the polyamidic acid of 6 mass%, and then acetic anhydride (5.4 〇g) as an imidization catalyst, and pyridine ( 4. 18g), the reaction was carried out for 3.5 hours at 90 ° C. The reaction solution was poured into methanol (300 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol at 1 Torr. (: Polyimine powder was obtained after drying under reduced pressure. The imidization ratio of the polyimine was 81%, and the number average molecular weight was 1,900. The weight average molecular weight was 49,500. The liquid phase alignment treatment agent [22] was obtained by adding NMP (22.0 g) and BCS (25 g) to the polyimine powder (3.01 g). - 201030055 No abnormality such as turbidity or precipitation was observed in the treatment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [22], the liquid crystal cell was produced in the same manner as in Example 2, and the pretilt angle was observed. The results are shown in Table 15. The liquid crystal cells produced in the same manner as in Example 21 were observed by a polarizing microscope except that the rubbing treatment was carried out, and it was confirmed that the liquid crystals were uniformly aligned vertically. Example 2 1 The liquid crystal cell produced in the same manner was subjected to evaluation of voltage holding ratio, evaluation of relaxation of residual charge, and evaluation after high temperature standing. The results are shown in Table 16 and Table 17. &lt;Example 23&gt; BODA (3.55) g, 14.2 mmol), PBCH5DAB ( 3.68 g,

8.51 mmol)、二胺(B2) ( 2.91 g, 11.4 mmol )、及 DBA (1.30g,8.51 mmol)於 NMP (23.6g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA(2.78g, 14·2 mmol )與 NMP ( 18.9g ),在4 0 °C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.〇g)中加入NMP’稀釋至聚醯 胺酸之含有量爲6質量%後’作爲亞胺化觸媒加入乙酸酐( 2.51g)、及吡啶(1.93g) ’在80°C進行4小時反應。將該 反應溶液投入於甲醇(280ml)中’過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨’在100艺進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲55 %’數平 -104 &gt; 201030055 均分子量爲1 8,200,重量平均分子量爲47,200。 於該聚醯亞胺粉末(3.11g)加入NMP ( 22.7g )、及 BCS ( 25.8g),得到液晶配向處理劑〔23〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔23〕,與實施例21同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 ❹ 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例24&gt; 將 BODA ( 3_51g,14.0 mmol ) 、PBCH5DAB ( 3.64g,8.51 mmol), diamine (B2) (2.91 g, 11.4 mmol), and DBA (1.30 g, 8.51 mmol) were mixed in NMP (23.6 g), and after 5 hours of reaction at 8 ° C, CBDA was added ( 2.78 g, 14·2 mmol) and NMP (18.9 g) were reacted at 40 ° C for 6 hours to obtain a polyaminic acid solution. After the NMP' was added to the polyamic acid solution (20. g) to be diluted to a content of polyglycolic acid of 6 mass%, acetic anhydride (2.51 g) and pyridine (1.93) were added as an imidization catalyst. g) 'A reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (280 ml), and the resulting precipitate was separated by filtration. The precipitate was washed with methanol to dryness under reduced pressure at 100% to obtain a polyimine powder. The imidization ratio of the polyimine was 55 % 'number - 104 &gt; 201030055 The average molecular weight was 1,800 and the weight average molecular weight was 47,200. NMP (22.7 g) and BCS (25.8 g) were added to the polyimine powder (3.11 g) to obtain a liquid crystal alignment treatment agent [23]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [23], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 21 was used, and the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 24&gt; BODA (3_51 g, 14.0 mmol), PBCH5DAB (3.64 g,

8.42 mmol)、二胺(B3) ( 0.76g, 2.81 mmol)、及 DBA (2.56g, 16·8 mmol)於 NMP ( 22.0g)中進行混合,在 80°C進行5小時反應後,加入CBDA(2.75g, 14.0 mmol)與 NMP ( 17.6g) ’在40 °C進行6小時反應後得到聚醯胺酸溶 液。該聚醯胺酸溶液之數平均分子量爲22,600,重量平均 分子量爲54,600。 於所得之聚醯胺酸溶液(1 5.〇g )加入NMP ( 1 0· 1 g ) 、及BCS ( 25.0g),得到液晶配向處理劑〔24〕。於該液 -105- 201030055 晶配向處理劑中未見到混濁或析出等異常現象,確認樹脂 成分爲均勻地溶解。 使用所得之液晶配向處理劑〔24〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均句地垂直配 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例25&gt; 將 BODA ( 3.48g,13.9 mmol ) 、PBCH5DAB ( 1.81g,8.42 mmol), diamine (B3) (0.76 g, 2.81 mmol), and DBA (2.56 g, 16·8 mmol) were mixed in NMP (22.0 g). After 5 hours at 80 ° C, CBDA was added. (2.75 g, 14.0 mmol) and NMP (1.76 g)' were reacted at 40 ° C for 6 hours to give a polyaminic acid solution. The polyaminic acid solution had a number average molecular weight of 22,600 and a weight average molecular weight of 54,600. NMP (10.1 g) and BCS (25.0 g) were added to the obtained polyamic acid solution (1. g) to obtain a liquid crystal alignment treatment agent [24]. No abnormality such as turbidity or precipitation was observed in the liquid-to-treatment agent in the liquid-105-201030055, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [24], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was vertically aligned in a uniform manner. Further, using the liquid crystal cell produced in the same manner as in Example 21, the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 25&gt; BODA (3.48 g, 13.9 mmol), PBCH5DAB (1.81 g,

4.17 mmol)、二胺(B4) ( 1 · 8 0 g, 8 . 3 5 mmol )、及 DBA (2.33g,15.3 mmol)於 NMP ( 20.2g)中進行混合,在 8〇 °C進行5小時反應後,加入CBD A ( 2.73 g,1 3.9 mmol )與 NMP ( 16.lg),在4(TC進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.3 1g)、及吡啶(3.34g),於90°C進行3.5小時反應。將 該反應溶液投入於甲醇(260ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在l〇〇°C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲80%,數 -106- 201030055 平均分子量爲17,100,重量平均分子量爲46,000。 於該聚醯亞胺粉末(3.0〇g)加ANMP(22.1g)、及 BCS ( 25.3g),得到液晶配向處理劑〔2 5〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔25〕,與實施例21同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例26&gt; 將 BODA ( 3.50g, 14.0 mmol ) 、PBCH5DAB ( 1.82g,4.17 mmol), diamine (B4) (1·80 g, 8.3 mmol), and DBA (2.33 g, 15.3 mmol) were mixed in NMP (20.2 g) for 5 hours at 8 °C After the reaction, CBD A (2.73 g, 1 3.9 mmol) and NMP (16 lg) were added, and after 4 hours of TC reaction, a polyaminic acid solution was obtained. In the polyamic acid solution (20.0 g) After adding NMP and diluting to a content of polyglycolic acid of 6% by mass, acetic anhydride (4.31 g) and pyridine (3.34 g) were added as an imidization catalyst, and the reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (260 ml), and the obtained precipitate was separated by filtration, and the precipitate was washed with methanol, and dried under reduced pressure at 10 ° C to obtain a polyimine powder. The imidization ratio is 80%, the number -106-201030055 average molecular weight is 17,100, and the weight average molecular weight is 46,000. The polyimine powder (3.0 〇g) plus ANMP (22.1 g), and BCS (25.3) g) A liquid crystal alignment treatment agent [25] was obtained. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [25], a liquid crystal cell was produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. The same as in Example 21 except that the rubbing treatment was not performed. The liquid crystal cell produced was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 21 was used to evaluate the voltage holding ratio, the evaluation of the residual charge, and the high temperature. Evaluation after standing. The results are shown in Table 16 and Table 17. &lt;Example 26&gt; BODA (3.50 g, 14.0 mmol), PBCH5DAB (1.82 g,

4.20 mmol)、二胺(B5) ( 0.60g, 2.80 mmol)、及 DBA (3.19g,2 1.0 mmol )於 NMP(19.7g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA(2.74g,14.0mmol)與 NMP ( 15.7g),在4〇°C進行6小時反應後得到聚醢胺酸溶 液。 於該聚醯胺酸溶液(25.0g )加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 3.13g)、及吡啶(2.42g),在80°C進行4小時反應。將該 -107- 201030055 反應溶液投入於甲醇(3 40ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1〇〇 °C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 3 %,數平 均分子量爲19,400,重量平均分子量爲49,300。 於該聚醯亞胺粉末(4.01g)加入NMP(29.3g)、及 BCS ( 33.3g),得到液晶配向處理劑〔26〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔26〕,與實施例21同樣 地製作液晶胞,進行預傾角之評估。結果如表15所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表1 6及表1 7所示。 &lt;實施例2 7 &gt; 將 BODA ( 3.52g,14.1 mmol ) 、PBCH5DAB ( 2.43g,4.20 mmol), diamine (B5) (0.60 g, 2.80 mmol), and DBA (3.19 g, 2 1.0 mmol) were mixed in NMP (19.7 g), and after 5 hours at 8 ° C, CBDA was added. (2.74 g, 14.0 mmol) and NMP ( 15.7 g) were reacted at 4 ° C for 6 hours to obtain a polyaminic acid solution. After adding NMP to the polyamic acid solution (25.0 g) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (3.13 g) as an imidization catalyst and pyridine (2.42 g) were added. The reaction was carried out at 80 ° C for 4 hours. The -107-201030055 reaction solution was poured into methanol (3 40 ml), and the resulting precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 1 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 53%, an average number average molecular weight of 19,400, and a weight average molecular weight of 49,300. NMP (29.3 g) and BCS (33.3 g) were added to the polyimine powder (4.01 g) to obtain a liquid crystal alignment treatment agent [26]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [26], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 21 was used, and the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 2 7 &gt; BODA (3.52 g, 14.1 mmol), PBCH5DAB (2.43 g,

5.63 mmol)、二胺(B6) ( 1 .21 g, 5.63 mmol )、及 DBA (2‘57g, 1 6_9 mmol )於 NMP ( 20.7g )中進行混合,在 80°C進行5小時反應後,加入CBDA(2.76g,14.1 mmol)與 NMP ( 16.6g),在40°C進行6小時反應後得到聚醯胺酸溶 液。 -108- 201030055 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 2.51g)、及吡啶(1.93g),在80°C進行4小時反應。將該 反應溶液投入於甲醇(28 0ml )中,過瀘分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在100°C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲5 5 %,數平 均分子量爲1 8,300,重量平均分子量爲48,3 00。 於該聚醯亞胺粉末(4.00g)加入NMP(32.7g)、及 BCS ( 30.lg),得到液晶配向處理劑〔27〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔27〕,與實施例21同樣 地製作液晶胞,進行預傾角之評估。結果如表15所示。且 ,未經摩擦處理以外,將與實施例1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均句地垂直配 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例28&gt; 將 BODA ( 3.50g,14.0 mmol ) 、PBCH5DAB ( 2.42g,5.63 mmol), diamine (B6) (1.21 g, 5.63 mmol), and DBA (2'57 g, 1 6_9 mmol) were mixed in NMP (20.7 g), and reacted at 80 ° C for 5 hours. CBDA (2.76 g, 14.1 mmol) and NMP (16.6 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain a polyaminic acid solution. -108- 201030055 After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride (2.51 g) and pyridine were added as an imidization catalyst. (1.93 g), the reaction was carried out at 80 ° C for 4 hours. The reaction solution was poured into methanol (280 ml), and the obtained precipitate was separated. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide has an imidization ratio of 55 %, an average number average molecular weight of 1,800, and a weight average molecular weight of 48,300. NMP (32.7 g) and BCS (30. lg) were added to the polyimine powder (4.00 g) to obtain a liquid crystal alignment treatment agent [27]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [27], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 1 was observed by a polarizing microscope, and it was confirmed that the liquid crystal was vertically aligned in a uniform sentence. Further, using the liquid crystal cell produced in the same manner as in Example 21, the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 28&gt; BODA (3.50 g, 14.0 mmol), PBCH5DAB (2.42 g,

5.60 mmol )、二胺(B7) ( 1 .2 8 g, 5.60 mmol)、及 DBA (2.55g,16.8 mmol)於 NMP (20.8g)中進行混合,在 -109- 201030055 80 °C進行5小時反應後,加入CB DA (2.74g,14.0 mmol )與 NMP ( 16.6g ),在4〇t進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.Og)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.318)、及吡啶(3.348),於90°(:進行3.5小時反應。將 該反應溶液投入於甲醇(260ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 6,300,重量平均分子量爲46,300。 於該聚醯亞胺粉末(3.51g)加入NMP(22.8g)、及 BCS ( 3 2. lg),得到液晶配向處理劑.〔2 8〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔2 8〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又’使用與實施例2 1同樣所製作之液晶胞,進彳了電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例29&gt; -110- 201030055 將 BODA ( 3.51g,14.0 mmol ) 、P B C H 5 D A B ( 3.64 g,5.60 mmol), diamine (B7) (1.28 g, 5.60 mmol), and DBA (2.55 g, 16.8 mmol) were mixed in NMP (20.8 g) for 5 hours at -109-201030055 80 °C After the reaction, CB DA (2.74 g, 14.0 mmol) and NMP (16. 6 g) were added, and the mixture was reacted at 4 Torr for 6 hours to obtain a polyaminic acid solution. After adding NMP to the polyamic acid solution (20. Og) and diluting to a content of polyamine acid of 6 mass%, acetic anhydride (4.318) and pyridine (3.348) were added as an imidization catalyst. The reaction was carried out at 90° (the reaction was carried out for 3.5 hours). The reaction solution was poured into methanol (260 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and dried under reduced pressure at 100 ° C to obtain a poly The imine imide powder has an imidization ratio of 81%, a number average molecular weight of 16,300, and a weight average molecular weight of 46,300. The polyamidimide powder (3.51 g) is added with NMP (22.8 g). And BCS (3 2. lg), a liquid crystal alignment treatment agent was obtained. [28] No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The alignment treatment agent [28] was prepared in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. The same procedure as in Example 21 was carried out except that the rubbing treatment was not performed. The liquid crystal cell was observed by a polarizing microscope, and it was confirmed that the liquid crystal was present. The liquid crystal cell produced in the same manner as in Example 2 was evaluated by the evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high temperature standing. The results are shown in Table 16 and Table 17. &lt;Example 29&gt; -110- 201030055 BODA (3.51 g, 14.0 mmol), PBCH 5 DAB ( 3.64 g,

8.42 mmol)、二胺(B8) ( 0.64g, 2.81 mmol )、及 DBA (2.56g, 16.8 mmol )於 NMP (20.8g)中進行混合,在 80T:進行5小時反應後,加入CBDA(2_75g,14.0mmol)與 NMP ( 16.6g),在40°C進行6小時反應後得到聚醯胺酸溶 液。該聚醯胺酸溶液之數平均分子量爲21,500,重量平均 分子量爲52,300 。 於所得之聚醯胺酸溶液(20.1g)加入NMP ( 10.0g ) 、及BCS(36.7g),得到液晶配向處理劑〔29〕。於該液 晶配向處理劑中未見到混濁或析出等異常現象,確認樹脂 成分爲均勻地溶解。 使用所得之液晶配向處理劑〔29〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例30&gt; 將 BODA ( 3.50g,14.0 mmol ) 、P B C Η 5 D A B ( 3.6 3 g,8.42 mmol), diamine (B8) (0.64 g, 2.81 mmol), and DBA (2.56 g, 16.8 mmol) were mixed in NMP (20.8 g), and after 80 hours: 5 hours reaction, CBDA (2_75 g, 14.0 mmol) and NMP (16. 6 g) were reacted at 40 ° C for 6 hours to obtain a polyaminic acid solution. The polyamic acid solution had a number average molecular weight of 21,500 and a weight average molecular weight of 52,300. NMP (10.0 g) and BCS (36.7 g) were added to the obtained polyamic acid solution (20.1 g) to obtain a liquid crystal alignment treatment agent [29]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [29], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 21, the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 30&gt; BODA (3.50 g, 14.0 mmol), P B C Η 5 D A B (3.6 3 g,

8.39 mmol )、二胺(B9) ( 1.44g, 5.60 mmol)、及 DBA (2.13g,14.0 mmol)於 NMP ( 22.3g)中進行混合,在 -111 - 201030055 8〇°C進行5小時反應後,加入cBDA(2_74g,14.0mmol)與 NMP ( 17.9g) ’在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4 · 3 1 g )、及吡啶(3 · 3 5 g ),於9 0 °C進行3.5小時反應。將 該反應溶液投入於甲醇(3 00ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲7 8 %,數 平均分子量爲1 7,900,重量平均分子量爲49,100。 於該聚醢亞胺粉末(3.20g)加入NMP(20.8g)、及 BCS ( 29.3g),得到液晶配向處理劑〔30〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 0〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果’確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例31&gt; -112- 201030055 將 BODA ( 3.48g, 13.9 mmol ) 、P B C H 5 D A B ( 2.4 1 g. 5.56 mmol )、二胺(BIO) ( 0.90g, 2.78 mmol )、及 DBA ( 2.96g, 19.5 mmol )於 NMP( 20.7g)中進行混合, 在80°C進行5小時反應後,加入CBDA(2.73g,13.9mm〇l) 與NMP ( 16.6g),在40°C進行6小時反應後得到聚醯胺酸 溶液。該聚醯胺酸溶液之數平均分子量爲20,100,重量平 均分子量爲50,100。 於所得之聚醯胺酸溶液(1 5 · 0 g )加入Ν Μ P ( 1 0 . 1 g ) 、及BCS ( 25.0g),得到液晶配向處理劑〔31〕。於該液 晶配向處理劑中未見到混濁或析出等異常現象,確認樹脂 成分爲均勻地溶解。 使用所得之液晶配向處理劑〔3 1〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ’除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例32&gt; 將 BODA ( 3.49g,14.0 mmol ) 、PBCH5DAB ( 3.62g, 8.37 mmol )、二胺(Bll) ( 1.79g, 5.58 mmol)、及 DBA(2.12g, 14.0 mmol)於 NMP(22.9g)中進行混合, -113- 201030055 在80°C進行5小時反應後,加入CBDA(2.74g,14.0mmol) 與NMP ( 18.3g) ’在4〇t進行6小時反應後得到聚醯胺酸 溶液。 於該聚醯胺酸溶液(20.0g)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.318)、及吡啶(3.358),於90艺進行3.5小時反應。將 該反應溶液投入於甲醇(290ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 8,200,重量平均分子量爲48,400。 於該聚醯亞胺粉末(3.31g)加入NMP(21.5g)、及 BCS(30.3g) ’得到液晶配向處理劑〔η〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 2〕,與實施例2 1同樣 地製作液晶胞’進行預傾角之評估。結果如表1 5所示。且 ’除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又’使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例33&gt; -114- 201030055 將 BODA ( 3.50g,14.0 mmol) 、P B C H 5 D AB ( 3.6 3 g, 8.39 mmol )、二胺(B12) ( 2.58g, 8.39 mmol )、及 DBA(1.70g,11·2 mmol)於 NMP(23.5g)中進行混合, 在80°C進行5小時反應後,加入CBDA(2.74g, 14.0 mmol ) 與NMP ( 18.8g ) ’在4〇°C進行6小時反應後得到聚醯胺酸 溶液。 於該聚醯胺酸溶液(20.2g)加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 4 · 3 2 g )、及吡啶(3.3 4 g ),於9 0 °C進行3 · 5小時反應。將 該反應溶液投入於甲醇(280ml)中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在1 0 0 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 0%,數 平均分子量爲17,100,重量平均分子量爲47,100。 於該聚醯亞胺粉末(3.50g)加入NMP(22.8g)、及 BCS ( 32.lg) ’得到液晶配向處理劑〔33〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 3〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ’除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均句地垂直配 向。 又’使用與實施例1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 -115- 201030055 。結果如表1 6及表1 7所示。 &lt;實施例34&gt; 將 BODA ( 3.48g,13.9 mmol ) 、p B C Η 7 D AB ( 3.8 4 g, 8.35 mmol)、二胺(Bl) ( 1 .3 5 g, 5.56 mmol )、及 DBA (2.12g,13.9 mmol)於 NMP(22.4g)中進行混合,在 80°C進行5小時反應後,加入CBDA ( 2_73g,13·9 mmol)與 NMP ( 18.Og),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.Og)中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.318)、及吡啶(3.348),於90°(:進行3.5小時反應。將 該反應溶液投入於甲醇(270ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100°C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 8,900,重量平均分子量爲48,900。 於該聚醯亞胺粉末(3.11g)加入NMP(20.2g)、及 BCS ( 28.4g),得到液晶配向處理劑〔3 4〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 4〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均句地垂直配 -116- 201030055 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例35&gt; 將 BODA ( 3.51g,14.0mol ) 、PBCH7DAB ( 3.88g, 8.42 mmol)、二胺(Bl) ( 2.04g, 8.42 mmol)、及 DBA (1.71g,11.2 mmol)於 NMP (23.1g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA(2.75g,14.0mmol)與 NMP ( 18.4g),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.2g )加入NMP,稀釋至聚醯胺 酸的含有量爲6質量%後,加入作爲亞胺化觸媒之乙酸酐( 4_52g)、及吡啶(3.61g),於9(TC進行5小時反應。將該 ® 反應溶液投入於甲醇(3 1 0ml )中,過濾分離出所得之沈 澱物。將該沈澱物以甲醇洗淨,在1 0 0 °C進行減壓乾燥後 得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲9 2 %,數平 均分子量爲17,100,重量平均分子量爲46,900。 於該聚醯亞胺粉末(3_51g)加入NMP(22.8g)、及 BCS ( 32.1g ),得到液晶配向處理劑〔35〕。於該液晶配 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 5〕,與實施例2 1同樣 -117- 201030055 地製作液晶胞’進行預傾角之評估。結果如表1 5所示。且 ’除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例2 1同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;實施例36&gt; 將 BODA ( 3.50g, 14.0 mmol ) 、BPCH5DAB ( 3.59g, 8.39 mmol)、二胺(Bl) ( 2.03g, 8.39 mmol)、及 DBA (1.70g, 11.2 mmol)於 NMP(22.5g)中進行混合,在 8〇°C進行5小時反應後,加入CBDA(2.74g,14.0mmol)與 NMP ( 18.Og),在40°C進行6小時反應後得到聚醯胺酸溶 液。 於該聚醯胺酸溶液(20.0g )中加入NMP,稀釋至聚醯 胺酸之含有量爲6質量%後,作爲亞胺化觸媒加入乙酸酐( 4.31呂)、及吡啶(3.348),於90°(:進行3.5小時反應。將 該反應溶液投入於甲醇(270ml )中,過濾分離出所得之 沈澱物。將該沈澱物以甲醇洗淨,在100 °C進行減壓乾燥 後得到聚醯亞胺粉末。該聚醯亞胺之亞胺化率爲8 1 %,數 平均分子量爲1 8,900,重量平均分子量爲48,900。 於該聚醯亞胺粉末(3.11g)加入NMP(22_7g)、及 BCS ( 25.8g),得到液晶配向處理劑〔36〕。於該液晶配 201030055 向處理劑中未見到混濁或析出等異常現象,確認樹脂成分 爲均勻地溶解。 使用所得之液晶配向處理劑〔3 6〕,與實施例2 1同樣 地製作液晶胞,進行預傾角之評估。結果如表1 5所示。且 ,除未經摩擦處理以外,與實施例2 1同樣所製作之液晶胞 以偏光顯微鏡進行觀察結果,確認出液晶呈均勻地垂直配 向。 又,使用與實施例21同樣所製作之液晶胞,進行電壓 保持率之評估、殘留電荷之緩和評估及高溫放置後之評估 。結果如表16及表17所示。 &lt;印刷性試験&gt; 使用實施例1〜16、21〜36、比較例1、2、5、及6所 得之液晶配向處理劑進行印刷。印刷機使用曰本照片印刷 公司製簡易印刷機(S 1 5型)。印刷爲於洗淨之鉻蒸鍍基 板上,印刷面積8cmx8cm、印壓0.2mm、捨棄基板5片、印 刷至假乾燥之時間爲90秒,假乾燥溫度70°C、5分鐘下進 行。 針孔之確認於鈉燈下以目視觀察進行’表11及表1 5中 針孔數作爲印刷性表示。 -119- 201030055 [表9] 液晶配向 處理劑 酸二酐成分 二胺成分 二胺化飾 (A) 二胺化飾 (B) 二胺化合物 (C) 實施例1 [1] CBDA (14.0mmoO BODA (14.0mrr&gt;oO m-PBCH5DABz (4.20 mm οί} B1 (8.39mmol) DBA (15.4mmo0 實施例2 [2】 CBDA (14.0mmoi) BODA (14.0mmoD fn-PBCH5DABz (8.42mmoO B1 (5.61 mmoO DBA (HOmnnol) 實施例3 [3] CBDA (14.0 mmol) BODA (14_2mmol) m-PBCH5DABz (8.39 mmol) B2 (112mmol) DBA (8.39 mmol) 實施例4 [4] CBDA (13.9 mmol) BODA (13.9mmol) m-PBCH5DABz (8.35 mm 〇0 B3 C2.78mmoO DBA (16.7mm〇0 實施例5 [5] CBDA (14.0mm〇0 BODA (14-Ommol) m-PBCH5DABz (450mmd) B4 (8.39 mmol) DBA (15.4mmol) 實施例6 [6] CBDA (14.0mmol) BODA (14.0mmoD m-P8CH5DABz (4-20 mmol) B5 (2.80 mmol) DBA (21.0mmol) 實施例7 [7] CBDA (14.0nvno〇 BODA (14-Ommol) m-PBCH5DABz (5.60 mmol) B6 (5,60 mmot) DBA (16_8mmot) 實施例8 [8] CBDA (t4.0mmoO BODA (14.0mmoD m-PBCH5DABz (5.61 mmol) B7 (5.60 mmot) DBA (16.8mm〇0 實施例9 193 CBDA (14.0 mmol) BODA (14-0mmot) m-PBCH5DABz ¢8.42 mmol) B8 (2.81 mmol) DBA (16.8mmol) 實施例 [10] CBDA (14.0mmoO BODA (14.0mmot) m-PBCH5DABz (8.42mm of) B9 (5.6ImmoO DBA (T4.〇mmol) 實施例” [11] CBDA (13-9 mmol) BODA (13.9mnx)0 m-PBCH5DABz ¢5.56 mm ot) B10 (2.78mmo0 DBA (19.5 mmot) 實施例12 [12] CBDA (14.0mmoO BODA (14.0 mmol) m-PBCH5DABz (8.39 mmol) B11 (5.60 mmol) DBA (14.0 mmoO 實施例13 [13] CBDA (14.0mmo〇 BODA (14.0mnfK&gt;D m-P8CH5DABz (8.39mm ot) B12 Cfi.39 mmot) DBA (11 &gt;2 mmol〉 實施例Μ [14] CBDA (14.0mmo〇 BODA (14.0mm〇D m-PBCH7DABz (8.42 mmol) 61 (5.61 mmoi) DBA (14.0mmot) 實施例15 [15] CBDA (14.0mmoi) BODA (14-Ommol) m-8PCH5DABz (8.39mm ot) B1 (8.39 mmoO DBA (112mmot) 實施例16 [16] CBDA C I3.9mmo〇 BODA (13.9mmot) p-PBCH5DAB2 (8.35mmo0 B1 (8.35 mmol) DBA (n.lmmol)8.39 mmol), diamine (B9) (1.44 g, 5.60 mmol), and DBA (2.13 g, 14.0 mmol) were mixed in NMP (22.3 g) and reacted at -111 - 201030055 8 °C for 5 hours. Then, cBDA (2_74 g, 14.0 mmol) and NMP (1.79 g) were added to carry out a reaction at 40 ° C for 6 hours to obtain a polyaminic acid solution. After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride (4·3 1 g) and pyridine were added as an imidization catalyst. 3 · 3 5 g ), the reaction was carried out at 90 ° C for 3.5 hours. The reaction solution was poured into methanol (300 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 78%, a number average molecular weight of 17,900, and a weight average molecular weight of 49,100. To the polyimine powder (3.20 g), NMP (20.8 g) and BCS (29. 3 g) were added to obtain a liquid crystal alignment treatment agent [30]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [30], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 21 was used, and the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 31&gt; -112- 201030055 BODA (3.48 g, 13.9 mmol), PBCH 5 DAB (2.4 1 g. 5.56 mmol), diamine (BIO) (0.90 g, 2.78 mmol), and DBA ( 2.96 g) , 19.5 mmol) was mixed in NMP (20.7 g), and after reacting at 80 ° C for 5 hours, CBDA (2.73 g, 13.9 mm 〇l) and NMP (16. 6 g) were added, and the reaction was carried out at 40 ° C for 6 hours. After that, a polyaminic acid solution was obtained. The polyaminic acid solution had a number average molecular weight of 20,100 and an average weight molecular weight of 50,100. To the obtained polyaminic acid solution (10.5 g), hydrazine P (10. 1 g) and BCS (25.0 g) were added to obtain a liquid crystal alignment treatment agent [31]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [31], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, using the liquid crystal cell produced in the same manner as in Example 21, the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 32&gt; BODA (3.49 g, 14.0 mmol), PBCH5DAB (3.62 g, 8.37 mmol), diamine (Bll) (1.79 g, 5.58 mmol), and DBA (2.12 g, 14.0 mmol) in NMP ( Mixing in 22.9 g), -113-201030055 After 5 hours of reaction at 80 ° C, CBDA (2.74 g, 14.0 mmol) and NMP ( 18.3 g) were added to react at 4 Torr for 6 hours to obtain polydecylamine. Acid solution. After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride (4.318) and pyridine (3.358) were added as an imidization catalyst. The 90 art was subjected to a 3.5 hour reaction. The reaction solution was poured into methanol (290 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to obtain a polyimine powder. The polyamidimide had an imidization ratio of 81%, a number average molecular weight of 1,800, and a weight average molecular weight of 48,400. To the polyimine powder (3.31 g), NMP (21.5 g) and BCS (30.3 g) were added to obtain a liquid crystal alignment treatment agent [η]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [3 2], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 2 was used, and the evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 33&gt; -114- 201030055 BODA (3.50 g, 14.0 mmol), PBCH 5 D AB (3.63 g, 8.39 mmol), diamine (B12) ( 2.58 g, 8.39 mmol), and DBA (1.70) g, 11·2 mmol) was mixed in NMP (23.5 g), and after reacting at 80 ° C for 5 hours, CBDA (2.74 g, 14.0 mmol) and NMP ( 18.8 g ) were added at 4 ° C. After the hour reaction, a polyaminic acid solution was obtained. After adding NMP to the polyamic acid solution (20.2 g) and diluting to a content of polyglycolic acid of 6 mass%, acetic anhydride (4 · 3 2 g ) as an imidization catalyst, and pyridine ( 3.3 4 g ), 3 · 5 hours reaction at 90 ° C. The reaction solution was poured into methanol (280 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol, and dried under reduced pressure at 100 ° C to give a polyimine powder. The polyamidimide had an imidization ratio of 80%, a number average molecular weight of 17,100, and a weight average molecular weight of 47,100. To the polyimine powder (3.50 g), NMP (22.8 g) and BCS (32.lg) were added to obtain a liquid crystal alignment treatment agent [33]. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment agent, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [3 3], liquid crystal cells were produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was vertically aligned in a uniform manner. Further, using the liquid crystal cell produced in the same manner as in Example 1, evaluation of voltage holding ratio, evaluation of relaxation of residual charge, and evaluation after high-temperature placement were carried out -115-201030055. The results are shown in Table 16 and Table 17. &lt;Example 34&gt; BODA (3.48 g, 13.9 mmol), p BC Η 7 D AB (3.8 4 g, 8.35 mmol), diamine (Bl) (1.35 g, 5.56 mmol), and DBA ( 2.12 g, 13.9 mmol) was mixed in NMP (22.4 g), and after reacting at 80 ° C for 5 hours, CBDA (2_73 g, 13.9 mmol) and NMP (18 Og) were added, and the reaction was carried out at 40 ° C. After the hour reaction, a polyaminic acid solution was obtained. After adding NMP to the polyamic acid solution (20. Og) and diluting to a content of polyamine acid of 6 mass%, acetic anhydride (4.318) and pyridine (3.348) were added as an imidization catalyst. The reaction was carried out at 90° (the reaction was carried out for 3.5 hours. The reaction solution was poured into methanol (270 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and dried under reduced pressure at 100 ° C to obtain a poly Yttrium imide powder. The imidization ratio of the polyimine is 81%, the number average molecular weight is 1,800, and the weight average molecular weight is 48,900. NMP (20.2 g) is added to the polyimine powder (3.11 g). And the BCS (28.4 g), the liquid crystal alignment treatment agent [3 4] was obtained. No abnormality such as turbidity or precipitation was observed in the liquid crystal alignment treatment agent, and it was confirmed that the resin component was uniformly dissolved. The obtained liquid crystal alignment treatment agent was used. [3 4] A liquid crystal cell was produced in the same manner as in Example 2, and the pretilt angle was evaluated. The results are shown in Table 15. The liquid crystal cell produced in the same manner as in Example 21 except that the rubbing treatment was not performed. Observed by a polarizing microscope, it was confirmed that the liquid crystal was in a uniform sentence. Further, the liquid crystal cell produced in the same manner as in Example 21 was used for the evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high-temperature standing. The results are shown in Table 16 and Table 17. &lt;Example 35&gt; BODA (3.51 g, 14.0 mol), PBCH7DAB (3.88 g, 8.42 mmol), diamine (Bl) (2.04 g, 8.42 mmol), and DBA (1.71 g, 11.2 mmol) The mixture was mixed in NMP (23.1 g), and after reacting at 8 ° C for 5 hours, CBDA (2.75 g, 14.0 mmol) and NMP (18. 4 g) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain polylysine. After adding NMP to the polyamic acid solution (20.2 g) and diluting to a content of polyglycine of 6% by mass, acetic anhydride (4-52 g) as an imidization catalyst and pyridine (3.61 g) were added. The reaction was carried out at 9 (TC) for 5 hours. The reaction solution was poured into methanol (30 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and then at 100 ° C. After drying under reduced pressure, a polyimine powder is obtained. The imidization ratio of the polyimine is 92%, and the number average molecular weight is 17,100. The amount average molecular weight was 46,900. NMP (22.8 g) and BCS (32.1 g) were added to the polyimine powder (3 - 51 g) to obtain a liquid crystal alignment treatment agent [35]. No turbidity was observed in the liquid crystal alignment treatment agent. Or an abnormal phenomenon such as precipitation, and it was confirmed that the resin component was uniformly dissolved. Using the obtained liquid crystal alignment treatment agent [35], the liquid crystal cell was produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. Further, the liquid crystal cell produced in the same manner as in Example 21 except for the rubbing treatment was observed by a polarizing microscope, and it was confirmed that the liquid crystal was uniformly aligned vertically. Further, the liquid crystal cell produced in the same manner as in Example 21 was used, and the evaluation of the voltage holding ratio, the evaluation of the relaxation of the residual charge, and the evaluation after the high-temperature standing were performed. The results are shown in Table 16 and Table 17. &lt;Example 36&gt; BODA (3.50 g, 14.0 mmol), BPCH5DAB (3.59 g, 8.39 mmol), diamine (Bl) (2.03 g, 8.39 mmol), and DBA (1.70 g, 11.2 mmol) in NMP ( The mixture was mixed in 22.5 g), and after reacting at 8 ° C for 5 hours, CBDA (2.74 g, 14.0 mmol) and NMP (18 Og) were added, and the reaction was carried out at 40 ° C for 6 hours to obtain a polyaminic acid solution. . After adding NMP to the polyamic acid solution (20.0 g) and diluting to a content of polyglycine of 6 mass%, acetic anhydride (4.33 L) and pyridine (3.348) were added as an imidization catalyst. The reaction was carried out at 90° (the reaction was carried out for 3.5 hours). The reaction solution was poured into methanol (270 ml), and the obtained precipitate was separated by filtration. The precipitate was washed with methanol and dried under reduced pressure at 100 ° C to obtain a poly The imine imide powder has an imidization ratio of 81%, a number average molecular weight of 1,800, and a weight average molecular weight of 48,900. The polyamidimide powder (3.11 g) is added with NMP (22_7 g), And BCS (25.8g), the liquid crystal alignment agent [36] was obtained. In the liquid crystal distribution 201030055, no abnormal phenomenon such as turbidity or precipitation was observed in the treatment agent, and it was confirmed that the resin component was uniformly dissolved. [6 6] A liquid crystal cell was produced in the same manner as in Example 21, and the pretilt angle was evaluated. The results are shown in Table 15. The liquid crystal cell produced in the same manner as in Example 21 except that the rubbing treatment was not performed. Observed by a polarizing microscope, confirmed The liquid crystal cells were uniformly aligned vertically. The evaluation of the voltage holding ratio, the evaluation of the residual charge, and the evaluation after the high-temperature standing were carried out using the liquid crystal cell produced in the same manner as in Example 21. The results are shown in Table 16 and Table 17. &lt;Printability Test&gt; Printing was carried out using the liquid crystal alignment treatment agents obtained in Examples 1 to 16, 21 to 36, and Comparative Examples 1, 2, 5, and 6. The printing machine was a simple printing machine manufactured by Sakamoto Photo Printing Co., Ltd. ( S 1 5 type). Printing on the washed chromium evaporation substrate, printing area 8cmx8cm, printing pressure 0.2mm, 5 pieces of substrate discarded, printing to false drying time of 90 seconds, false drying temperature 70 ° C, 5 In the minute, the pinhole was confirmed by visual observation under the sodium lamp. The number of pinholes in Table 11 and Table 15 is shown as a printability. -119- 201030055 [Table 9] Liquid crystal alignment treatment agent acid dianhydride component diamine component Diamined (A) diamined (B) diamine compound (C) Example 1 [1] CBDA (14.0 mmoO BODA (14.0 mrr) oO m-PBCH5DABz (4.20 mm οί} B1 (8.39 mmol) DBA (15.4mmo0 Example 2 [2] CBDA (14.0mmoi) BODA (14.0mmoD fn-PBCH5DABz (8.42 mmoO B1 (5.61 mmoO DBA (HOmnnol) Example 3 [3] CBDA (14.0 mmol) BODA (14_2 mmol) m-PBCH5DABz (8.39 mmol) B2 (112 mmol) DBA (8.39 mmol) Example 4 [4] CBDA ( 13.9 mmol) BODA (13.9 mmol) m-PBCH5DABz (8.35 mm 〇0 B3 C2.78mmoO DBA (16.7mm〇0 Example 5 [5] CBDA (14.0mm〇0 BODA (14-Ommol) m-PBCH5DABz (450mmd) B4 (8.39 mmol) DBA (15.4 mmol) Example 6 [6] CBDA (14.0 mmol) BODA (14.0mmoD m-P8CH5DABz (4-20 mmol) B5 (2.80 mmol) DBA (21.0 mmol) Example 7 [7] CBDA (14.0 nvno〇BODA (14-Ommol) m-PBCH5DABz (5.60 mmol) B6 (5,60 mmot) DBA (16_8mmot) Example 8 [8] CBDA (t4.0mmoO BODA (14.0mmoD m-PBCH5DABz (5.61 mmol) B7 (5.60 mmot) DBA (16.8 mm 〇 0 Example 9 193 CBDA (14.0 mmol) BODA (14-0mmot) m-PBCH5DABz ¢ 8.42 mmol) B8 (2.81 mmol) DBA (16.8 mmol) Example [10] CBDA (14.0mmoO BODA (14.0mmot) m-PBCH5DABz (8.42mm of) B9 (5.6ImmoO DBA (T4.〇mmol) Example) [11] CBDA (13-9 mmol) BODA (13.9mnx)0 m-PBCH5DABz ¢ 5.56 mm ot) B10 (2.78mmo0 DBA (19.5 mmot) Example 12 [12] CBDA (14.0mmoO BOD A (14.0 mmol) m-PBCH5DABz (8.39 mmol) B11 (5.60 mmol) DBA (14.0 mmoO Example 13 [13] CBDA (14.0mmo〇BODA (14.0mnfK&gt;D m-P8CH5DABz (8.39mm ot) B12 Cfi.39 Mmot) DBA (11 &gt; 2 mmol) Example Μ [14] CBDA (14.0mmo〇BODA (14.0mm〇D m-PBCH7DABz (8.42 mmol) 61 (5.61 mmoi) DBA (14.0mmot) Example 15 [15] CBDA (14.0mmoi) BODA (14-Ommol) m-8PCH5DABz (8.39mm ot) B1 (8.39 mmoO DBA (112mmot) Example 16 [16] CBDA C I3.9mmo〇BODA (13.9mmot) p-PBCH5DAB2 (8.35mmo0 B1 (8.35 mmol) DBA (n.lmmol)

-120- 201030055 [表 ι〇] 液晶配向 處理劑 酸二酐成分 二胺成分 二胺化飾 (A) 二胺化飾 旧) 二胺化合物 (Ο 比較例1 [17] CBDA (14.0 mmol) BODA (14.0 mmol) PCH7DAB (4^1mmol) B1 (8.42nimo〇 DBA (l5.4mmol) 比較例2 [18] GBOA (14.0 mmol) BODA C 14.0mm〇l) PCH7D/B (14.0 mmol) B1 (5.60mmol) DBA (8.39mmol) 比較例3 CBDA (14.0 mmol) BODA (14.0mmol) m-PBCH5DABEs (8.39 mmol) 81 (5j60mmol) DBA (14.0mmo() 比較例4 CBDA (14.0 mmol) BODA (U.Ommol) PBP5DAB (8.37mm ol) B1 (5.58 mmol) DBA (14.0mmol) 比較例5 [19] CBDA (13.9 mmol) BODA (l3.9mm〇0 PBCH5DAB (8.35 mmol) B1 (5.56 mmol) p-PDA (t3.9mmol) 比較例6 [20] CBDA (14.0 mmol) BODA (14.0mmol) PBCH5DAB (8.39 mmol) S1 (5.60 mmol) DBA (14.0 mmol)-120- 201030055 [Table 〇] Liquid Crystal Alignment Treatment Agent Acid dianhydride Diamine Component Diamined (A) Diamined Diamine) Diamine Compound (Ο Comparative Example 1 [17] CBDA (14.0 mmol) BODA (14.0 mmol) PCH7DAB (4^1 mmol) B1 (8.42 nimo 〇 DBA (l5.4 mmol) Comparative Example 2 [18] GBOA (14.0 mmol) BODA C 14.0 mm 〇l) PCH7D/B (14.0 mmol) B1 (5.60 mmol) DBA (8.39 mmol) Comparative Example 3 CBDA (14.0 mmol) BODA (14.0 mmol) m-PBCH5DABEs (8.39 mmol) 81 (5j60 mmol) DBA (14.0mmo() Comparative Example 4 CBDA (14.0 mmol) BODA (U.Ommol) PBP5DAB (8.37mm ol) B1 (5.58 mmol) DBA (14.0 mmol) Comparative Example 5 [19] CBDA (13.9 mmol) BODA (l3.9 mm 〇0 PBCH5DAB (8.35 mmol) B1 (5.56 mmol) p-PDA (t3. 9mmol) Comparative Example 6 [20] CBDA (14.0 mmol) BODA (14.0 mmol) PBCH5DAB (8.39 mmol) S1 (5.60 mmol) DBA (14.0 mmol)

-121 201030055 [表η] 液晶配向 處理劑 亞胺化率 (%) BCS導入比11 (Si%) 預傾角 C ) 印刷性 (針孔數) 實施例1 [1] 54 59 54.6 &lt;5 實施例2 [2] 80 53 87.5 &lt;5 實施例3 [3] 56 55 87.6 &lt;5 實施例4 [4] *2 53 87.5 &lt;5 實施例5 [5] 81 53 54.8 &lt;5 實施例6 [6] 55 53 54.6 &lt;5 實施例7 [7] 56 48 86.5 &lt;5 實施例8 C8] 80 59 86.3 &lt;5 實施例Θ [9] *2 59 88.4 &lt;5 實施例1〇 [10] 79 59 87.5 &lt;5 實施例η [Π] *2 53 86.2 &lt;5 實施例12 [12] 80 59 87.1 &lt;5 實施例13 [13] 81 59 86.5 &lt;5 實施例Η [Μ] 80 59 86.8 &lt;5 實施例15 [15] 54 59 87.4 &lt;5 實施例16 [16] 79 53 86.5 &lt;5 比較例1 [17] 54 53 15.2 &lt;5 比較例2 [18] 55 53 86.9 &lt;30 比較例3 - 54 43 *3 &gt;50 比較例4 — 55 43 *3 &gt;50 比較例5 [19] 55 53 82.5 &lt;5 比較例S [20] 54 53 85.0 &lt;5 -122 - 1 1 :液晶配向處理劑中之溶劑全體所佔之BCS使用比率。 * 2 :聚醣胺酸。 * 3 :因有樹脂成分之析出,故無法評估。 201030055 [表 12] 液晶配向 處理劑 電壓保持率(%&gt; 液晶胞製作時 高溫放置後 16.67ms 1667ms 16.67ms 1667ms 實施例1 [1] 98.2 67.7 98.0 67.1 實施例2 [2] 98.7 68.7 98.4 68.8 實施例3 [3] 97.8 67.7 98.0 67.0 實施例4 [4] 97.4 65.3 96.7 65.1 實施例5 [5] 98.6 68.7 98.4 68.4 實施例6 [6] 98.1 67.6 98.5 66.9 實施例7 [7] 98.4 67.7 98.4 67.3 實施例β [8] 98.8 68.7 98.4 68.7 實施例9 [9] 97.7 67.6 97.1 67.4 實施例10 [1〇] 98.7 68.5 98.1 68.1 實施例&quot; [&quot;] 97.6 67.5 97.Ϊ 67.2 實施例12 [12] 98.6 68.7 98.4 68.3 實施例13 [13] 98.7 68.6 98.3 68.2 實施例Η [Η] 98.6 68.6 98.3 68.4 實施例15 [15] 98.4 68.7 98.4 68.2 實施例16 ⑽ 98.6 68.6 98.5 68.6 比較例1 [17] 96.6 64.5 96.2 63.2 比較例2 [1S] 98.0 67.1 98.0 67.0 比較例3 — *\ *1 *1 *1 比較例4 - *1 *1 *ί 比較例5 [19] 97.8 66.8 97.5 66.8 比較例6 [20] 97.7 66.6 97.4 66.5-121 201030055 [Table η] Liquid crystal alignment treatment agent imidization ratio (%) BCS introduction ratio 11 (Si%) Pretilt angle C) Printability (number of pinholes) Example 1 [1] 54 59 54.6 &lt;5 Implementation Example 2 [2] 80 53 87.5 &lt;5 Example 3 [3] 56 55 87.6 &lt;5 Example 4 [4] *2 53 87.5 &lt;5 Example 5 [5] 81 53 54.8 &lt;5 Example 6 [6] 55 53 54.6 &lt;5 Example 7 [7] 56 48 86.5 &lt;5 Example 8 C8] 80 59 86.3 &lt;5 Example Θ [9] *2 59 88.4 &lt;5 Example 1 [10] 79 59 87.5 &lt;5 Example η [Π] *2 53 86.2 &lt;5 Example 12 [12] 80 59 87.1 &lt;5 Example 13 [13] 81 59 86.5 &lt;5 Example Η [ Μ] 80 59 86.8 &lt;5 Example 15 [15] 54 59 87.4 &lt;5 Example 16 [16] 79 53 86.5 &lt;5 Comparative Example 1 [17] 54 53 15.2 &lt;5 Comparative Example 2 [18] 55 53 86.9 &lt;30 Comparative Example 3 - 54 43 *3 &gt; 50 Comparative Example 4 - 55 43 *3 &gt; 50 Comparative Example 5 [19] 55 53 82.5 &lt;5 Comparative Example S [20] 54 53 85.0 &lt;;5 -122 - 1 1 : The ratio of BCS used by the entire solvent in the liquid crystal alignment agent. * 2: Glycine. * 3 : It cannot be evaluated because of the precipitation of the resin component. 201030055 [Table 12] Liquid crystal alignment treatment agent voltage retention rate (%> 16.67 ms 1667 ms 16.67 ms 1667 ms after high temperature placement in liquid crystal cell fabrication Example 1 [1] 98.2 67.7 98.0 67.1 Example 2 [2] 98.7 68.7 98.4 68.8 Implementation Example 3 [3] 97.8 67.7 98.0 67.0 Example 4 [4] 97.4 65.3 96.7 65.1 Example 5 [5] 98.6 68.7 98.4 68.4 Example 6 [6] 98.1 67.6 98.5 66.9 Example 7 [7] 98.4 67.7 98.4 67.3 Implementation Example β [8] 98.8 68.7 98.4 68.7 Example 9 [9] 97.7 67.6 97.1 67.4 Example 10 [1〇] 98.7 68.5 98.1 68.1 Example &quot;[&quot;] 97.6 67.5 97.Ϊ 67.2 Example 12 [12] 98.6 68.7 98.4 68.3 Example 13 [13] 98.7 68.6 98.3 68.2 Example Η [Η] 98.6 68.6 98.3 68.4 Example 15 [15] 98.4 68.7 98.4 68.2 Example 16 (10) 98.6 68.6 98.5 68.6 Comparative Example 1 [17] 96.6 64.5 96.2 63.2 Comparative Example 2 [1S] 98.0 67.1 98.0 67.0 Comparative Example 3 - *\ *1 *1 *1 Comparative Example 4 - *1 *1 *ί Comparative Example 5 [19] 97.8 66.8 97.5 66.8 Comparative Example 6 [20] 97.7 66.6 97.4 66.5

* 1 :因有樹脂成分之析出,故無法評估。* 1 : It cannot be evaluated because of the precipitation of the resin component.

-123- 201030055 [表 13] 液晶配向 處理劑 殘留電荷之緩和(V) 液晶胞製作時 髙雛置後 50秒後 1000秒後 50秒後 1000秒後 實施例1 [1] 2.46 029 2.55 035 實施例2 [2] 3.74 0.70 3.80 102 實施例3 [3] 2.98 0.60 3.28 0.65 實施例4 [4] 0.79 0.12 0.90 0.14 實施例5 [5] 2.84 0.55 2.96 0.61 實施例6 [6] 2.54 0.30 2.61 0.38 實施例7 [73 2.65 058 2.84 0.49 實施例8 [8] 3.53 0.63 2.44 03Ϊ 實施例9 [9] 0.75 0.1 1 0.84 0.13 實施例叩 ⑽ 3.72 0.67 3.80 050 實施例11 [&quot;] 0.73 0.10 0.85 0.11 實施例12 [12] 3.81 0.69 3.80 088 實施例13 [13] 3.65 0.63 3.81 084 實施例Η [14] 3.61 0.61 3.78 030 實施例15 [15] 3.90 0.75 4.00 104 赏胞例16 [16] 3.61 0.62 3.92 090 比較例1 [Π] 2.56 0.32 2.64 0.41 比較例2 [18] 3.03 0.74 3.34 077 比較例3 *1 *1 *1 比較例4 *1 *1 *1 *1 比較例5 [19] 4.02 0-98 4.59 138 比較例β [20] 4.12 1.03 4.61 2J04 * 1 :因有樹脂成分之析出,故無法評估。 124 201030055 [表 14]-123- 201030055 [Table 13] Releasing the residual charge of the liquid crystal alignment agent (V) After the liquid crystal cell was fabricated, 50 seconds later, 1000 seconds later, 50 seconds later, and 1000 seconds later, Example 1 [1] 2.46 029 2.55 035 Implementation Example 2 [2] 3.74 0.70 3.80 102 Example 3 [3] 2.98 0.60 3.28 0.65 Example 4 [4] 0.79 0.12 0.90 0.14 Example 5 [5] 2.84 0.55 2.96 0.61 Example 6 [6] 2.54 0.30 2.61 0.38 Implementation Example 7 [73 2.65 058 2.84 0.49 Example 8 [8] 3.53 0.63 2.44 03Ϊ Example 9 [9] 0.75 0.1 1 0.84 0.13 Example 叩 (10) 3.72 0.67 3.80 050 Example 11 [&quot;] 0.73 0.10 0.85 0.11 Example 12 [12] 3.81 0.69 3.80 088 Example 13 [13] 3.65 0.63 3.81 084 Example Η [14] 3.61 0.61 3.78 030 Example 15 [15] 3.90 0.75 4.00 104 Reward 16 [16] 3.61 0.62 3.92 090 Example 1 [Π] 2.56 0.32 2.64 0.41 Comparative Example 2 [18] 3.03 0.74 3.34 077 Comparative Example 3 *1 *1 *1 Comparative Example 4 *1 *1 *1 *1 Comparative Example 5 [19] 4.02 0-98 4.59 138 Comparative Example β [20] 4.12 1.03 4.61 2J04 * 1 : Due to the precipitation of the resin component, it cannot be evaluated. 124 201030055 [Table 14]

液晶配向 處理劑 酸二酐成分 二胺成分 二胺化合物 (A) 二胺化合物 (B) 二胺化合物 (Ο 實施例21 [2J] GBDA (14.0m mot) BOD/K (14.0iryn〇0 PBCH5DAB (4J21 mmol} B1 (8.42m moi) DBA (15.4mmo0 實施例22 [22] CBDA (I4.0mm〇l) BODA ( PBCH5DAB (8.37mmol) B1 (5.58m moO DBA (t4.0mmol) 實施例2 3 [231 CBDA (i4.2mmoi) BODA (ί 42mmoi) PBCH5DAB (8.51 mmol) B2 (11.4mm〇l) DBA (8.51 mmol) 實施例24 [24] CBDA (H.Ommcrf) BODA (i4J0mm〇0 PBCH5DAB (8.42mmol) B3 (2.81rpm〇l) DBA (16.8mfTK)l) 實施例25 [25Ϊ CBDA (13.9m mo}) BODA (13,9mm〇0 PBCH50AB B4 (8.35mmol) DBA (15.3 mmol) 實施例26 [26] CBDA (14.0mm〇l) BODA (14.0mmot) PBCH5DAB (4_2〇mmol) B5 (2.80m mol) DBA (21 .Ommol) 實施例27 [27] CBDA (14.1 mmol) BODA (14.1mmo〇 PBCH5DAB (5.63 mmol) B6 (5.63m mol) DBA U6.9mfT&gt;ot) 實施例2B [28] CBDA (14.0mmoi) BODA (14.0mrnoi) PBCH50AB 〔5.60 mmol) 87 (5.6〇mmof) DBA (165mnx&gt;t) 實施例2 9 [29] CBDA (14.0mmol) BODA (I4.0mmot) PBCH5DAB ¢8.42 mmol) ΒΘ (2.81mm〇i) DBA (16.8mmo() 實施例30 [30] CBDA (i4.0mm〇i) BODA 〇 4.0mmoi) PBCH5DA8 (8.39 mmol) 89 (5.6〇mfn〇l) DBA (I4,0mm〇|) 實施例31 [31 ] CBDA (l3.9mmoi) BODA (l35mfr»ot) PBCH5DAB (5.56 mmol) B10 (2.78m mol) DBA (I9.5mmo〇 實施例32 [32] CBDA (14.0mmoi) BODA {14.0mmo〇 PBCH5DAB (8.37 mmol) Bil (5.58m mol) DBA (14.0mrr&gt;〇0 實施例33 [33] CBDA (14.0m mol) BODA (14.0ίτϊτπ〇0 PBCH5DAB (8.39 mmol) B12 (8.39m mol) DBA (112mmol) 實施例34 [34] CBDA (13.9m mol) BODA (13.9mm〇l) PBCH7DAB (835mmol) ΒΪ (5.56mmol) DBA (13.9mmol) 實施例35 [35] CBDA (14.0mmoi) BODA PBCH7DAB (8.42 mmol) B1 (8.42m moi) DBA ()12mmol) 實施例36 [36} CBDA (14.0m mol) BODA (Ϊ 4.0mmoO BPCH5DAB (8.39 mmol) B1 ¢8.39m mol) DBA C11.2mmot) -125- 201030055 [表 15] 液晶配向 處理劑 亞胺化率 (%) bcs導入比η (%) 預網 c* ) 印刷性 (針孔數) 實施例2! [2«] 55 59 53.4 &lt;5 實施例22 Γ22] 81 53 873 &lt;5 實施例23 [231 55 53 87.5 &lt;5 實施例24 「24] *2 53 87^ &lt;5 實施例25 【25] 80 53 54.5 &lt;5 實施例26 L26J 53 53 54 J2 &lt;5 實施例27 [27] 55 48 86:2 &lt;5 實施例28 [28] 8! 59 86.1 &lt;5 實施例29 1291 *2 59 88.3 &lt;5 實施例30 (30) 78 5d S7.4 &lt;5 實施例31 [313 *2 53 85.9 &lt;5 實施例32 [321 81 S9 87.0 &lt;5 實施例33 CJ3| 80 59 86.3 &lt;5 實施例Μ [34] 81 59 86.5 &lt;5 實施例35 [35] 92 59 86 J &lt;5 實施例36 [36] 81 53 86.3 &lt;5 * 1 :液晶配向處理劑中之溶劑全體所佔之BCS的使用比率。 * 2 ··聚醣胺酸》 -126- 201030055 【91«】 i£w- I s ^.s S9 •s CK9 •89 •5 9§ 3 ε o5 s 0s U9 •S9 ·£ 游蟹s 0^0S0 霞铟 —9.91 iA99l issLiquid crystal alignment treatment agent Acid dianhydride component Diamine component Diamine compound (A) Diamine compound (B) Diamine compound (Ο Example 21 [2J] GBDA (14.0m mot) BOD/K (14.0iryn〇0 PBCH5DAB ( 4J21 mmol} B1 (8.42 m moi) DBA (15.4 mmo0 Example 22 [22] CBDA (I4.0 mm〇l) BODA (PBCH5DAB (8.37 mmol) B1 (5.58 m moO DBA (t4.0 mmol) Example 2 3 [ 231 CBDA (i4.2mmoi) BODA (ί 42mmoi) PBCH5DAB (8.51 mmol) B2 (11.4mm〇l) DBA (8.51 mmol) Example 24 [24] CBDA (H.Ommcrf) BODA (i4J0mm〇0 PBCH5DAB (8.42mmol) B3 (2.81 rpm 〇 l) DBA (16.8 mfTK) l) Example 25 [25 Ϊ CBDA (13.9 m mo}) BODA (13, 9 mm 〇 0 PBCH 50 AB B4 (8.35 mmol) DBA (15.3 mmol) Example 26 [26 CBDA (14.0mm〇l) BODA (14.0mmot) PBCH5DAB (4_2〇mmol) B5 (2.80m mol) DBA (21.Ommol) Example 27 [27] CBDA (14.1 mmol) BODA (14.1mmo〇PBCH5DAB (5.63 Methyl) B6 (5.63m mol) DBA U6.9mfT&gt; ot) Example 2B [28] CBDA (14.0mmoi) BODA (14.0mrnoi) PBCH50AB [5.60 mmol) 87 (5.6〇mmof) DBA (165mnx&gt;t) Example 2 9 [29] CBDA (14.0mmol) BODA (I4.0mmot) PBCH5DAB ¢8.42 m Mol) ΒΘ (2.81mm〇i) DBA (16.8mmo() Example 30 [30] CBDA (i4.0mm〇i) BODA 〇4.0mmoi) PBCH5DA8 (8.39 mmol) 89 (5.6〇mfn〇l) DBA (I4 , 0mm〇|) Example 31 [31 ] CBDA (l3.9mmoi) BODA (l35mfr»ot) PBCH5DAB (5.56 mmol) B10 (2.78m mol) DBA (I9.5mmo〇 Example 32 [32] CBDA (14.0mmoi BODA {14.0mmo〇PBCH5DAB (8.37 mmol) Bil (5.58m mol) DBA (14.0mrr> 〇0 Example 33 [33] CBDA (14.0m mol) BODA (14.0ίτϊτπ〇0 PBCH5DAB (8.39 mmol) B12 (8.39 m mol) DBA (112 mmol) Example 34 [34] CBDA (13.9 m mol) BODA (13.9 mm 〇l) PBCH7DAB (835 mmol) ΒΪ (5.56 mmol) DBA (13.9 mmol) Example 35 [35] CBDA (14.0mmoi) BODA PBCH7DAB (8.42 mmol) B1 (8.42 m moi) DBA () 12 mmol) Example 36 [36} CBDA (14.0 m mol) BODA (Ϊ 4.0mmoO BPCH5DAB (8.39 mmol) B1 ¢8.39m mol) DBA C11.2mmot -125- 201030055 [Table 15] Liquid crystal alignment treatment agent imidization ratio (%) bcs introduction ratio η (%) Pre-network c*) Printability (number of pinholes) Example 2! [2«] 55 59 53.4 &lt;5 Example 22 Γ22] 81 53 873 &lt;5 Example 23 [231 55 53 87.5 &lt; 5 Example 24 "24] *2 53 87^ &lt;5 Example 25 [25] 80 53 54.5 &lt;5 Example 26 L26J 53 53 54 J2 &lt;5 Example 27 [27] 55 48 86:2 &lt; 5 Example 28 [28] 8! 59 86.1 &lt;5 Example 29 1291 *2 59 88.3 &lt;5 Example 30 (30) 78 5d S7.4 &lt;5 Example 31 [313 * 2 53 85.9 &lt; 5 Example 32 [321 81 S9 87.0 &lt; 5 Example 33 CJ3| 80 59 86.3 &lt;5 Example Μ [34] 81 59 86.5 &lt;5 Example 35 [35] 92 59 86 J &lt; 5 Example 36 [36] 81 53 86.3 &lt;5 * 1 : The ratio of use of BCS in the liquid crystal alignment agent. * 2 ··Glycanic acid》126-201030055 【91«】i£w- I s ^.s S9 •s CK9 •89 •5 9§ 3 ε o5 s 0s U9 •S9 ·£ 游蟹s 0 ^0S0 Xia Indium—9.91 iA99l iss

986 26 9-6 寸96 Ϊ86 Γ卜6 26 0-6 Gs 26 «86 S.S6 S6 0.86 $86 I B S9 S9 i •s •卜9 -91° •ε 6S ·£ ·£ •s Ms ts 8·2 8卜9 i 靈 •s® 8·8β •86 1°卜6 i 9.卜6 S6 56 i i 086 896 i986 26 9-6 inch 96 Ϊ86 Γ布 6 26 0-6 Gs 26 «86 S.S6 S6 0.86 $86 IB S9 S9 i •s • Bu 9 -91° • ε 6S · £ · £ • s Ms ts 8· 2 8卜9 i Ling•s® 8·8β •86 1°Bu 6 i 9.Bu 6 S6 56 ii 086 896 i

Isitsej ιέ § ca s log 【si § 【s】 【s】 s § M § 9i层 m_s H_s mis 0^1« ^1« s 麗w ΰ 1Λ 9ms SIW 產辑取 5_* 識§ 13麗w -127- 201030055 s 班麵蠢if 蠢§1 ia &lt;Λ^:α&gt;&lt;ΛΛρ&lt;3&gt; 〇 — 〇〇〇〇〇〇〇〇〇〇〇〇 — 〇 — Qc〇rrCviU&gt;cpc〇 ir&gt;ocou&gt;»— *-* ιηοοοσ&gt;〇&lt;οα6^οο oooqcqcacop ο 〇4^iciQ&lt;r&gt;c4c*i^4C&gt; ci C&gt; ci ci ci d 孽 11¾ (&gt;)«!雜忉 Mwssi纸 蠢i 〇_产竹&lt;〇,-〇 寸 〇〇&gt; —卜 l〇U&gt;VP^ 〇r-&lt;o — if&gt;c〇&lt;o&lt;o — &lt;〇 — no to o &lt;〇 ooooooobooboodoo 游ts 0*0«·&gt;0 CMCMCMOO &lt;Ο〇«Τ5&lt;Λί?0ί^ K脚堪 ®aa&lt; 灌 ^ «·« ·—t » » * » r 1 c , » Ι·ΠΆ J V · 1 * t^_&lt; t^t i—* «__( I _· I_I . · .· U^l Immi U^T Urn* «·*·&gt;&gt; si 堤K S麗K isigK iK οε 議Μ I 握κ βζ_« 5_κ 9is SZ_M I辑H iyi 揖K tCSIri [產業上可利用性] 使用由本發明之液晶配向處理劑所得之液晶配向膜而 製作之液晶顯示元件,其爲信賴性優異者,可適合利用於 大畫面且高精細之液晶電視等,於產業上有用。 且,2008年9月24日所申請之日本專利出願2008-245037號、及2008年9月24日所申請之日本專利出願2008-24 5 03 8號之說明書、申請專利範圍、及摘要之全内容皆引 用於此,作爲本發明之說明書揭示內容而引用者 -128-Isitsej ιέ § ca s log [si § [s] [s] s § M § 9i layer m_s H_s mis 0^1« ^1« s 丽 w ΰ 1Λ 9ms SIW production series 5_* 识§ 13 丽 w -127 - 201030055 s Class noisy if stupid §1 ia &lt;Λ^:α&gt;&lt;ΛΛρ&lt;3&gt;〇—〇〇〇〇〇〇〇〇〇〇〇〇—〇—Qc〇rrCviU&gt;cpc〇ir&gt;ocou&gt;»—*-*ιηοοοσσ&gt;〇&lt;οα6^οο oooqcqcacop ο 〇4^iciQ&lt;r&gt;c4c*i^4C&gt; ci C&gt; ci ci ci d 孽113⁄4 (&gt;)«! Chowder Mwssi paper stupid i 〇_竹竹&lt;〇,-〇寸〇〇&gt;-卜l〇U&gt;VP^ 〇r-&lt;o — if&gt;c〇&lt;o&lt;o — &lt;〇— no to o &lt;〇 Ooooooobooboodoo ts 0*0«·&gt;0 CMCMCMOO &lt;Ο〇«Τ5&lt;Λί?0ί^ K-foot®aa&lt; 灌^ «·« ·-t » » * » r 1 c , » Ι·ΠΆ JV · 1 * t^_&lt; t^ti—* «__( I _· I_I . · .· U^l Immi U^T Urn* «·*·&gt;&gt; si 堤丽丽K isigK iK οε I grip κ βζ_« 5_κ 9is SZ_M I series H iyi 揖K tCSIri [Industrial Applicability] Using a liquid crystal alignment film obtained by the liquid crystal alignment treatment agent of the present invention The liquid crystal display device is excellent in reliability, and is suitable for use in a large-screen, high-definition liquid crystal television, and is industrially useful. Moreover, Japanese Patent Application No. 2008-245037 filed on September 24, 2008, And the entire contents of the specification, the scope of the patent application, and the abstract of the Japanese Patent Application No. 2008-24 5 03 8 filed on Sep. 24, 2008, the entire contents of

Claims (1)

.201030055 七、申請專利範園: 1.—種液晶配向處理劑,其特徵爲含有共聚物者,該 共聚合物爲將含有下述式〔1〕所示二胺化合物(A)、下 述式〔2〕所示二胺化合物(B)、分子内具有羧基之二胺 化合物的二胺化合物(C)之二胺成分、與四羧酸二酐進 行反應所得者; [化1] P [1] [2] (式〔1〕中,p爲0或1的整數,X!爲伸苯基,x2爲伸苯基 或伸環己基,x3爲伸環己基,X4爲碳數3〜12的烷基、碳 數3〜12的氟烷基、碳數3〜12的烷氧基、或碳數3〜12的 氟烷氧基;式〔2〕中,丫1爲-〇-、-NH-、-N(CH3)-、 -CONH-、-NHCO-、-CH20-、-OCO-、-CON(CH3)-、或 φ -N(CH3)CO-,Υ2爲單鍵、碳數1〜20的脂肪族烴基、非芳 香族環式烴基、或芳香族烴基,γ3爲單鍵、-Ο-、-ΝΗ-、 -N(CH3)-、-CONH-、-NHCO-、-COO-、-OCO-、 -CON(CH3)-、-N(CH3)CO-' 或- 〇(CH2)m-(m爲 1 〜5的整數 ),Y4爲含氮芳香族雜環,η爲1〜4的整數)。 2 ·如申請專利範圍第1項之液晶配向處理劑,其中前 述二胺化合物(Α)爲下述式〔1'〕所示二胺化合物(a, -129- 201030055 [化2] NH, Η2Ν- 11^5^0、χ,Χ2'χ3/Χ4 [Γ] (式〔1’〕中,Xi、χ2、χ3、及χ4與前述式〔 3.如申請專利範圍第1項之液晶配向處理 述二胺化合物(A )爲下述式〔1 ’'〕所示二胺 1〕同義) ί,其中前 :合物(Α&quot; [化3].201030055 VII. Patent application garden: 1. A liquid crystal alignment treatment agent characterized by containing a copolymer which contains a diamine compound (A) represented by the following formula [1], the following a diamine compound (B) represented by the formula [2], a diamine component of a diamine compound (C) having a diamine compound having a carboxyl group in the molecule, and a reaction with a tetracarboxylic dianhydride; [Chemical Formula 1] P [ 1] [2] (In the formula [1], p is an integer of 0 or 1, X! is a phenyl group, x2 is a phenyl or cyclohexyl group, x3 is a cyclohexyl group, and X4 is a carbon number of 3 to 12. An alkyl group, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms; in the formula [2], 丫1 is -〇-, - NH-, -N(CH3)-, -CONH-, -NHCO-, -CH20-, -OCO-, -CON(CH3)-, or φ-N(CH3)CO-, Υ2 is a single bond, carbon number 1 to 20 aliphatic hydrocarbon group, non-aromatic cyclic hydrocarbon group, or aromatic hydrocarbon group, γ3 is a single bond, -Ο-, -ΝΗ-, -N(CH3)-, -CONH-, -NHCO-, -COO -, -OCO-, -CON(CH3)-, -N(CH3)CO-' or - 〇(CH2)m- (m is an integer from 1 to 5), Y4 is a nitrogen-containing aromatic heterocycle, and η is 1 to 4 Number). 2. The liquid crystal alignment treatment agent according to the first aspect of the invention, wherein the diamine compound (Α) is a diamine compound represented by the following formula [1'] (a, -129- 201030055 [Chemical 2] NH, Η2Ν - 11^5^0, χ, Χ 2'χ3/Χ4 [Γ] (In the formula [1'], Xi, χ2, χ3, and χ4 are the same as the above formula [3] Liquid crystal alignment processing according to item 1 of the patent application scope The diamine compound (A) is a diamine 1] synonymous with the following formula [1 ''], wherein the former compound (Α&quot; [Chemical 3] [Γ] (式〔厂’〕中,乂''1爲1,4-伸苯基或1,4-伸環己 碳數3〜I2的烷基、碳數3〜12的氟烷基、碳數 氧基、或碳數3〜12的氟烷氧基)。 4·如申請專利範圍第2項之液晶配向處理笑 胺化合物(A')爲下述式〔丨| a〕所示二胺化合今 [化4] 基,Χ&quot;2爲 3〜12的烷 ίϋ,其中二[Γ] (In the formula [厂], 乂''1 is a 1,4-phenylene group or a 1,4-cycloalkylene group having a carbon number of 3 to 12, a fluoroalkyl group having a carbon number of 3 to 12, A carbon number oxy group or a fluoroalkoxy group having a carbon number of 3 to 12). 4. The liquid crystal alignment treatment of the amine compound (A') as in the second paragraph of the patent application is a diamine compound represented by the following formula [丨| a], and the oxime &quot; 2 is an alkane of 3 to 12 ϋ, two of them (式〔l'a〕中’ X5爲碳數3〜12的烷基、碳數3 基、碳數3〜12的烷氧基、或碳數3〜12的氟烷 〜12的氟烷 氧基,I,4· -130- 201030055 伸環己基之順-反式異構性各爲反式異構物)。 5 ·如申請專利範圍第2項之液晶配向處理劑,其中二 胺化合物(A')爲下述式〔1 'b〕所示二胺化合物; [化5](In the formula [l'a], 'X5 is an alkyl group having 3 to 12 carbon atoms, an alkyl group having 3 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkane having a carbon number of 3 to 12 and a fluoroalkane of 12 to 12; Base, I, 4· -130- 201030055 The cis-trans isomerism of the cyclohexyl group is each a trans isomer). 5. The liquid crystal alignment treatment agent of claim 2, wherein the diamine compound (A') is a diamine compound represented by the following formula [1 'b]; (式〔l’b〕中,X6爲碳數3〜12的烷基、碳數3〜12的氟 烷基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基, I,4·伸環己基的順-反式異構性爲反式異構物)。 6.如申請專利範圍第3項之液晶配向處理劑,其中二 胺化合物(A&quot;)爲下述式〔l&quot;a〕所示二胺化合物; [化6](In the formula [l'b], X6 is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluoroalkoxy group having 3 to 12 carbon atoms. The cis-trans isomer of the group, I, 4·cyclohexylene is a trans isomer). 6. The liquid crystal alignment treatment agent of claim 3, wherein the diamine compound (A&quot;) is a diamine compound represented by the following formula [1 &quot;a]; (式〔l&quot;a〕中,X&quot;3爲碳數3〜12的烷基、碳數3〜12的氟 烷基、碳數3〜12的烷氧基、或碳數3〜12的氟烷氧基, 1,4-伸環己基的順-反式異構性爲各反式異構物)。 7.如申請專利範圍第3項之液晶配向處理劑,其中二 胺化合物(A&quot;)爲下述式〔l’’b〕所示二胺化合物; •131 - 201030055 [化7](In the formula [l&quot;a], X&quot;3 is an alkyl group having 3 to 12 carbon atoms, a fluoroalkyl group having 3 to 12 carbon atoms, an alkoxy group having 3 to 12 carbon atoms, or a fluorine having 3 to 12 carbon atoms. The alkoxy group, the cis-trans isomer of 1,4-cyclohexylene is each trans isomer). 7. The liquid crystal alignment treatment agent of claim 3, wherein the diamine compound (A&quot;) is a diamine compound represented by the following formula [1''b]; • 131 - 201030055 [Chem. 7] 烷基、碳數3〜I2的院氧基、或碳數3〜12的氣院氧基’ 1,4 -伸環己基的順-反式異構性爲反式異構物)。 8 .如申請專利範圍第2項至第7項中任一項之液晶配向 處理劑,其中式〔2〕中之Υι爲·0-、-NH-、-CONH·、 -NHCO-、-CON(CH3)-、或-CH20-。 9·如申請專利範圍第2項至第8項中任一項之液晶配向 處理劑’其中式〔2〕中之Υ2爲單鍵、碳數1〜5的直鏈或 分支烷基、或苯環。 1 〇 .如申請專利範圍第2項至第9項中任一項之液晶配 向處理劑’其中式〔2〕中之Υ3爲單鍵、-〇_、-CONH-、 -NHCO-、_c〇0_、_0C0_' 或-CKCHaU· ( „!爲 i 〜5的整數 11.如申請專利範圍第2項至第10項中任一項之液晶配 向處理劑’其中式〔2〕中之Y4爲吡咯環、咪唑環、吡哩 環、妣啶環、或嘧啶環。 1 2.如申請專利範圍第2項至第I〗項中任一項之液晶配 向處理劑’其中式〔2〕中之n爲1〜3的整數。 項 項之液晶配 -132 .201030055 -CONH-、 向處理劑,其中式〔2〕中之γ^_〇_、_NH -NHCO-、-CON(CH3)-、或- CH20-’ γ2 爲碳數卜5的直鏈 或分支院基’ Υ3爲單鍵’ Υ4爲耻略環、咪哩環、枇嗖環、 吡啶環、或嘧啶環,η爲1〜3的整數。 1 4.如申請專利範圍第2項至第7項中任一項之液晶配 向處理劑’其中式〔2〕中的¥1爲_〇_、-Nh_、_c〇NH_、 -NHCO-、_CON(CH3)_、或 ,γ2爲苯環,。爲 〇_The alkyl group, the alkoxy group having a carbon number of 3 to 12, or the cis-trans isomer of the gas oxy-' 1,4 -cyclohexylene having a carbon number of 3 to 12 is a trans isomer). 8. The liquid crystal alignment treatment agent according to any one of claims 2 to 7, wherein Υι in the formula [2] is -0-, -NH-, -CONH·, -NHCO-, -CON (CH3)-, or -CH20-. 9. The liquid crystal alignment treatment agent according to any one of claims 2 to 8, wherein Υ2 in the formula [2] is a single bond, a linear or branched alkyl group having a carbon number of 1 to 5, or benzene ring. The liquid crystal alignment treatment agent of any one of the second to the ninth aspect of the invention, wherein the Υ3 in the formula [2] is a single bond, -〇_, -CONH-, -NHCO-, _c〇 0_, _0C0_' or -CKCHaU· ( „! is an integer of i 〜5. 11. The liquid crystal alignment treatment agent according to any one of claims 2 to 10, wherein Y4 in the formula [2] is pyrrole a ring, an imidazole ring, a pyridinium ring, an acridine ring, or a pyrimidine ring. 1 2. A liquid crystal alignment treatment agent according to any one of claims 2 to 1 wherein n in the formula [2] An integer of 1 to 3. The liquid crystal of the item is -132.201030055 -CONH-, a treatment agent, wherein γ^_〇_, _NH-NHCO-, -CON(CH3)-, or - CH20-' γ2 is a linear or branched base of carbon number 5 'Υ3 is a single bond' Υ4 is a salicious ring, a oxime ring, an anthracene ring, a pyridine ring, or a pyrimidine ring, and η is 1 to 3 In the liquid crystal alignment treatment agent of any one of the second to seventh aspects of the invention, wherein the ¥1 in the formula [2] is _〇_, -Nh_, _c〇NH_, -NHCO- , _CON(CH3)_, or, γ2 is a benzene ring, which is 〇_ 、-CONH-、_NHC0·、_C〇〇_、_〇c〇_、或 〇(CH2)m ( m爲 1〜5的整數),Y4爲吡咯環、咪唑環、吡哩環、吡啶環、 或嘧啶環,η爲1的整數。 I5.如申請專利範圍第2項至第14項中任—項之液晶配 向處理劑’其中二胺化合物(C)爲下述式〔3〕所示二胺 化合物; [化8] (c〇〇H)k [3] h2n/Zi、nh2 (式〔3〕中,Zl爲具有碳數6〜3〇的芳香族環之有機基, k爲1〜4的整數)^ 1 6.如申請專利範圍第丨5項之液晶配向處理劑,其中 式〔3〕的二胺化合物爲選自下述式〔3a〕、式〔3b〕、 式、式〔3d〕及式〔3e〕所成群之至少1種的二胺 化合物; -133- 201030055 [化9], -CONH-, _NHC0·, _C〇〇_, _〇c〇_, or 〇(CH2)m (m is an integer from 1 to 5), and Y4 is a pyrrole ring, an imidazole ring, a pyridinium ring, a pyridine ring, Or a pyrimidine ring, η is an integer of 1. I. The liquid crystal alignment treatment agent of any one of Items 2 to 14 wherein the diamine compound (C) is a diamine compound represented by the following formula [3]; 〇H)k [3] h2n/Zi, nh2 (In the formula [3], Z1 is an organic group having an aromatic ring having a carbon number of 6 to 3 Å, and k is an integer of 1 to 4) ^1. The liquid crystal alignment treatment agent of the fifth aspect of the invention, wherein the diamine compound of the formula [3] is a group selected from the group consisting of the following formula [3a], formula [3b], formula, formula [3d] and formula [3e] At least one diamine compound; -133- 201030055 [Chemical 9] (CH^nuCOOH(CH^nuCOOH (CH2)m6COC 6cooh h2 Η2Ν-〇-?-〇·ΝΗ2 (CH2)m5COOH [3c] [3d] (CO〇H)m7 [3e] (式〔3a〕中,⑴爲】〜4的整數;式〔3b〕中,Z2爲單鍵 、-CH2-、-C2H4-、-C(CH3)2-、-CF2-、-C(CF3)-、-0-、 -CO-、-NH-、-N(CH3)·、-CONH-、-NHCO-、-CH20-、 -OCH2-、-COO-、-OCO-、-CON(CH3)…或-N(CH3)CO-, m2及1η3各表示〇〜4的整數,且m2 + m3表示1〜4的整數;式 〔3c〕中’ m4&amp;m5各爲1〜5的整數;式〔3(1〕中,z3爲碳 數1〜5的直鏈或分支烷基,„!6爲1〜5的整數;式〔3e〕中 ,Z4爲單鍵、-CH2-、-C2H4-、-C(CH3)2-、-CF2-、 -C(CF3)-、-Ο- ' _c〇-、-NH-、-N(CH3)-、-CONH-、 -NHCO-、-CH2O-、-〇CH2-、-COO-、-OCO-、-CON(CH3)-、或-N(CH3)C〇-,…爲!〜‘的整數)e 1 7 .如申請專利範圍第丨6項之液晶配向處理劑,其中 式〔3a〕中’ 1^爲1〜2的整數。 1 8 ·如申請專利範圍第! 6項之液晶配向處理劑,其中 -134- .201030055 式〔3b〕中 ’ Z2 爲單鍵、_(^2-、-(:2114-'-〇:((:113)2-、-〇-、-CO-、-NH-、-N(CH3)-、-CONH-、-NHCO-、-COO-、 或-OCO-,m2及m3同時爲1的整數。 19.如申請專利範圍第16項之液晶配向處理劑,其中 式〔3e〕中 ’ Z4爲單鍵、_cH2-、-Ο-、-CO.、-NH-、 -CONH-、-NHCO-、-CH20-、-OCH2-、-COO-、或-OCO-, ΙΠ7爲1〜2的整數。 2 〇 .如申請專利範圍第2項至第1 9項中任一項之液晶配 向處理劑’其中二胺成分中,二胺化合物(Α)對於二胺 化合物(C)之1莫耳而言爲〇, 5〜5〇莫耳,二胺化合物(β )對於二胺化合物(C)之1莫耳而言爲〇.5〜1〇莫耳。 21.如申請專利範圍第2項至第20項中任一項之液晶配 向處理劑,其中液晶配向處理劑中含有5〜7 0質量%之弱溶 劑。 22.如申請專利範圍第2項至第21項中任一項之液晶配 向處理劑’其中液晶配向處理劑中之共聚物爲使聚醯胺酸 進行脫水閉環而得之聚醯亞胺。 23· —種液晶配向膜,其特徵爲使用如申請專利範圍 第2項至第22項中任一項之液晶配向處理劑所得者。 24· —種液晶顯示元件,其特徵爲具有如申請專利範 圍第23項之液晶配向膜者。 -135- 201030055 四、指定代表圖: (一) 本案指定代表圖為:無 (二) 本代表圖之元件符號簡單說明:無(CH2)m6COC 6cooh h2 Η2Ν-〇-?-〇·ΝΗ2 (CH2)m5COOH [3c] [3d] (CO〇H)m7 [3e] (in the formula [3a], (1) is an integer of ~4; In [3b], Z2 is a single bond, -CH2-, -C2H4-, -C(CH3)2-, -CF2-, -C(CF3)-, -0-, -CO-, -NH-, - N(CH3)·, -CONH-, -NHCO-, -CH20-, -OCH2-, -COO-, -OCO-, -CON(CH3)... or -N(CH3)CO-, m2 and 1η3 An integer of 〇~4, and m2 + m3 represents an integer of 1 to 4; in the formula [3c], 'm4&amp;m5 are each an integer of 1 to 5; in the formula [3(1), z3 is a carbon number of 1 to 5; Linear or branched alkyl, „!6 is an integer from 1 to 5; in the formula [3e], Z4 is a single bond, -CH2-, -C2H4-, -C(CH3)2-, -CF2-, -C (CF3)-, -Ο- ' _c〇-, -NH-, -N(CH3)-, -CONH-, -NHCO-, -CH2O-, -〇CH2-, -COO-, -OCO-, - CON(CH3)-, or -N(CH3)C〇-,... is an integer of !~') e 1 7 . The liquid crystal alignment treatment agent of claim 6 of the patent application, wherein '1 in the formula [3a] ^ is an integer of 1 to 2. 1 8 · As claimed in the patent scope! 6 liquid crystal alignment treatment agent, wherein -134-.201030055 [3b] in 'Z2 is a single Key, _(^2-, -(:2114-'-〇:((:113)2-, -〇-, -CO-, -NH-, -N(CH3)-, -CONH-, -NHCO -, -COO-, or -OCO-, m2 and m3 are integers of 1. 19. The liquid crystal alignment treatment agent of claim 16, wherein in the formula [3e], 'Z4 is a single bond, _cH2-, -Ο-, -CO., -NH-, -CONH-, -NHCO-, -CH20-, -OCH2-, -COO-, or -OCO-, ΙΠ7 is an integer from 1 to 2. 2 〇. The liquid crystal alignment treatment agent according to any one of the items 2 to 9 wherein the diamine compound (Α) is 〇, 5 to 1 mol of the diamine compound (C). 5〇摩尔, the diamine compound (β) is 〇.5 〜1 〇 mol for 1 mol of the diamine compound (C). 21. As in any of claims 2 to 20 The liquid crystal alignment treatment agent, wherein the liquid crystal alignment treatment agent contains a solvent of 5 to 70% by mass in the liquid crystal alignment treatment agent. 22. The liquid crystal alignment treatment agent of any one of the second to the twenty-first aspect of the invention, wherein the liquid crystal alignment The copolymer in the treating agent is a polyimine obtained by subjecting polylysine to dehydration ring closure. A liquid crystal alignment film which is obtained by using the liquid crystal alignment treatment agent according to any one of claims 2 to 22. A liquid crystal display element characterized by having a liquid crystal alignment film according to item 23 of the patent application. -135- 201030055 IV. Designated representative map: (1) The representative representative of the case is: None (2) The symbol of the representative figure is simple: No 201030055 五、本案若有化學式時,請揭示最能顯示發明特徵的化學 式:(化1) (化1)201030055 5. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: (Chemical 1) (Chemical 1) 4)n [2]4)n [2]
TW098132085A 2008-09-24 2009-09-23 Using the same liquid crystal alignment treating agent to the liquid crystal display element TWI457368B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008245038 2008-09-24
JP2008245037 2008-09-24

Publications (2)

Publication Number Publication Date
TW201030055A true TW201030055A (en) 2010-08-16
TWI457368B TWI457368B (en) 2014-10-21

Family

ID=42059718

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098132085A TWI457368B (en) 2008-09-24 2009-09-23 Using the same liquid crystal alignment treating agent to the liquid crystal display element

Country Status (5)

Country Link
JP (1) JP5382372B2 (en)
KR (1) KR101613751B1 (en)
CN (1) CN102165365B (en)
TW (1) TWI457368B (en)
WO (1) WO2010035719A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633128B (en) * 2011-05-27 2018-08-21 日產化學工業股份有限公司 Composition, liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
TWI678385B (en) * 2014-12-25 2019-12-01 日商日產化學工業股份有限公司 Liquid crystal alignment treatment agent, liquid crystal alignment film and liquid crystal display element

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005219450B2 (en) * 2004-03-02 2011-08-04 Poly Coat Pty Ltd Paintable primer system
WO2011132752A1 (en) 2010-04-22 2011-10-27 日産化学工業株式会社 Liquid-crystal alignment agent, liquid-crystal alignment film, and liquid-crystal display element
CN103026291B (en) * 2010-06-10 2015-08-19 日产化学工业株式会社 Aligning agent for liquid crystal, liquid crystal orientation film and liquid crystal display cells
JP5643985B2 (en) * 2010-08-19 2014-12-24 Jnc株式会社 Diamine, liquid crystal aligning agent, liquid crystal aligning film, and liquid crystal display element
JP5537345B2 (en) * 2010-09-03 2014-07-02 株式会社ジャパンディスプレイ Liquid crystal display
WO2012121259A1 (en) * 2011-03-07 2012-09-13 日産化学工業株式会社 Composition, liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element
CN103502312B (en) * 2011-03-07 2015-07-29 日产化学工业株式会社 Composition, aligning agent for liquid crystal, liquid crystal orientation film and liquid crystal display device
KR20140045556A (en) * 2011-07-12 2014-04-16 닛산 가가쿠 고교 가부시키 가이샤 Composition liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
KR102224531B1 (en) * 2011-09-08 2021-03-05 닛산 가가쿠 가부시키가이샤 Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element
JP5949070B2 (en) 2012-04-03 2016-07-06 Jsr株式会社 Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display element
TWI522392B (en) * 2013-05-22 2016-02-21 奇美實業股份有限公司 Liquid crystal alignment composition, liquid crystal alignment film and liquid crystal display device having thereof
CN103305236B (en) * 2013-06-25 2015-07-08 深圳市华星光电技术有限公司 Liquid crystal display (LCD) panel and uses of its alignment films in preparing liquid crystal display
TWI482801B (en) * 2013-09-18 2015-05-01 Chi Mei Corp Liquid crystal alignment composition, liquid crystal alignment film and liquid crystal display element having thereof
TWI513737B (en) * 2013-11-29 2015-12-21 Daxin Materials Corp Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display
CN107407839B (en) * 2014-12-25 2020-09-18 日产化学工业株式会社 Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element
JP7425415B2 (en) 2019-01-22 2024-01-31 日産化学株式会社 Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element
CN114561029A (en) * 2020-11-27 2022-05-31 臻鼎科技股份有限公司 Polymer dispersion liquid, preparation method thereof, polymer composite membrane and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308771A4 (en) * 2000-07-07 2004-03-24 Nissan Chemical Ind Ltd Liquid crystal orientating agent and liquid crystal display element using the same
JP4228614B2 (en) * 2002-08-06 2009-02-25 チッソ株式会社 Phenylenediamine with ester bond
JP2005097377A (en) * 2003-09-24 2005-04-14 Fuji Photo Film Co Ltd Alignment layer, polymer, retardation plate using it, its preparing method and liquid crystal display device
CN101490188B (en) 2006-07-18 2012-07-04 日产化学工业株式会社 Liquid crystal orienting agent and liquid crystal oriented film and liquid crystal display element using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633128B (en) * 2011-05-27 2018-08-21 日產化學工業股份有限公司 Composition, liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
TWI678385B (en) * 2014-12-25 2019-12-01 日商日產化學工業股份有限公司 Liquid crystal alignment treatment agent, liquid crystal alignment film and liquid crystal display element

Also Published As

Publication number Publication date
KR20110056523A (en) 2011-05-30
CN102165365A (en) 2011-08-24
TWI457368B (en) 2014-10-21
JP5382372B2 (en) 2014-01-08
JPWO2010035719A1 (en) 2012-02-23
KR101613751B1 (en) 2016-04-19
CN102165365B (en) 2013-11-06
WO2010035719A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
TWI457368B (en) Using the same liquid crystal alignment treating agent to the liquid crystal display element
TWI449727B (en) A liquid crystal alignment agent, and a liquid crystal display device using the liquid crystal display device
TWI477478B (en) Diamine compounds, polyamic acid, polyimide and liquid crystal alignment treatment agent
JP5663876B2 (en) Liquid crystal aligning agent and liquid crystal display element using the same
TWI429617B (en) Diamine compounds, polyamic acid, polyimide and liquid crystal alignment treatment agent
TW201209077A (en) Liquid-crystal alignment agent, liquid-crystal alignment film, and liquid-crystal display element
TW200948860A (en) Liquid-crystal alignment material, liquid-crystal alignment film, and liquid-crystal display element
TWI596158B (en) Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element
TWI591098B (en) Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element
TW201514248A (en) Liquid-crystal orientation treatment agent, liquid-crystal orientation film, and liquid-crystal display element
TWI564283B (en) A liquid crystal alignment agent, a liquid crystal alignment film, and a liquid crystal display device
TW200906769A (en) Diamine compound, polyamic acid, polyimide and liquid crystal aligning agent
TWI520984B (en) Liquid crystal alignment film and a liquid crystal display element to the processing agent, with the liquid crystal
TW201219380A (en) Liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
TW201313780A (en) Composition, liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element
TW201522422A (en) Liquid crystal aligning agent and liquid crystal display element using same
TW201422677A (en) Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display element
TWI504637B (en) Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element
TWI624494B (en) Composition, liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
TWI494374B (en) A liquid crystal alignment agent, a liquid crystal alignment film, and a liquid crystal display device using the same
TW201634589A (en) Liquid crystal alignment treatment agent, liquid crystal alignment film, and liquid crystal display element
TWI683857B (en) Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display element
TW201500463A (en) Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display element

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent